Scholarly article on topic 'Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders'

Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders Academic research paper on "Biological sciences"

Share paper
Academic journal
Pharmacology & Therapeutics
OECD Field of science
{"Fear extinction" / "Exposure therapy" / "Augmented relearning" / Reconsolidation / "Drug development" / "Cognitive enhancer"}

Abstract of research paper on Biological sciences, author of scientific article — N. Singewald, C. Schmuckermair, N. Whittle, A. Holmes, K.J. Ressler

Abstract Pathological fear and anxiety are highly debilitating and, despite considerable advances in psychotherapy and pharmacotherapy they remain insufficiently treated in many patients with PTSD, phobias, panic and other anxiety disorders. Increasing preclinical and clinical evidence indicates that pharmacological treatments including cognitive enhancers, when given as adjuncts to psychotherapeutic approaches [cognitive behavioral therapy including extinction-based exposure therapy] enhance treatment efficacy, while using anxiolytics such as benzodiazepines as adjuncts can undermine long-term treatment success. The purpose of this review is to outline the literature showing how pharmacological interventions targeting neurotransmitter systems including serotonin, dopamine, noradrenaline, histamine, glutamate, GABA, cannabinoids, neuropeptides (oxytocin, neuropeptides Y and S, opioids) and other targets (neurotrophins BDNF and FGF2, glucocorticoids, L-type-calcium channels, epigenetic modifications) as well as their downstream signaling pathways, can augment fear extinction and strengthen extinction memory persistently in preclinical models. Particularly promising approaches are discussed in regard to their effects on specific aspects of fear extinction namely, acquisition, consolidation and retrieval, including long-term protection from return of fear (relapse) phenomena like spontaneous recovery, reinstatement and renewal of fear. We also highlight the promising translational value of the preclinial research and the clinical potential of targeting certain neurochemical systems with, for example d-cycloserine, yohimbine, cortisol, and L-DOPA. The current body of research reveals important new insights into the neurobiology and neurochemistry of fear extinction and holds significant promise for pharmacologically-augmented psychotherapy as an improved approach to treat trauma and anxiety-related disorders in a more efficient and persistent way promoting enhanced symptom remission and recovery.

Academic research paper on topic "Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders"

Accepted Manuscript

Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders

N. Singewald, C. Schmuckermair, N. Whittle, A. Holmes, K.J. Ressler

PII: S0163-7258(14)00233-2

DOI: doi: 10.1016/j.pharmthera.2014.12.004

Reference: JPT 6746

To appear in: Pharmacology and Therapeutics

Please cite this article as: Singewald, N., Schmuckermair, C., Whittle, N., Holmes, A. & Ressler, K.J., Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders, Pharmacology and Therapeutics (2014), doi: 10.1016/j.pharmthera.2014.12.004

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

P&T #22611

Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders

Singewald N1*#, Schmuckermair C1*, Whittle N1, Holmes A2 and Ressler KJ3

1 Department of Pharmacology and Toxicology, Institute of Chemistry and Pharmacy, LeopoldFranzens University of Innsbruck, Innrain 80-82, A-6020 Innsbruck, Austria

2 Laboratory of Behavioral and Genomic Neuroscience, National Institute on Alcohol Abuse and Alcoholism, NIH, Bethesda, MD, USA

3 Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia

*These authors contributed equally, # corresponding author: Nicolas Singewald, Department of Pharmacology & Toxicology, Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck

Innrain 80-82, A-6020 Innsbruck, Austria; Fax: +43-512-507-58889, E-mail:


Pathological fear and anxiety are highly debilitating and, despite considerable advances in

psychotherapy and pharmacotherapy they remain insufficiently treated in many patients with PTSD,

phobias, panic and other anxiety disorders. Increasing preclinical and clinical evidence indicates that

pharmacological treatments including cognitive enhancers, when given as adjuncts to

psychotherapeutic approaches [cognitive behavioral therapy including extinction-based exposure

therapy] enhance treatment efficacy, while using anxiolytics such as benzodiazepines as adjuncts can

undermine long-term treatment success. The purpose of this review is to outline the literature

showing how pharmacological interventions targeting neurotransmitter systems including serotonin,

dopamine, noradrenaline, histamine, glutamate, GABA, cannabinoids, neuropeptides (oxytocin,

neuropeptides Y and S, opioids) and other targets (neurotrophins BDNF and FGF2, glucocorticoids, L-type-calcium channels, epigenetic modifications) as well as their downstream signaling pathways, can augment fear extinction and strengthen extinction memory persistently in preclinical models. Particularly promising approaches are discussed in regard to their effects on specific aspects of fear extinction namely, acquisition, consolidation and retrieval, including long-term protection from return of fear (relapse) phenomena like spontaneous recovery, reinstatement and renewal of fear. We also highlight the promising translational value of the preclinial research and the clinical potential of targeting certain neurochemical systems with, for example D-cycloserine, yohimbine, cortisol, and L-DOPA. The current body of research reveals important new insights into the neurobiology and neurochemistry of fear extinction and holds significant promise for pharmacologically-augmented psychotherapy as an improved approach to treat trauma and anxiety-related disorders in a more efficient and persistent way promoting enhanced symptom remission and recovery.

6 keywords

Fear extinction Exposure therapy Augmented relearning Reconsolidation Drug development Cognitive enhancer


1 Introduction...........................................................................................................................................7

2 Neuronal substrates of fear extinction...............................................................................................11

3 Neurochemical and molecular substrates of fear extinction..............................................................13

4 Pharmacologically enhancing extinction.............................................................................................15

4.1 Serotonergic system....................................................................................................................15

4.2 Dopaminergic system..................................................................................................................22

4.3 Noradrenergic system .................................................................................................................27

4.4 Glutamatergic system..................................................................................................................31

4.5 y-aminobutyric acid (GABA)........................................................................................................41

4.6 Cannabinoids...............................................................................................................................47

4.7 Neuropeptides (Oxytocin, Neuropeptide Y, Neuropeptide S, Opioids)......................................52

a) Oxytocin .......................................................................................................................................52

b) Neuropeptide Y ............................................................................................................................54

c) Neuropeptide S ............................................................................................................................55

d) Opioids .........................................................................................................................................55

4.8 Glucocorticoids............................................................................................................................59

4.9 Neurotrophins and miscellaneous targets..................................................................................64

a) Fibroblast growth factor—2..........................................................................................................64

b) Brain-derived neurotrophic factor...............................................................................................65

c) Nitric oxide and methylene blue..................................................................................................67

d) Histamine.....................................................................................................................................68

e) Voltage gated calcium channels..................................................................................................68

4.10 Epigenetics...................................................................................................................................74

a) Histone modifications..................................................................................................................74

b) DNA methylation.........................................................................................................................78

c) Non-coding RNA..........................................................................................................................79

5 Discussion and final conclusions.........................................................................................................81

6 References...........................................................................................................................................88

List of abbreviations

5-HT 5-hydroxytryptamine = serotonin

AC adenylate cyclase

AMPA a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid

AMY amygdala

BA basal amygdala

BDNF brain-derived neurotrophic factor

BLA basolateral amygdaloid complex

BZD benzodiazepine

CaMKII Ca2+/calmodulin-dependent protein kinase II

cAMP 3'-5'-cyclic adenosine monophosphate

Cav 1.2 L-type calcium channel alpha 1C isoform

Cav 1.3 L-type calcium channel alpha 1D isoform

CBT cognitive behavioral therapy

CCK cholecystokinin

CeA central amygdala

CeM centromedial amygdala

CeL centrolateral amygdala

CNS central nervous system

CREB cAMP response element binding

CS conditioned stimulus

DA dopamine

DCS D-cycloserine

DNA deoxyribonucleic acid

eCB endogenous cannabinoiod

ERK extracellular regulated kinase

ERP exposure and prevention CBT

FGF2 fibroblast growth factor-2

GABA y-aminobutyric acid

GABAa GABAA receptor

GAD generalized anxiety disorder

GAD (65/67) glutamate decarboxylase 65/67

GluN NMDA receptor subtype

GR glucocorticoid receptor




histone H3 protein

histone H4 protein

histone acetyltransferase

histone deacetylase

histone deacetylase 2

hypothalamic-pituitary-adrenal axis



infralimbic cortex

intercalated cell masses


kappa opioid receptor lateral amygdala levodopa

mitogen-activated protein kinase 3,4-methylenedioxy-N-methylamphetamine magnesium ion

metabotropic glutamate receptor micro-RNA

medial prefrontal cortex messenger ribonucleic acid

entinostat (Pyridin-3-ylmethyl N-[[4-[(2-aminophenyl)carbamoyl]



NMDA receptor

not studied

nitric oxide

neuropeptide S

neuropeptide Y

obsessive-compulsive disorder


periaqueductal gray

4-[2-(Phenylsulphonylamino)ethylthio]-2,6-difluorophenoxyacetamide as Ca2+ /phospholipid-dependent protein kinase C post-traumatic stress disorder

PL prelimbic cortex

SAD social anxiety disorder

SAHA vorinostat (N-hydroxy-N'-phenyl-octanediamide)

SNP single nucleotide polymorphism

SNRI selective noradrenaline reuptake inhibitor

SSRI selective serotonin reuptake inhibitor

TrkB tropomyosin-related kinase B

US unconditioned stimulus

VGCC voltage-gated calcium channel

VRET virtual reality exposure

Zn2+ zinc ion

1 Introduction

Fear, anxiety and trauma-related disorders are associated with excessive fear reactions triggered by specific objects, situations or internal and external cues in the absence of any actual danger, and often include an inability to extinguish learned fear and to show adequate safety learning [(Michael et al., 2007; Wessa & Flor, 2007; Milad et al., 2009; Jovanovic et al., 2012; Milad et al., 2013) reviewed in (Holmes & Singewald, 2013) and (Kong et al., 2014)]. Pathological fear and anxiety occur in a range of psychiatric conditions, including various types of phobia (e.g. social phobia, agoraphobia or specific phobia), panic disorder with/without agoraphobia, obsessive-compulsive disorder (OCD), generalized anxiety (GAD) and post-traumatic stress disorder (PTSD) (ICD-10, 1994; DSM-5, 2013). These disorders comprise the most common mental disorders and are estimated to have a life-time prevalence of up to 28% amongst western populations (Kessler et al., 2005; Wittchen et al., 2011; Kessler et al., 2012). In addition to the personal suffering of patients, the economic burden caused by anxiety disorders is heavy (Gustavsson et al., 2011).

Available pharmacological and psychotherapeutic treatments (Bandelow et al., 2007) which aim to reduce fear and anxiety are associated with decreased symptom severity, but up to 40% of anxiety patients show only partial long-term benefit, and a majority of them fail to achieve complete remission (Hoffman & Mathew, 2008; Stein et al., 2009; Bandelow et al., 2012) clearly underlining the need for further improvement. Current pharmacological approaches either induce rapid anxiolytic effects (e.g. benzodiazepines, some antipsychotics) or require prolonged, chronic treatment (e.g. antidepressants) to attenuate symptoms of pathological fear and anxiety. Commonly employed psychotherapeutic interventions apply cognitive behavioral strategies and exposure techniques to help patients overcome the maladaptive beliefs and avoidance behaviors that reinforce the pathology related to fear-eliciting cues. Meta-analyses show that cognitive behavioral therapy (CBT) does have efficacy for several anxiety disorders, including PTSD, but patients have

difficulty bearing the demanding and exhausting process of therapy and many who do manage to cope with it respond only partially and often relapse with time (Choy et al., 2007).

One strategy to improve CBT is to augment psychotherapy with adjunctive pharmacological treatments. Early attempts at combining 'CBT' with anxiolytic medications [e.g. benzodiazepines (BZD)] showed that the combination was no more effective [in some instances even counterproductive (Marks et al., 1993; Wilhelm & Roth, 1997)] than psycho- or pharmacotherapy alone [for details see (Otto et al., 2010a; Otto et al., 2010b; Rodrigues et al., 2011; Dunlop et al., 2012; Hofmann, 2012)]. However, at least in some cases, this failure may have reflected idiosyncratic effects of the drugs tested (especially BZDs) rather than utility of the strategy itself, and there has been an intense search to identify agents that serve as more effective adjuncts to CBT. The preclinical assay most frequently used in this search is fear extinction - the focus of this current review. Extinction of fear following Pavlovian fear learning (Pavlov, 1927) in animals is procedurally similar to exposure-based CBT (Milad & Quirk, 2012). We will briefly outline different aspects of Pavlovian fear learning [(which is thought to be involved in the etiology and maintenance of anxiety disorders, e.g. (Amstadter et al., 2009)] and extinction highlighting the key processes that could be targeted to augment fear extinction (see Figure 1 for an overview).

Fear and fear extinction

Experimentally, fear conditioning occurs when a previously neutral stimulus [conditioned stimulus (CS) - such as a tone or light-] is paired with an aversive, unconditioned stimulus (US - e.g. electric shock to the forearm in humans, mild foot shock in rodents), resulting in a CS-US association whereby the CS alone elicits a conditioned fear response (e.g. freezing in rodents or increased skin conductance in humans). Following a successful CS-US association, fear memories require consolidation, a process involving a cascade of molecular and cellular events that alter synaptic efficacy, as well as a prolonged systems level interaction between brain regions, to stabilize the memory (McGaugh, 2000). Once consolidated, fear memories, reactivated by presenting the CS, are

de-stabilized to render the original fear memory liable to pharmacological/behavioral interference (see overview in Figure 1) and this is then followed by a second phase of molecular and cellular events to re-stabilize (re-consolidate) the (adapted) memory (Nader et al., 2000).

Fear memories can be attenuated by various processes and interventions (including pharmacological and psychological approaches), some producing temporary blunting of fear behaviors and others causing more long-lasting relief. Interfering with the re-consolidation by inhibiting molecular and cellular events supporting fear memory re-stabilization [Figure 1C, (Nader et al., 2000; Lee et al., 2006)], for example with G-adrenoceptor blockers (Debiec & Ledoux, 2004; Kindt et al., 2009), has been proposed as a clinical approach to alleviating fear memories. For discussion on this and other means of reducing fear (e.g. via US habituation) we refer the reader to some excellent prior reviews (Graham et al., 2011; Schwabe et al., 2014). Other potential ways to relieve fear include safety learning (Rogan et al., 2005; Kong et al., 2014) and erasure-like mechanisms such as destruction of erasure-preventing perineuronal nets (Gogolla et al., 2009).

Alternatively, fear memories can also be extinguished. Fear extinction, a process originally described by Pavlov (Pavlov, 1927), entails repeated exposure to anxiety-provoking cues to establish a new memory that counters the original fear memory. The process is highly relevant to fear, anxiety and trauma-related disorders which are associated with negative emotional reactions triggered by specific objects, situations or internal and external cues that are excessive to the actual danger posed. Moreover, extinction in animals is procedurally similar to forms of CBT that rely on exposure to anxiety-provoking cues (see Figure 1) (Milad & Quirk, 2012), and anxiety disorders are associated with an inability to extinguish learned fear and to respond adequately to safety signals (Michael et al., 2007; Wessa & Flor, 2007; Milad et al., 2009; Jovanovic et al., 2012; Milad et al., 2013) [reviewed in (Holmes & Singewald, 2013)]. Thus, fear extinction has considerable translational utility. The key processes that can be targeted to pharmacologically augment fear extinction are summarized in Figure 1.

Extinction is a learning process driven by violation of the original CS=US contingency (termed 'prediction error' for review see (Pearce & Bouton, 2001; McNally & Westbrook, 2006)], but it also contains other elements including habituation and desensitization some also say erasure/destabilization (Lin et al., 2011). Some authors therefore favor the term 'relearning' over extinction [for discussion see (Riebe et al., 2012)]. As with fear learning, extinction occurs in two phases: extinction acquisition and extinction consolidation retrieval. The decrement in the fear response during 'extinction training' is also termed 'within-session extinction'. Similar to fear memory, stabilization of the extinction memory requires both a cascade of overlapping, but dissociable, molecular and cellular events [for review see (Myers & Davis, 2007; Orsini & Maren, 2012)] that alter synaptic efficacy and brain systems-level interactions (Pape & Pare, 2010). The strength of extinction memory can be assessed at some interval (usually >1 day) after extinction training in "extinction retrieval" sessions (also termed 'extinction retention' or 'extinction expression', but note that we use the term "extinction retrieval" throughout this review).

That extinction memories are prone to re-emergence (due to insufficient 'longterm extinction') indicates that the original fear memory is still in place and the extinction memory is weaker/more labile than the fear memory. This may be particularly true of older ('remote') fear memories (Tsai & Graff, 2014). The re-emergence of extinguished fear occurs under multiple circumstances: (i) renewal, when the CS is presented in a different context to that in which extinction training occurred; (ii) reinstatement, when the original US or another stressor as is given unexpectedly; and (iii) spontaneous recovery, when a significant period of time has elapsed following successful extinction training (Myers & Davis, 2007; Herry et al., 2010). The likelihood of fear re-emergence is dependent on the strength of the extinction memory which is also determined by the type of extinction protocol used see e.g. (Li & Westbrook, 2008; Laborda & Miller, 2013). Spontaneous recovery (Rowe & Craske, 1998b, a; Schiller et al., 2008), reinstatement (Schiller et al., 2008) and renewal (Effting & Kindt, 2007) are all observable in clinical settings, and can be readily exploited in the laboratory to identify

drug- and other interventions that can prevent or fear re-emergence in animals and relapse in humans (Vervliet et al., 2013).

Our goal in the current review is to offer a comprehensive overview of preclinical work on the possible pharmacological approaches (see Box 1 for an overview) to augment fear extinction and protect against the re-emergence of fear, and to discuss the potential translational value of these candidates as adjuncts to exposure-based CBT in anxiety patients.

2 Neuronal substrates of fear extinction

Using a number of complementary techniques (including electrophysiology, immediate-early gene

mapping, tracing studies, lesioning/inactivation approaches and optogenetics) research is revealing

the complex and interconnected brain circuitry mediating fear extinction. Several key brain areas

including the amygdala (AMY), hippocampus (HPC), medial prefrontal cortex (mPFC), periaqueductal

grey (PAG), bed nucleus of the stria terminalis and others have been implicated in extinction [for

recent detailed reviews see (Myers & Davis, 2007; Ehrlich et al., 2009; Herry et al., 2010; Pape &

Pare, 2010; Knapska et al., 2012; Orsini & Maren, 2012; Duvarci & Pare, 2014)]. Of these, we focus on

the AMY, HPC and mPFC as major, well-defined components of the fear circuitry (see Figure 2).

While the AMY and the mPFC are crucial for the formation and maintenance of fear extinction

memories, the HPC, linked with the mPFC and the AMY (Pape & Pare, 2010), processes contextual

information linked with extinction (Orsini & Maren, 2012). Altering these hippocampal contributions

to extinction memory or mimicking the hippocampal response within the extinction context (see

below) may be mechanisms that render extinction context-independent. The AMY is a core hub in

fear extinction processing. Data in rodents and humans suggest sustained AMY activity in extinction-

impaired individuals, possibly resulting from a failure to engage pro-extinction circuits in cortical

areas and subregions of the AMY [reviewed in (Holmes & Singewald, 2013)]. Different AMY

subregions and neuronal populations have differential contributions to extinction. The centromedial

AMY (CeM) is the major output station of the AMY that drives fear via its connections to the

hypothalamus and brainstem regions (LeDoux et al., 1988; Fendt & Fanselow, 1999; Maren, 2001), and its responding is modulated following extinction via intra-amygdala and remote inputs. Extinction training has been shown to cause a rapid reduction of CS-evoked responses of lateral AMY (LA) neurons possibly via depotentiation of thalamic inputs (Duvarci & Pare, 2014). The basal AMY (BA) contains extinction-encoding neurons which drive GABAergic cells in the medial intercalated cell masses (ITC) and neurons in the centrolateral AMY (CeL) to inhibit the centromedial AMY (CeM) and the expression of fear (Herry et al., 2008; Duvarci & Pare, 2014). Following from these initial findings, additional studies involving optogenetic approaches, have shown that a subpopulation of the BA pyramidal neurons which express the Thy1 gene may mark the extinction neuron subpopulation (Jasnow et al., 2013).

It is also becoming apparent that different ITCs are part of a GABAergic feed-forward relay station interconnecting AMY nuclei with distinct networks within the ITCs that are engaged in particular fear stages exerting different influences on extinction (Whittle et al., 2010; Busti et al., 2011; Duvarci & Pare, 2014). Separate neuronal populations in the CeL have been found to have contrasting roles in fear and fear extinction. CeL-OFF neurons (PKC5+ phenotype) inhibit fear-promoting CeM neurons, while CeL-ON (PKC5- phenotype) cells stimulate fear-promoting CeM neurons (Ciocchi et al., 2010; Haubensak et al., 2010). Additionally, a very recent finding suggests that a subpopulation of neurons within the CeM -that of the Tac2 peptide-expressing cells -, is critically involved in fear learning and fear expression (Andero et al., 2014).

Another important node within the extinction circuitry is the mPFC, which shares strong interconnections with the HPC and the AMY. Fear extinction recruits the ventral segment of the mPFC, the infralimbic (IL) subdivision [the rodent correlate of the human ventromedial PFC (vmPFC)] which projects to BA extinction and ITC neurons and can thereby inhibit the activity of CeM fear output neurons [reviewed in (Amir et al., 2011; Senn et al., 2014)]. When a conditioned cue following extinction is presented in the extinction (therapy) context, the HPC activates the IL (an activation which is absent or less in a novel context), supporting subsequent CeM inhibition (Herry et al., 2010).

The IL subdivision is involved in the consolidation of extinction memory and synaptic plasticity in this region and is crucial for successful extinction retrieval (Mueller & Cahill, 2010). Impaired extinction has been associated with relatively low activity in IL neurons, and successful extinction with relatively high IL neuronal activity [reviewed in (Holmes & Singewald, 2013)]. The region of the vmPFC neighboring the IL [the prelimbic cortex (PL) in rodents and the dorsal anterior cingulate in humans] plays an opposite role to the IL in regulating fear and extinction [reviewed in (Milad & Quirk, 2012)]. The PL interacts with BA fear neurons, augmenting output of the basolateral amygdaloid complex (BLA) and hence CeM activity (Senn et al., 2014).

There is now strong evidence from both animal and human studies that these various components of the neural circuit underlying extinction are functionally disturbed in individuals with impaired extinction (reviewed in (Holmes & Singewald, 2013) and importantly that successful extinction in animals (Whittle et al., 2010) and exposure therapy in humans (Hauner et al., 2012) can correct these abnormalities by triggering a lasting reorganization of this network.

3 Neurochemical and molecular substrates of fear extinction

Research is revealing that the activity of a number of specific intracellular signaling cascades [reviewed in (Orsini & Maren, 2012)] carrying biological information from the cell surface to the nucleus, is the key to successful extinction by modulating gene transcription and ultimately promoting synaptic plasticity in extinction-relevant brain regions. The consolidation of extinction memories requires new protein synthesis initiated by molecular signaling cascades within the AMY, HPC and prefrontal cortex. The extinction-related molecular signaling and gene expression modulation can differ considerably in these brain areas (Cestari et al., 2014). Key molecules in the amygdala include calcium (Ca2+) influx via NMDA- [in an interaction with a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors] and VGCCs-mediated activation of Ca2+/calmodulin-dependent protein kinase II (CaMKII) and kinases such as Ca2+ /phospholipid-

dependent protein kinase (PKC), and cAMP-dependent protein kinase (PKA). Once activated, these kinases merge into a common mitogen-activated protein kinase (MAPK)/extracellular regulated kinase (ERK) signaling pathway initiating cAMP response element binding (CREB) phosphorylation and transcription of plasticity proteins [reviewed in ((Orsini & Maren, 2012), see Figure 3 for overview]. Aspects of this intracellular signaling seem to be disrupted in deficient extinction, as exemplified by the correlation of impaired extinction with reduced ERK activity in extinction-relevant brain areas (Cannich et al., 2004; Herry et al., 2006; Ishikawa et al., 2012). Similarly, aberrant expression of memory-related genes in these areas is correlated with impaired extinction (Holmes & Singewald, 2013).

To enable selective therapeutic targeting, an important aim in the extinction field is to identify neural mechanisms and intracellular pathways in fear extinction that are different from those involved in fear memory formation. Many of the intracellular mechanisms are similar, however there are also a number of distinct processes and features in fear vs fear extinction learning, including differences in protein synthesis dependence, in brain area- and neuronal population-specific localization and recruitment of signaling pathways, in time course of recruitment, in distinct involvement of certain isoforms of key signaling components (e.g. ERK1 vs ERK2) and resulting gene expression (Lattal et al., 2006; Guedea et al., 2011; Tronson et al., 2012; Cestari et al., 2014). While there are examples of the direct targeting of pharmacologically important components of the aforementioned intracellular signaling, e.g. the MAPK/ERK pathway (Lu et al., 2001; Herry et al., 2006; Fischer et al., 2007) to modulate fear extinction, they were mainly targeted indirectly via membrane receptors e.g. (Cannich et al., 2004; Matsuda et al., 2010) or ion channels (Davis & Bauer, 2012; Ishikawa et al., 2012). These findings have stimulated the hypothesis that boosting specific synaptic plasticity mechanisms by pharmacological means may constitute novel drug targets to promote fear extinction. Indeed, as outlined below, systemic and brain region specific drug studies have identified a number of promising compounds which augment the behavioral and neurobiological effects of fear extinction. The results of these studies are building a framework upon which novel therapeutic interventions to

facilitate the efficacy of CBT may be rationally developed and which may ultimately help to enhance symptom remission and recovery.

4 Pharmacologically enhancing extinction 4.1 Serotonergic system

The serotonin (5-HT) system is positioned to modulate the extinction circuitry via ascending 5-HT projections arising from midbrain raphe nuclei that innervate certain brain structures including the AMY (BLA > LA >>CeA), the HPC, the mPFC and the bed nucleus of the stria terminalis [reviewed in (Burghardt & Bauer, 2013)]. The acquisition and expression of conditioned fear increases 5-HT release in the BLA, mPFC and dPAG (Kawahara et al., 1993; Yokoyama et al., 2005; Zanoveli et al., 2009) though possible changes in 5-HT release during acquisition and consolidation of fear extinction have not been reported to the best of our knowledge.

There are 16 5-HT receptor subtypes classified into 7 receptor families (5-HT1-7) (Figure 4). All 5-HT receptors, excluding the 5-HT3 family - a member of a superfamily of ligand-gated ion channels, are metabotropic, coupled to Gs (5-HT6 and 5-HT7), Gi/0 (5-HTi, 5-HT4 and 5-HT5) or Gq (5-HT2) proteins.

To date, research has largely focused on the role of 3 of the 5-HT receptors in fear extinction; namely

5 HT1A, 5-HT2 and 5-HT3 (Table 1, Figure 4). Selective activation of 5-HT1A (Saito et al., 2013; Wang et al., 2013) or 5-HT2A receptors (Catlow et al., 2013; Zhang et al., 2013) enhances extinction. This might occur via 5-HT1A and 5-HT2A receptors expressed in the mPFC and the LA (Chalmers & Watson, 1991; Cornea-Hebert et al., 1999; Santana et al., 2004). Both of these receptors regulate mPFC and LA excitability via direct activation of pyramidal cells and/or GABAergic interneurons (Rainnie, 1999; Stutzmann & LeDoux, 1999; Llado-Pelfort et al., 2012). 5HT2A agonists increase presynaptic glutamate release (Aghajanian & Marek, 1999) and increase NMDA receptor sensitivity (Arvanov et al., 1999)

and these are mechanisms well characterized as being important in extinction (see Section 4.4 Glutamatergic system).

The roles in extinction of other 5-HT receptors or other components of the 5-HT system, such as melatonin ((Huang et al., 2014) have not been extensively explored. For example, recent work indicating that the 5-HT7 receptor regulates emotional memories (Eriksson et al., 2012), has not been followed up with studies on extinction. However, 5-HT3 receptors have been alsoassociated with fear extinction mechanisms (Table 1). While 5-HT3 antagonists have been found to improve extinction (Park & Williams, 2012), constitutive deletion of 5-HT3 receptors has the opposite effect, possibly due to developmental changes in the 5-HT system (Kondo et al., 2014).

Despite the limited knowledge that we have so far regarding specific 5-HT receptor contributions to extinction, chronic treatment with SSRIs to enhance 5-HT availability is the first-line therapy for many anxiety disorders. Acute SSRI treatment induces anxiogenic effects, which can be prevented with 5-HT2C antagonists in rodents and mimicked by 5-HT2C agonists administered systemically (Bagdy et al., 2001; Salchner & Singewald, 2006) or locally into the BLA (Campbell & Merchant, 2003). Chronic treatment with some SSRIs (e.g., fluoxetine) but not all (e.g., citalopram) enhances extinction in rodents (Table 1) [for a recent review see (Burghardt & Bauer, 2013)], including models of impaired extinction [(Camp et al., 2012; Fitzgerald et al., 2014b) see Table 1]. Venlafaxine - a combined 5-HT and noradrenaline reuptake inhibitor with weaker affinity to the noradrenaline transporter (Owens et al., 1997) - also improves extinction retrieval and protects against fear reinstatement in rodents (Yang et al., 2012). Chronic fluoxetine treatment does not strengthen fear conditioning or fear expression (Camp et al., 2012) suggesting relative selectivity for extinction. Another clinically relevant attribute of chronic fluoxetine treatment is the protection it provides against the return of fear, as assayed by spontaneous recovery or fear renewal (Deschaux et al., 2011; Karpova et al., 2011; Deschaux et al., 2013). Furthermore, an important molecular mechanism through which fluoxetine produces extinction-associated reductions in fear may be the transformation of adult plasticity mechanisms to a juvenile state (Karpova et al., 2011).

These encouraging preclinical discoveries will hopefully stimulate comprehensive clinical assessment of the efficacy of SSRIs in augmenting CBT in anxiety patients (Table 1A). There have been small-scale clinical trials showing, for example, that paroxetine augments fear reductions (assessed using CAPS scores) and is associated with higher remission rates when combined with CBT in PTSD patients as compared with a placebo/CBT group. An optional treatment maintenance for an additional 12 weeks revealed that symptomatic improvements were long-lasting and consistent although no further improvements could be detected. However, this may have been due to enhanced drop-out of patients who had remitted in earlier phases of the study (Schneier et al., 2012). More evidence is available in panic disorder (Table 1). There is evidence that chronic SSRI treatment (fluvoxamine, paroxetine) increases CBT-induced fear reductions in panic disorder patients (de Beurs et al., 1995; Oehrberg et al., 1995). However results concerning the extinction-augmenting ability of SSRIs are not consistent as SSRIs, including fluvoxamine, fluoxetine, sertraline and paroxetine, have failed to demonstrate efficacy in primary outcomes [clinical global impression; (Stein et al., 2000; Blomhoff et al., 2001; Haug et al., 2003; Davidson et al., 2004; Koszycki et al., 2011). Despite their common effect of serotonin transporter inhibition, SSRIs are known to differ with regard to their pharmacological properties. Along these lines, some SSRIs (e.g. paroxetine) show additional noradrenaline transporter-inhibiting properties via their metabolites (Owens et al., 1997), while others (e.g. citalopram) show continued selectivity for the serotonergic system (Deupree et al., 2007). In this respect, differential effect sizes of SSRIs are to be expected.

Nevertheless, a number of outstanding questions remain, including that concerning the specificity of SSRIs in augmenting fear extinction as opposed to fear learning (as observed with fluoxetine in preclinical models; see above). In this respect, the finding that prior fear conditioning administration of escitalopram augments extinction learning in healthy volunteers without influencing fear acquisition (Bui et al., 2013) may hint at a potential selectivity of SSRIs to preferentially engage extinction mechanisms. However, this remains to be tested.

In summary, the clinical studies performed so far have demonstrated that SSRI augmented psychotherapy holds some benefits for panic disorder patients and possibly for PTSD and SAD patients. However, further studies of different SSRIs in larger patient cohorts will be needed, as well as adequate follow-up time to reveal long-term effects, before more definite conclusions can be drawn. Until such studies, as well as studies investigating receptor selective approaches are available, it seems rational to recommend combined treatment involving exposure-based psychotherapy together with antidepressants including SSRIs such as fluoxetine, as there is more evidence supporting than disproving such a strategy at the moment.

Table 1 Serotonergic signaling in fear extinction (preclinical studies)



SERT KO6 ns no effect - ns ns no drug no drug (Hartley et al., 2012) (Wellman et al., 2007)

acute fluoxetine (SSRI) (-)## no effect ns ip (Lebron-Milad et al., 2013)

subchronic no ns ns ip (Burghardt et al., 2013)

citalopram (SSRI, 9d) effect

chronic citalopram (SSRI, 22d) - (-) ns ip (Burghardt et al., 2013)

chronic (14d) fluoxetine (SSRI)

(+)# (+) ns p° (Lebron-Milad et al., 2013)

no effect + + (Ren-A, SR, Re-in) ip (Karpova et al., 2011)

chronic Fluoxetine (SSRI) no effect ns + (Re-in) ip,po (Deschaux et al., 2011; Deschaux et al., 2013)

no +*4 ns p° (Camp et al., 2012)


no effect + ns p° (Popova et al., 2014)

acute venlafaxine no + ns ip (Yang et al., 2012)

(SSRI) effect

chronic venlafaxine ns ns + ip (Yang et al., 2012)

(SSRI) (Re-in)

8-OH-DPAT (5HT1 +*5 ns ip (Wang et al., 2013)

tandospirone (5HT1 ag) ns +* ns ip (Saito et al., 2013)

tcb2 (5H12A ag) psilocybin (5HT2A ag) (+) ns ns ns ns ip ip (Zhang et al., 2013) (Catlow et al., 2013)

5-HT3 OE no effect ns ns no drug (Harrell & Allan, 2003)



5,7- dihydroxytryptamine

(+)# + ns BLA (Izumi et al., 2012)

5,7- dihydroxytryptamine no effect no effect ns IL (Izumi et al., 2012)

no drug

5HT3 KO ns - ns (Kondo et al., 2014)

MDL11,939 (5HT2A ant) - Ns ns ip (Zhang et al., 2013)

ketanserin (5HT2A/C ant)

(+) Ns ns ip (Catlow et al., 2013)

granisetron (5HT3 ant) no effect (+) ns ip (Park & Williams, 2012)

Mrug administration fo lowing extinction training; 2 SERr -KO results in increased synaptic 5-HT

levels; 3 7 days; 4 protection from context over-generalization; 5 valproate-induced model of autism, 6 SERT-KO results in increased synaptic 5-HT levels

* facilitates rescue of impaired fear extinction; # reduced fear expression at the beginning of extinction training; ## enhanced fear expression at the beginning of extinction training

+, improved; -, impaired; (+) or (-), only minor effects; po, peroral administration; ip, intraperitoneal injection; ns, not studied; BLA, intra-basolateral amygdala administration; IL, infralimbic cortex; RenA, Fear renewal in conditioning context; SR, spontaneous recovery; Re-in, reinstatement; ag, agonist; ant, antagonist, KO, knock-out; OE, over-expression

In "Extinction training" (or 'within-session extinction'), an effect on the reduction of the behavioural response (e.g. freezing) in response to repeated CS presentations is described

In "Extinction retrieval", an effect on the recall of the extinction memory 24h following extinction training is described

In "Long-term extinction" an effect on the robustness of the extinction memory in terms of protection against spontaneous recovery of fear (passage of time), fear renewal (re-exposure to conditioning context or a novel context which is distinct to the conditioning and extinction context) and fear reinstatement (US re-exposure) is described

In this review we aimed to summarize (draggable) systems involved in fear extinction and how pharmacological compounds have been utilized to augment fear extinction in preclinical (rodent) and small-scale clinical studies. We did not differentiate between data gained from either mice or rats as this would have gone beyond the scope of this review. However, excellent species differentiation has been provided by others (e.g. (Makkar et al., 2010; Myers et al., 2011; Bowers et al., 2012; Riaza Bermudo-Soriano et al., 2012; Burghardt & Bauer, 2013; Fitzgerald et al., 2014a)

Table 1A: Human trials: Serotonergic drugs combined with CBT

Disorder Study Design Outcome (compared to placebo control group) Reference

Healthy volunteers 14 days po escitalopram pretreatment; Fear conditioning paradigm Accelerated extinction learning (skin conductance responses) (Bui et al., 2013)

Panic disorder with/without agoraphobia Fluvoxamine or placebo followed by exposure therapy; psychological panic management followed by exposure therapy or exposure therapy alone Self-reported measures All treatments effective, however fluvoxamine plus CBT superior to all other treatments (de Beurs et al., 1995)

Panic disorder with/without agoraphobia 12 weeks paroxetine or placebo plus CBT Reduced number of panic attacks in paroxetine/CBT group (Oehrberg et al., 1995)

Panic disorder with/without agoraphobia 10 weeks of ^paroxetine or placebo plus CBT in week 5 and 7 No significant difference in primary CGI outcome. Secondary outcome: Higher proportion of panic-free patients in paroxetine-CBT group. (Stein et al., 2000)

Panic disorder with/without agoraphobia 12 weeks fluvoxamine or placebo with or without CBT All groups except placebo without CBT improved. No difference within other groups. (Sharp et al., 1997)

Panic disorder with/without agoraphobia 12 weeks of sertraline or placebo treatment plus self-administered CBT or no CBT Reduced anticipatory anxiety in sertraline plus self-administered CBT No significant improvements in CGI. (Koszycki et al., 2011)

Social anxiety disorder 24 weeks of sertraline/ placebo with or without exposure therapy (8 sessions in the first 12 weeks of treatment) All groups improved (also placebo without CBT) Sertraline treatment (without CBT) showed higher improvement than CBT groups (placebo or sertraline). Placebo without CBT showed lowest benefits. (Blomhoff et al., 2001)

Social anxiety disorder Follow-up study of (Blomhoff et al., 2001) Assessment of long-term effects 28 weeks after cessation of medical treatment Exposure therapy alone (without placebo or sertraline) showed a further improvement in CAPS 28 weeks after treatment cessation, however only reached improvement levels comparable with those of the sertraline alone group after the initial 24 weeks (Haug et al., 2003)

CAPS score in the other groups (Exposure + placebo or sertraline and placebo alone) stayed constant (no improvement compared to 24 week CAPS score)

Social anxiety disorder 14 weeks of fluoxetine or placebo plus weekly CBT or no CBT CBT consisted of group treatment combining in vivo exposure, cognitive restructuring and social skills training All treatments were superior to placebo (without CBT) but no differences between groups themselves (Davidson et al., 2004)

PTSD 10 exposure therapy sessions (1x / week) plus paroxetine CR Optional 12 weeks of maintenance treatment Greater CAPS improvement in paroxetine group vs placebo after 10 weeks Higher rate of remission (61.5% vs 23.1% in placebo group) after 10 weeks No changes after additional 12 weeks. CAVE drop-out of remitters. (Schneier et al., 2012)

CR.. .controlled release

4.2 Dopaminergic system

An increasing amount of evidence suggests that dopamine (DA) signaling has an important role in extinction mechanisms (Figure 5) [for a recent detailed review, see (Abraham et al., 2014)]. The DAergic system innervates forebrain extinction circuits through ascending mesocortical/limbic DAergic projections from the ventral tegmental area targeting certain brain regions including the mPFC, HPC and AMY (Weiner et al., 1991; Pinard et al., 2008; Pinto & Sesack, 2008). There is increased dopamine release in the mPFC during and following extinction training (Hugues et al., 2007) and boosting DAergic signaling with DA precursors or DA-releasing drugs facilitates extinction consolidation (Abraham et al., 2012; Haaker et al., 2013) and can rescue impaired fear extinction in female rats (Rey et al., 2014). Conversely, reducing DAergic transmission by lesioning mesocortical DAergic projection neurons (with 6-OH-DOPA) impairs extinction memory formation (Morrow et al., 1999; Fernandez Espejo, 2003) (see summary in Table 2). More recently, there have been further insights into the mechanisms of how and where DAergic signaling can influence fear extinction have been made. These studies (see Table 2 and below) have revealed a complex two-pronged feature of DAergic signaling that can (i) gate the expression of fear, and (ii) influence fear extinction consolidation mechanisms.

Dopamine receptors are metabotropic and in the classical view, coupled to either Gs (increased cAMP, D1-like) or Gi/0 (decreased cAMP, D2-like) proteins. However, DAergic signals can also be transduced via Phospholipase C (PLC) activation (enhanced DAG, IP3) mediated by D1-like Ga proteins, by D2-like GPy subunits or by receptors forming D1/D2 heteromers (Felder et al., 1989; Lee et al., 2004) [for review see (Abraham et al., 2014)]. The D1-class receptor signaling modulates the excitability of BLA parvalbumin-positive interneurons (Bissiere et al., 2003; Loretan et al., 2004; Kroner et al., 2005) and ITCs (Manko et al., 2011). In concert with D2-like receptors in the CeL/CeC (Perez de la Mora et al., 2012), DAergic signaling exerts tight control over CeM-mediated expression of fear. To date, however, pharmacological manipulation of DAergic signaling in the AMY has

produced conflicting results with regard to extinction (Hikind & Maroun, 2008; Fiorenza et al., 2012) (see Table 2).

Preclinical work has aimed to clarify the role of DA receptor activity in extinction. However, research has been largely complicated by the lack of receptor subtype-selective compounds, leaving many investigations reliant on drugs acting on D1-like (D1, D5) and D2-like (D2, D3, D4) receptor subfamilies. One reliable finding, however, is that DA antagonism (see Table 2) specifically in the mPFC impairs the retrieval of extinction memories (Pfeiffer & Fendt, 2006; Hikind & Maroun, 2008; Mueller et al., 2010). In this case, DAergic effects on glutamatergic NMDA receptor signaling may be involved. As discussed below (Section 4.4 Glutamatergic system), NMDA receptor-mediated burst activity of mPFC neurons is associated with stabilization of extinction memories (Burgos-Robles et al., 2007) and D1-like receptor agonists facilitate NMDA receptor currents via Gs mediated increases in adenylate cyclase (AC) activity (Snyder et al., 1998). There is also the possibility that D2 receptor mechanisms in the PFC support extinction, as (Mueller et al., 2010) showed that a pre-extinction IL injection of the D2 antagonist raclopride impaired the consolidation of extinction memory. However, following systemic administration of the (less selective) D2 receptor antagonist sulpiride, accelerated extinction was found by (Ponnusamy et al., 2005).

In summary, the results of preclinical studies do not yet fully clarify the specific DA receptor or receptor class mediating the extinction augmenting effect of enhanced dopaminergic signaling. Work still needs to be done on the use of receptor-selective agonists and antagonists, as well as biased ligands (showing functional selectivity for either AC or PLC signal transduction pathways) to reveal receptor-specific functions and their modulation of downstream signaling cascades in extinction. Pharmacologically increasing the DA tone promotes extinction. L-DOPA administration following extinction training enhances fear extinction in mice and healthy humans, rendering extinction resistant to fear renewal, reinstatement and spontaneous recovery (Haaker et al., 2013). L-DOPA is a precursor for all catecholamines, but preferentially enhances dopaminergic turnover in the frontal

cortex (Dayan & Finberg, 2003), eliciting D1- and D2-like receptor responses (Trugman et al., 1991).

Indeed, L-DOPA augments extinction-related neural activity in the mPFC (IL) of mice and increases mPFC functional coupling in humans (Haaker et al., 2013). These findings have immediate translational potential because L-DOPA is a US Food and Drug Administration-approved compound used in the treatment of Parkinson's disease, typically in combination with carbidopa (a peripheral decarboxylase inhibitor) to maximize central availability and minimize peripheral side effects. While there are abuse related issues with any DA enhancer, this could be mitigated by supervised, acute treatment during CBT. Encouragingly, a small-scale clinical trial found improved efficacy of psychotherapy in treatment-resilient PTSD patients by administration of another DA-enhancing drug, MDMA (Mithoefer et al., 2011) and a follow-up indicated robust and fear reductions for up to 74 months [(Mithoefer et al., 2013), see Table 2A]. A caveat here is that it is unclear whether these effects of MDMA are solely attributable to its effects on DA, and not also to its effect on other targets of MDMA, notably 5-HT. Nonetheless, boosting DA transmission in conjunction with CBT could have significant potential translational value.

Table 2 Dopaminergic signaling in fear extinction (preclinical studies)



L-DOPA ns +1 (SR, Re-in2 ip (Haaker et al., 2013)

, Ren-A

- ns ns ip (Borowski & Kokkinidis, 1998)

amphetami no ns

ns ip (Carmack et al., 2010)

ne effect

(+)3 (-) ns ip (Mueller et al., 2009)

cocaine - ns ns ip (Borowski & Kokkinidis, 1998)

Methyl- + (+) ns ip (Abraham et al., 2012)

phenidate ns +1 ns ip (Abraham et al., 2012)

SKF38393 - ns ns ip (Borowski & Kokkinidis, 1998)

(pAg D1) +*4 ns ns ip (Dubrovina & Zinov'eva, 2010)

ns +1 ns CA1 (Fiorenza et al., 2012)

ns no effect1 ns BLA (Fiorenza et al., 2012)

ns no effect1 +6 ns IL (Fiorenza et al., 2012)

ns 7 ns ns ip iP (Rey et al., 2014) (Rey et al., 2014)

Quinpirole (D2 ag) ns - ns ns iP iP (Ponnusamy et al., 2005) (Nader & LeDoux, 1999)

4 ns ns iP (Dubrovina & Zinov'eva, 2010)



(Morrow et al., 1999)

(Fernandez Espejo, 2003)

D1 knockout

global KO

(El-Ghundi et al., 2001)

SCH23390 (D1 ant)

no effect

no effect1

no effect

no effect1

(Fiorenza et al., 2012)

(Hikind & Maroun, 2008)

(Hikind & Maroun, 2008)

(Fiorenza et al., 2012)

(Fiorenza et al., 2012)

Sulpiride (D2 ant)

no effect

no effect

(Dubrovina & Zinov'eva, 2010)

(Ponnusamy et al., 2005)

(Mueller et al., 2010)

Raclopride (D2 ant)

no effect

no effect

(Mueller et al., 2010)

(Mueller et al., 2010)

Haloperidol (D2/D3 ant)

(Holtzman-Assif et al., 2010)

(Holtzman-Assif et al., 2010)

(Holtzman-Assif et al., 2010)

L-741,741 (D4 ant)

no effect

(Pfeiffer & Fendt, 2006)

1 drug administration following extinction training, 2 37 days, 3 increased locomotion, 4 passive avoidance paradigm, 5 reduced locomotion with 0.3mg/kg, no effect on locomotion, extinction training and retrieval with 0.1mg/kg, 6 rescued impaired extinction retrieval in estrus/metestrus/diestrus, 7 impairs extinction retrieval in proestrus

* facilitates rescue of impaired fear extinction; # reduced fear expression at the beginning of extinction training; ## enhanced fear expression at the beginning of extinction training

+, improved; -, impaired; (+) or (-), only minor effects; ip, intraperitoneal injection; ns, not studied; BLA, intra-basolateral amygdala administration; IL, infralimbic cortex; mPFC, medial prefrontal

cortex; CA1, cornu ammonis 1; NAcb, nucleus accumbens; Ren-A, Fear renewal in conditioning context; SR, spontaneous recovery; Re-in, reinstatement; ag, agonist; ant, antagonist, KO, knock-out;

Table 2A: Human trials: Dopaminergic enhancers combined with CBT

Disorder Study Design Outcome (compared to placebo control group) Reference

Healthy volunteers Fear conditioning paradigm, L-DOPA po following extinction training Protection from renewal (skin conductance responses) (Haaker et al., 2013)

PTSD (treatment-refractory ) 2 single oral MDMA prior to 8h therapy session (3-5 weeks apart, patients also received therapy prior to first MDMA exposure as well as between and in follow-up) MDMA augmented CBT in comparison to placebo (83% vs 25% response) (2 month follow-up); open-label MDMA use offered to patients from the placebo group after last assessment (Mithoefer et al., 2011)

PTSD (treatment-refractory ) Follow-up study from (Mithoefer et al., 2011) MDMA augmented CBT produced long-lasting effects (17-74 months) (Mithoefer et al., 2013)

4.3 Noradrenergic system

The noradrenergic system is crucial for both the formation and the maintenance of fear memories, as well as for extinction memories (reviewed in (Holmes & Quirk, 2010; Mueller & Cahill, 2010)). Noradrenaline can enhance neuronal excitability in extinction-relevant brain regions such as the IL (Mueller et al., 2008) and successful fear extinction is associated with enhanced extracellular levels of noradrenaline in the mPFC (Hugues et al., 2007). Boosting noradrenaline levels, via administration of either noradrenaline itself (Merlo & Izquierdo, 1967) or of compounds such as yohimbine (see below) or methylphenidate (Abraham et al., 2012) enhances fear extinction (Table 3). There is evidence from preclinical studies that activating P-adrenoceptors, one target receptor of noradrenaline, can also facilitate fear extinction (Table 3) [for recent review, see (Fitzgerald et al., 2014a)]. Conversely, depleting central noradrenaline or lesioning ascending noradrenaline projections from the locus coeruleus, impairs extinction, as does systemic alpha1 or G adrenoceptor blockade (Table 3) [reviewed in (Mueller & Cahill, 2010)].

There has been interest in the clinical utility of targeting noradrenergic mechanisms to augment extinction. Here, we focus on a2-adrenoceptors given the recent clinical findings supporting the utility of a2-adrenoceptor antagonists in improving extinction. Based on results of rodent studies (Cain et al., 2004), two small clinical studies (Powers et al., 2009; Smits et al., 2014) have shown that combining yohimbine with CBT can reduce anxiety in patients with social anxiety disorder and claustrophobic fear (Table 3A). A third study found no CBT-augmenting benefit of yohimbine in patients with fear of flying; however, CBT may have exerted a 'ceiling effect' that occluded the drug's effect (Meyerbroeker et al., 2012).

In rodents, blocking a2-adrenoceptors (e.g., with yohimbine) that function as autoreceptors on locus

coeruleus neurons increases locus coeruleus activity and noradrenaline release in terminal regions

(Singewald & Philippu, 1998). Yohimbine is anxiogenic and increases neuronal activity in widespread

brain areas, including extinction-relevant areas such as the amygdala, mPFC and HPC (Singewald et

al., 2003). Downstream targets of yohimbine-induced noradrenaline release include pi-adrenoceptors, and increasing activity at these receptors in locus coeruleus terminal regions (mPFC) enhances extinction (Do-Monte et al., 2010b), possibly via facilitating extinction-relevant long-term potentiation (Gelinas & Nguyen, 2005) in a BDNF-dependent manner (Furini et al., 2010). Yohimbine facilitates extinction in rodents, including extinction-impaired subjects (Hefner et al., 2008), 2008), though a more selective a2-adrenoceptor, atipamezole, does not (Table 3) [for further discussion, see (Holmes & Quirk, 2010)]. Yohimbine also protects against spontaneous fear recovery, in a manner similar to the effect of a noradrenaline uptake inhibitor, atomoxetine (Janak & Corbit, 2011). However, yohimbine reduces fear only in the extinction context in which the drug was administered (Morris & Bouton, 2007), which would be a limitation of the clinical goal of achieving context-independent reductions in fear. Thus, other strategies may be needed, including combination strategies where drugs which do produce context-independent extinction, for example targeting HDACs (see Section 4.10 Epigenetics), are combined with yohimbine.

Table 3 Noradrenergic (NE) signaling in fear extinction (preclinical studies)



noradrenaline ns + ns icv (Merlo & Izquierdo, 1967)

methylphenidate + + ns ip (Abraham et al., 2012)

noradrenaline ns +1 ns BLA (Berlau & McGaugh, 2006)

ns no effect1 ns BLA (Fiorenza et al., 2012)

ns no effect1 ns CA1 (Fiorenza et al., 2012)

ns 1 ns IL (Fiorenza et al., 2012)

atomoxetine (NE reuptake inhibitor) ns no effect6 + (SR)5 systemic (Janak & Corbit, 2011)

isoproterenol (P ag) no effect ns ns iP (subchronic) (Do-Monte et al., 2010b)

ns (+)1 ns iP (subchronic) (Do-Monte et al., 2010b)

ns (+)1 ns mPFC (Do-Monte et al., 2010b)

yohimbine (a2 ant)8 + ns ns sc (Cain et al., 2004)

ns no effect1 ns sc (Cain et al., 2004)

+#2 +2 ns sc (Cain et al., 2004)

+ + - iP (Morris & Bouton, 2007)

no effect7 no effect ns iP (Mueller et al., 2009)

ns +* ns iP (Hefner et al., 2008)

ns no effect6 + (SR)5 systemic (Janak & Corbit, 2011)

atipamezole (a2 ant)8 ns no effect4 ns sc (Davis et al., 2008)



no effect1 iP (subchronic)

prazosine (al ant) ns ns (Do-Monte et al., 2010a)

- ns ns ip (subchronic) (Do-Monte et al., 2010a)

- ns ns intra-mPFC (Do-Monte et al., 2010a)

propanolol (P ant) no effect ns ns sc (Cain et al., 2004)

ns no effect1 ns sc (Cain et al., 2004)

no effect2 (-)3 ns sc (Cain et al., 2004)

(+)# no effect ns ip (Rodríguez-Romaguera et al., 2009)

- - ns ip (subchronic) (Do-Monte et al., 2010b)

ns no effect1 ns iP (subchronic) (Do-Monte et al., 2010b)

- ns ns mPFC (Do-Monte et al., 2010b)

atenolol (P ant) ns no effect1 ns mPFC (Do-Monte et al., 2010b)

sotalol (P ant) no effect no effect ,1 ns iP (Rodríguez-Romaguera et al., 2009)

timolol (P ant) propanolol (P ant) ns no effect ns ns IL (Mueller et al., 2008)

ns no effect1 ns IL (Mueller et al., 2008)

timolol (P ant) ns +1 ns IL (Fiorenza et al., 2012)

ns no effect1 ns CA1 (Fiorenza et al., 2012)

drug administration following extinction training; spaced CS extinction, US=0.7mA; 3 spaced CS extinction when US=0.4mA; no effect when US=0.7mA, 4 cocaine-conditioned place preference, 5 4 weeks, 6 instrumental lever press response, 7 reduced fear expression at start of extinction training, if extinction is performed in the same context as conditioning, 8 note that the net effect of a2 blockade is enhancement of noradrenergic signaling (see text)

* facilitates rescue of impaired fear extinction; ** facilitates extinction of remote memories, *** only in older animals (7 months), younger ones (2 months) are not affected, # reduced fear expression at the beginning of extinction training

+, improved; -, impaired; (+) or (-), only minor effects; ip, intraperitoneal injection; injection; sc, subcutanous injection; icv, intracerebroventricular injection; ns, not studied; HPC, intra-hippocampal administration; BLA, intra-basolateral amygdala administration; IL, infralimbic cortex; PL, prelimbic cortex; CA1, cornu ammonis 1; Ren, Fear renewal; SR, spontaneous recovery; Re-in, reinstatement; ag, agonist; ant, antagonist, KO, knock-out; #, reduced fear expression at start of extinction training

Table 3A: Yohimbine combined with CBT in small-scale clinical trials

Disorder Study Design Outcome (compared to placebo control group) Reference

Social anxiety disorder (SAD) 4 sessions consisting of yohimbine being administered prior to a CBT a session Yohimbine augmented CBT-induced improvement in SAD (self-report measures; 21 day follow-up) (Smits et al., 2014)

Claustrophobic fear 1 single oral yohimbine dose prior to an exposure b session Yohimbine augment CBT-induced reduced fear of enclosed spaces (7 day follow-up) (Powers et al., 2009)

Fear of flying 2 single oral yohimbine prior to VRET session No fear augmenting effect of yohimbine c (Meyerbroeker et al., 2012)

a CBT involved an oral presentation on challenging topics in front of the therapists, other group members,

and confederates, b behavioral approach task,

c lack of yohimbine effect might possibly have been due to the powerful influence of VRET exposure itself leading to a greater impact on the results from this than from the manipulation (drug condition) that 'washed out' or overrode any effect of manipulation (Meyerbroeker et al., 2012), VRET, virtual reality exposure.

4.4 Glutamatergic system

Glutamatergic signaling plays a crucial role in synaptic plasticity and many forms of learning and memory, including fear extinction (see Figure 6 for an overview). Fast excitatory glutamatergic signaling is mediated by ionotropic receptors (NMDA and AMPA), and slower signaling by metabotropic (mGluR1-8) receptors. Group I (mGluRl and mGluR5) receptors are mainly expressed postsynaptically and coupled to Gq proteins enhancing phospholipase C (PLC) activity. Group II (mGluR2, mGluR3) and Group III (mGluR4, mGluR6-mGluR8) are both coupled to Gi proteins inhibiting adenylate cyclase (AC) activity and expressed on pre- as well as postsynaptic sites (Willard & Koochekpour, 2013).

Pharmacological potentiation of AMPA receptor activation (by PEPA) facilitates extinction learning and retrieval (Zushida et al., 2007; Yamada et al., 2009; Yamada et al., 2011), although it is ineffective in severely extinction-impaired subjects (Whittle et al., 2013). Studies using localized infusion of AMPA potentiators (Zushida et al., 2007) and blockers (Falls et al., 1992; Zimmerman & Maren, 2010; Milton et al., 2013) coupled with electrophysiological recordings suggest that AMPA-mediated effects on extinction are localized to the mPFC [(Zushida et al., 2007) see Table 4, for recent detailed reviews (Myers et al., 2011; Bukalo et al., 2014)].

The part played in extinction by the metabotropic glutamate receptors mGluR1, mGluR5 and mGluR7 has also been evaluated. Antagonizing mGluR1 (which is expressed on ITC innervating neurons (Busti et al., 2011) with CPCCOEt (Kim et al., 2007) and antagonizing mGluR5 receptors in the IL (Sepulveda-

Orengo et al., 2013) have been shown to impair extinction. Furthermore, gene mutations resulting in deficits in mGluR5 (Xu et al., 2009) or mGluR7 (Callaerts-Vegh et al., 2006; Fendt et al., 2008; Goddyn et al., 2008) impair extinction learning, while selective activation (Rodrigues et al., 2002; Fendt et al., 2008; Siegl et al., 2008; Morawska & Fendt, 2012; Toth et al., 2012b; Dobi et al., 2013; Whittle et al., 2013) improves extinction [see Table 4 for summary and (Myers et al., 2011; Bukalo et al., 2014) for more details].

The most extensively studied glutamate receptor in relation to fear extinction is the NMDA receptor (NMDAR). As shown in Table 4, systemic or local administration of NMDAR antagonists into the BLA or mPFC produces extinction deficits [reviewed in (Myers et al., 2011)]. Due to the potential for major side-effects (e.g. excitotoxicity) a general enhancement of NMDAR transmission is clinically undesirable and more subtle modulation of NMDAR signaling is required. NMDARs are specialized voltage-dependent, ligand-gated ion channels that are expressed as heterotetramers formed by GluN1 in combination with GluN2 or GluN3 subunits. To date, eight different splice variants of the GluN1 subunit, four distinctive GluN2 (GluN2A-D) subunits and two GluN3 (GluN3A-B) subunits have been identified [for review see (Paoletti et al., 2013)]. Activation of NMDARs requires L-Glutamate binding to GluNR2 subunits, L-glycine or D-serine binding to GluNR1 subunits and membrane depolarization relocating the channel pore-blocking Mg2+ and Zn2+ ions.

The repertoire of NMDAR subunits permits the assembly of a range of NMDARs with varying dissociable signaling properties. Systemic (Sotres-Bayon et al., 2007; Dalton et al., 2008; Dalton et al., 2012; Leaderbrand et al., 2014) or localized BLA (Sotres-Bayon et al., 2007; Laurent & Westbrook, 2008; Sotres-Bayon et al., 2009) or mPFC (Laurent & Westbrook, 2008; Sotres-Bayon et al., 2009) inhibition of GluN2B-containing NMDARs (via ifenprodil or Ro25-6981) disrupts extinction. Conversely, GluN2B overexpression enhances extinction (Tang et al., 1999). Recently, facilitated signaling of GluN2C/D -containing NMDARs in the BLA (via CIQ infusion) was also demonstrated to enhance extinction (Ogden et al., 2014). The contribution of other subunits, such as GluN2A, remains to be determined.

The organization of NMDARs provides additional druggable pharmacological targets. GluN1 and GluN2 subunits are endowed with binding sites for positive and negative allosteric regulations that enable fine-tuning of NMDAR activity. The GluN1 subunit contains an inhibitory H+ binding site rendering GluN2B/D-containing NMDARs in particular sensitive to local pH changes, as well as to endogenous molecules with redox potential (Banke et al., 2005). The GluNR2 subunit is responsive to allosteric modification of NMDAR signaling by polyamines such as spermidine. Spermidine-induced activation of GluN2B signaling facilitates the consolidation of extinction (Guerra et al., 2006; Gomes et al., 2010), while arcaine, an antagonistic polyamine, disrupts extinction (Gomes et al., 2010). A GluN2 allosteric binding site -still uninvestigated in the field of fear extinction - enables modulation of NMDAR signaling by neurosteroids (i.a. allopregnanolone) (Irwin et al., 1994). Nuanced pharmacological modulation of NMDARs can also be achieved by targeting the Zn2+ binding domain found on GluN2 subunits. Zn2+-binding to this modulatory site mainly inhibits GluN2A-containing NMDARs, by reducing NMDAR channel open probability (Paoletti et al., 1997). Brain Zn2+ signaling which, in addition to the NMDAR binding site, acts via other sites including the GPR39 Zn-sensing receptor (Holst et al., 2007), has been shown to exert both enhancing and attenuating effects on learning and memory via complex interactions with neurotransmitters and synaptic plasticity mechanisms (reviewed in (Takeda & Tamano, 2014). Dietary Zn2+ supplementation impairs extinction (Railey et al., 2010), while dietary-induced reduction of brain Zn2+ levels rescues greatly deficient extinction (Whittle et al., 2010). Although these effects may be mediated by Zn2+ modulation of NMDAR signaling, other actions cannot be excluded (e.g., see discussion on HDAC inhibition in Section 4.10: Epigenetics). The same is true for another NMDAR-modulating ion, Mg2+, which has also been shown to facilitate extinction when globally enhanced in the brain (Abumaria et al., 2011; Mickley et al., 2013).

The most extensively investigated allosteric modulation of NMDARs is mediated via the L-glycine binding site on the GluN1 subunit. As shown in Table 4, systemic administration of ligands on this binding site, D-serine or D-cycloserine (DCS), augments extinction consolidation [see (Myers et al.,

2011; Bukalo et al., 2014) for recent detailed reviews]. There is evidence (although not consistent) that DCS may promote generalization of the extinction effect (Ledgerwood et al., 2005; Vervliet, 2008) that is, to other cues (e.g. odors, sounds, visual stimuli) that acquired fear during a more complex conditioning situation. Generalized extinction could be of potential clinical benefit, provided that cues that trigger adaptive reactions are not affected. However, DCS administration outside the consolidation window can limit the drug's effectiveness. When extinction or exposure sessions are too short or yield insufficient fear inhibition, DCS can strengthen (re-)consolidation of the original fear memory. Along these lines, the extinction augmenting effects of DCS require the subject to show at least some ability to extinguish (Tomilenko & Dubrovina, 2007; Weber et al., 2007; Bouton et al., 2008; Hefner et al., 2008; Bolkan & Lattal, 2013; Smits et al., 2013b; Whittle et al., 2013). Finally, chronic DCS treatment leads to loss of effects on extinction, possibly via NMDAR desensitization (Quartermain et al., 1994; Parnas et al., 2005). It is of note, that chronic treatment with antidepressants also disrupts the facilitating effects of DCS on extinction, possibly by interfering with NMDAR function (Werner-Seidler & Richardson, 2007).

Notwithstanding these caveats, DCS represents one of the best examples of translational research paving the way for novel anxiety treatments. DCS augmentation of CBT has been clinically studied in various anxiety disorders (Table 4A) including among pediatric patients [see (Hofmann et al., 2013a) for a recent review]. To summarize the current clinical data, DCS-augmented CBT shows advantages in PTSD (de Kleine et al., 2012; Difede et al., 2014; Scheeringa & Weems, 2014), specific phobia (Ressler et al., 2004; Guastella et al., 2007; Nave et al., 2012), SAD (Hofmann et al., 2006; Guastella et al., 2008; Hofmann et al., 2013b; Smits et al., 2013c) and OCD [(Kushner et al., 2007; Wilhelm et al., 2008; Chasson et al., 2010; Storch et al., 2010; Farrell et al., 2013) but see (Mataix-Cols et al., 2014)]. Panic disorder patients (Otto et al., 2010c; Siegmund et al., 2011) also show faster symptom alleviation after DCS-augmented CBT. Reflecting the preclinical findings, negative outcomes were associated with short CBT sessions (Litz et al., 2012), insufficient within-session fear inhibition (Smits et al., 2013b; Tart et al., 2013), chronic DCS treatment (Heresco-Levy et al., 2002), DCS administration

outside the therapeutic temporal window (Storch et al., 2007) and subclinical levels of fear [(Guastella et al., 2007; Gutner et al., 2012) but see (Kuriyama et al., 2011)].

If these factors are properly attended to [see above, reviewed in (Hofmann, 2014)], the evidence supports the adjunctive treatment of CBT with DCS for a range of anxiety disorders. Table 4 Glutamatergic signaling in fear extinction (preclinical studies)



no effect* no effect* ns iP (Whittle et al., 2013)

PEPA (AMPA no effect* +* ns iP (Yamada et al., 2011)

potentiator) + (Re-in)

+# + iP (Yamada et al., 2009)

+ + ns iP (Zushida et al., 2007)


no effect no effect ns iP (Zushida et al., 2007)

PEPA (AMPA (+) (+) ns PL (Zushida et al., 2007)


+ + ns BLA/ceA (Zushida et al., 2007)


CNQX (AMPA ant) ns no effect ns BLA (Falls et al., 1992; Lin et al., 2003b; Zimmerman & Maren, 2010)



D-cycloserine ns + +i ns iP (Walker et al., 2002)

ns +1 +i ns + (Re-in) systemic systemic (Ledgerwood et al., 2003) (Ledgerwood et al., 2004)

ns +1 ns ns systemic iP (Ledgerwood et al., 2005) (Parnas et al., 2005)

ns ns + + ns ns ip ip (Yang & Lu, 2005) (Lee et al., 2006)

ns + no effect ns sc sc (Woods & Bouton, 2006) (Werner-Seidler & Richardson, 2007)

ns + ns systemic (Weber et al., 2007)

ns + ns ip (Yang et al., 2007)

ns + ns ip (Yang et al., 2007)

ns + ns ip (Hefner et al., 2008)

ns + ns p° (Yamamoto et al., 2008)

ns + ns ip (Matsumoto et al., 2008)

+ + ns ip (Silvestri & Root, 2008)

ns + ns (sc (Langton & Richardson, 2008)

ns + no effect sc (Bouton et al., 2008)

ns + ns ip (Lin et al., 2010)

+# + + (Re-in) ip (Yamada et al., 2009)

+ ns ns ip (Lehner et al., 2010)

ns +1 ns systemic (Langton & Richardson, 2010)

no effect* +* ns ip (Yamada et al., 2011)

no effect + ns ip (Toth et al., 2012b)

ns +1 ns ip (Toth et al., 2012b)

ns + ns ns systemic ip (Gupta et al., 2013) (Matsuda et al., 2010)

+ + ns ip (Bai et al., 2014)

ns +1* ns ip (Whittle et al., 2013)

ns + ns BLA (Walker et al., 2002)

ns +1 ns BLA (Ledgerwood et al., 2003)

ns + ns BLA (Lee et al., 2006)

ns + ns BLA (Mao et al., 2008)

ns + ns BLA (Lee et al., 2006)

ns + ns BLA (Akirav et al., 2009)

ns no effect ns BLA (Bolkan & Lattal, 2013)

ns + ns HPC (Bolkan & Lattal, 2013)

ns + ns HPC (Ren et al., 2013)

spermidine ns +1 ns HPC (Gomes et al., 2010)



MK-801 (noncompetitive ns - ns systemic (Baker & Azorlosa, 1996; Storsve et al., 2010)

NMDA ant) ns ns + (Re-in) sc (Johnson et al., 2000)

ns 1 ns ip (Lee et al., 2006; Liu et al., 2009)

ns - ns systemic (Langton et al., 2007; Chan & McNally, 2009)

CPP (competitive NMDA ant) no effect 5 ns ip (Santini et al., 2001; Sotres-Bayon et al., 2007)

no effect - ns mPFC (Burgos-Robles et al., 2007)

ns 1 ns mPFC (Burgos-Robles et al., 2007)

- - ns BLA (Parsons et al., 2010)

AP-5 (competitive NMDA ant) ns - ns BLA (Falls et al., 1992)

## - ns BLA (Lee & Kim, 1998)

ns 1 ns BLA (Lin et al., 2003a; Laurent et al., 2008) (Fiorenza et al., 2012)

no effect - ns BLA (Lin et al., 2003a; Zimmerman & Maren, 2010)

ns - ns CA1 (Szapiro et al., 2003)

ns 1 ns CA1 (Fiorenza et al., 2012)

ns 1 ns mPFC (Fiorenza et al., 2012)

ifenprodil (non-comp NR2B-NMDA ant) - 1 ns ip (Sotres-Bayon et al., 2007)

ns - ns ns systemic BLA Sotres-Bayon et al., 2009 (Sotres-Bayon et al., 2007; Laurent et al., 2008; Laurent & Westbrook, 2008)

ns no effect1 ns BLA (Laurent et al., 2008; Laurent & Westbrook, 2008; Sotres-Bayon et al., 2009)

no effect - ns mPFC (Laurent & Westbrook, 2008)

no effect no effect no effect 1 ns ns mPFC (Sotres-Bayon et al., 2009) (Laurent & Westbrook, 2008; Sotres-Bayon et al., 2009)

ns 1 ns HPC (Gomes et al., 2010)

Ro25-6981 (non-comp NR2B-NMDA ant) - no effect ns ip (Dalton et al., 2008; Dalton et al., 2012)



(mGluR5 pos +3 ns ns sc (Gass & Olive, 2009)


AMN082 +* +* ns ip (Whittle et al., 2013)

(mGluR7 ag) ns + ns p° (Fendt et al., 2008)

- no effect ns ip (Toth et al., 2012b)

ns i ns ip (Toth et al., 2012b)

(+) no effect ns BLA (Dobi et al., 2013)

- - ns mPFC (Morawska & Fendt, 2012)


CPCCOEt - - ns BLA (Kim et al., 2007)

(non-comp mGluR1 ant) no effect no effect no effect (SR) ip (Mao et al., 2013)

mGluR4 KO ns + ns no drug (Davis et al., 2013)

mGluR5 KO - - ns no drug (Xu et al., 2009)

MTEP no effect - (SR) ip (Mao et al., 2013)

(mGluR5 ant) ns ns (SR) BLA (Mao et al., 2013)

no effect no effect ns ip (Toth et al., 2012b)

MPEP ns no effect1 ns ip (Toth et al., 2012b)

(allosteric no effect - ns ip (Fontanez-Nuin et al., 2011)

mGluR5 ant) no effect - ns IL (Fontanez-Nuin et al., 2011)

- - ns IL (Sepulveda-Orengo et al., 2013)

4 ns ns no drug (Callaerts-Vegh et al., 2006; Goddyn et

mGluR7 KO al., 2008)

+ + ns no drug (Fendt et al., 2013)

siRNA knock-

down of 2 ns ns no drug (Fendt et al., 2008)


mGluR8 KO no effect* no effect ns no drug (Fendt et al., 2013)

(S)-3,4-DCPG (mGluR8 ag)

- no effect ns BLA (Dobi et al., 2013)

Mrug administration following extinction training; Conditioned taste aversion; 3 cocaine conditioned place preference; 4 food-rewarded operant conditioning, 5 reduced locomotion

* facilitates rescue of impaired fear extinction; # reduced fear expression at the beginning of extinction training; ## enhanced fear expression at the beginning of extinction training

+, improved; -, impaired; (+) or (-), only minor effects; po, peroral administration; ip, intraperitoneal injection; sc, subcutaneous injection; ns, not studied; BLA, intra-basolateral amygdala administration; HPC, hippocampus; IL, infralimbic cortex; SR, spontaneous recovery; Re-in, reinstatement; ag, agonist; ant, antagonist, KO, knock-out;

Table 4A: Human trials: D-cycloserine (DCS) combined with CBT

Disorder Study Design Outcome (compared to placebo control group) Reference

Healthy volunteers DCS or placebo 2-3h prior extinction training No effect on fear extinction or fear recovery in healthy volunteers (Guastella et al., 2007)

Healthy volunteers DCS, placebo, valproic acid or combination of DCS and Administration of DCS, valproic acid or DCS/valproic acid (Kuriyama et al., 2011)

valproic acid 1.5h prior extinction training combination facilitates fear extinction and protects from reinstatement

Healthy volunteers DCS or placebo 2h prior extinction training No effect on extinction learning and retention in healthy volunteers (Klumpers et al., 2012)

Acrophobia DCS or placebo 1h prior 2 sessions of virtual reality exposure 3 month follow-up reduced fear symptoms in DCS group at all timepoints (Ressler et al., 2004)

2 sessions virtual reality exposure plus DCS or placebo after the sessions no advantage of DCS over placebo augmented VRE (Tart et al., 2013)

Acrophobia 1 month follow-up Re-evaulation of Tart et al., 2013 DCS effect depends on success of exposure sessions (within-session fear reduction) (Smits et al., 2013a)

Snake phobia DCS or placebo 1h prior a single exposure session same level of improvement with DCS, but DCS group achieved fear reduction quicker (Nave et al., 2012)

Panic disorder DCS or placebo 1h prior CBT session 3-5 1 month follow-up DCS group showed greater reduction in panic symptom severity at all timepoints (Otto et al., 2010c)

Panic disorder with agoraphobia DCS or placebo 1h prior 3 individual exposure sessions + 8 group CBT sessions 5 months follow-up no benefits of DCS at all timepoints, but initial benefical effects in severely symptomatic patients? (Siegmund et al., 2011)

PTSD < DCS or placebo 1h prior 10 weekly exposure sessions No overall enhancement of treatment effects. Higher symptom reduction in severe cases. (de Kleine et al., 2012)

PTSD (combat- related) DCS or placebo 30min prior exposure session 2-6 Weaker symptom reduction compared to placebo group (Litz et al., 2012)

PTSD DCS or placebo 1.5h prior 12 weekly VRE session 6 months follow-up DCS group showed earlier and greater improvement as well as higher remission rates (Difede et al., 2014)

pediatric PTSD DCS or placebo 12 1h prior session 5-12 No difference in symptom reduction, DCS group showed trend for faster response and better retention in 3 month follow-up (Scheeringa & Weems, 2014)

SAD 1x psychoeducation; DCS or placebo 1h prior to 4h exposure session (5x, individual or group) Decreased self-reported social anxiety symptoms in DCS group after 1 month (Hoffmann et al., 2006)

1 month follow-up

SAD DCS or placebo 1h prior to 4h exposure therapy (5x) Fewer social fear and avoidance in DCS group. Significant differences in DCS vs placebo following 3rd exposure session. (Guastella et al., 2008)

SAD DCS or placebo with CBT Greater overall rates of improvement and lower post-treatment severity (Smits et al., 2013b)

SAD 12 weeks; DCS or placebo 1h prior 5 exposure sessions (12 sessions at all); 6-months follow-up similar response and remission rates, DCS group improved quicker (Hofmann et al., 2013b)

OCD D-cycloserine (DCS) or placebo 4h prior each exposure session, 12 weeks (one exposure session/week) No statistically significant difference. High response rates in treatment and placebo group. (Storch et al., 2007)

OCD 2x/week DCS or placebo 2h prior exposure and response prevention (ERP) sessions (max 10) 3 months follow-up Faster improvements in DCS group No difference between DCS and placebo group (no further benefit). (Kushner et al., 2007)

OCD 2x/week DCS or placebo 1h prior 10 ERP sessions 1 month follow-up Re-evaluation of Wilhelm et al., 2008 Faster improvements in DCS group No difference between DCS and placebo group (no further benefit). specific improvements of DCS in the first 5 sessions, 6x faster than placebo group (Wilhelm et al., 2008) (Chasson et al., 2010)

Pediatric OCD DCS or placebo 1h prior weekly session 4-10 (psychoeduction, cognitive training and ERP) for 10 wks modest reduction of obsessive symptoms (Storch et al., 2010)

Pediatric OCD DCS or placebo 1h prior session 5-9 ERP-CBT Significant improvements in OCD severity from posttreatment to 1-month follow-up in severe and difficult-to-treat pediatric OCD (Farrell et al., 2013)

Pediatric OCD DCS or placebo immediately after each of 10 CBT (ERP) sessions 1 year follow-up both groups improved; no significant advantage of DCS at any timepoint (Mataix-Cols et al., 2014)

4.5 Y-aminobutyric acid (GABA)

GABA is the main inhibitory neurotransmitter in the adult mammalian brain. Because extinction largely reflects the promotion of active inhibitory processes, it is not surprising that GABA serves as an important source of such inhibition. GABA signaling occurs largely via binding to ionotropic GABAa and metabotropic GABAB receptors (former GABAC receptors have been reclassified and are now termed GABAa rho-subclass receptors). GABAa receptors are pentameric, ligand-gated Cl- channels which, upon activation induce hyperpolarization of cells and hence reduce neuronal excitability. Seven classes of GABAA subunits (ai-6, p1-3, Yi-3, Pi-3, 5, 0) have been identified so far, permitting the assembly of highly variable GABAA receptors with distinct functions and signaling properties. Furthermore, several allosteric binding sites, in addition to the GABA binding pocket located at the a/P-subunit interface, allow nuanced modifications of GABAA receptor signaling. The allosteric benzodiazepine (BZD) binding site is localized at the interface of a-and y- subunits and when activated, facilitates GABAergic transmission by promoting GABA binding to the receptor and increasing the opening probability of the Cl- channel. The binding sites of other allosteric modulators of GABAA signaling including barbiturates and neurosteroids among others are not yet fully characterized [see Figure 7 and (Makkar et al., 2010; Gunn et al., 2014)].

In preclinical studies, the robust inhibitory effect of full GABAA receptor agonists at the GABA binding site (a/P-subunit interface) (e.g. muscimol), is often used to inactivate a brain region to clarify its participation in certain functions including extinction. Muscimol-injections into the BLA (Laurent et al., 2008; Laurent & Westbrook, 2008; Sierra-Mercado et al., 2011), mPFC/IL (Laurent & Westbrook, 2008, 2009; Sierra-Mercado et al., 2011) and HPC [(Corcoran et al., 2005; Sierra-Mercado et al., 2011), see Table 5 for a summary] disrupt extinction learning and memory, supporting the crucial involvement of these areas. However, muscimol infusion into the BLA and IL facilitates extinction in some studies (Akirav et al., 2006).

There is solid evidence that fear extinction learning is associated with upregulation of GABAergic markers in the AMY, underscoring the importance of a certain level of GABAergic signaling in this brain area for the successful formation of extinction memories. For example, levels of gephyrin, a clustering protein facilitating postsynaptic scaffolding of GABAa receptors, were enhanced 2 hours following extinction training along with enhanced surface expression of GABAa receptors in the BLA (Chhatwal et al., 2005a). Extinction learning also increases GABAa receptor a2- and p2 subunit mRNA and levels of the GABA-synthesizing enzyme glutamate decarboxylase (GAD) and the GABA transporter GAT1 (Heldt & Ressler, 2007). Further demonstrating the importance of GABAergic signaling to extinction, fear extinction learning is disrupted by mutation-induced deficits in the activity-dependent GAD isoform GAD65 (Sangha et al., 2009), and by viral knock-down of the constitutive GAD isoform GAD67 (Heldt et al., 2012). While these findings suggest that upregulation of GABAergic signaling supports extinction, GABAA receptor antagonists such as picrotoxin or bicuculline can enhance extinction memories when administered systemically (McGaugh et al., 1990), or when infused into the BLA (Berlau & McGaugh, 2006) or specific (fear promoting) areas (PL) of the mPFC (Thompson et al., 2010; Fitzgerald et al., 2014b). The reason for these apparent contradictions is not yet clear.

Preliminary findings from studies using genetically modified mice suggest that the development of subunit-selective GABAa receptor drugs could be a promising way to more distinctly utilize GABAergic mechanisms facilitating extinction. For example, there is reduced mRNA expression of a5 and y1 subunits in the AMY of a mouse model of enhanced anxiety (Tasan et al., 2011) displaying impaired extinction (Yen et al., 2012). In addition, deletion of a5-containing GABAA receptors in the HPC is sufficient to impair fear extinction recall (Yee et al., 2004) while global deletion of the GABAA a3 subunit produces modest improvements in extinction learning (Fiorelli et al., 2008).

An additional possible explanation for some paradoxical findings concerning GABA regulation and AMY function in extinction is the fact that most of the prior studies have performed pharmacological or genetic manipulations that affect either the entire brain, just the AMY, or even only AMY subregions. Despite this, we now know that GABA receptors are found on most of the neuronal cell types and thus even a subregion-specific manipulation is likely to affect many different cell populations which may have opposing functional effects. One recent attempt to address this complexity involved the use of an inducible GABAal knockout strategy limited only to the corticotropin-releasing-hormone containing neuronal population (Gafford et al., 2012) ), which revealed relatively specific effects, including enhanced anxiety and extinction deficits. It si likely that future studies aimed at cell-type specific manipulations will help address the vast complexity of the many different cell types combined with the large number of different GABA receptor populations.

As mentioned above, the multiple different binding sites found within GABAa receptors can be used to elicit a more nuanced modulation of GABAA receptor activity. Positive allosteric modulation of GABAA receptor activity via BZD, represents the most widely described drug-based strategy for acute treatment of anxiety states (Macaluso et al., 2010). The prevalence of BZD use among patients suffering from mental disorders is high, and is estimated to range between 40 and 70 % of these patients (Clark et al., 2004) However anxiolytic treatment with BZDs is recommended only for short periods of time, due to several disadvantages including its sedative effects, the development of dependence and difficulties with discontinuing chronic treatment (Otto et al., 2002). The sedating and calming effects of BZDs might in fact interfere with extinction possibly via reduced arousal and decreased release of neurochemicals (e.g. noradrenaline) and stress hormones (e.g. glucocorticoids) that support extinction [(Bentz et al., 2010), see Section 4.8 Glucocorticoids) for details]. BZDs may also render extinction memories dependent on the drug-induced internal anxiolytic-state (state dependent learning), which upon BZD discontinuation may no longer be accessible. These concerns are borne out by preclinical data showing that systemic (Goldman, 1977; Pereira et al., 1989; Bouton et al., 1990; Bustos et al., 2009; Hart et al., 2009, 2010; Hart et al., 2014) or intra-BLA (Hart et al.,

2009, 2010) BZD administration impairs extinction (Table 5), presumably also through state-dependent mechanisms. Systemic treatment with a BZD inverse agonist (Harris & Westbrook, 1998; Kim & Richardson, 2007, 2009) has similar effects (see Table 5 for a summary]. Hence, combining BZD with CBT needs careful consideration. As well as further development of BZDs targeting specific subunits of the GABAA receptor [reviewed in (Griebel & Holmes, 2013)], which provides some hope, there is preliminary evidence that putative novel anxiolytics that do not impair extinction learning [e.g. neuropeptide S; (Slattery et al., in press) see Section 4.7 Neuropeptides] can be developed to help reduce patients' aversion to the unpleasant and demanding procedure of recalling details of their traumatic memories, thus increasing their willingness to interact with the psychotherapist.

In contrast to the relatively large number of studies of the GABAA receptor, only a few studies have investigated the role of GABAB receptors. Functional GABAB receptors are heterodimers containing a GABAB1 and a GABAB2 subunit; the GABAB1 subunit has two isoforms - GABAB1a and GABAB1b (Fritschy et al., 1999). While functional deletion of GABAB receptors (GABABia/b knock-out) impairs extinction learning (Jacobson et al., 2006), pharmacological GABAB receptor antagonism does not (Heaney et al., 2012; Sweeney et al., 2013).. Systemic administration of (non-selective) agonists or positive allosteric modulators of GABAB signaling also has inconsistent effects (impairing or negative) on extinction [(Heaney et al., 2012; Sweeney et al., 2013) see Table 5]. A final answer to this question regarding the role of GABAB receptors may have to await the availability of GABAB1a-and GABAB1b-selective compounds

Taken together, the available evidence indicates that GABA signaling has a major, but spatially and

temporally restricted role in the formation of fear extinction memories. While GABA that is engaged

during extinction is likely to support synaptic plasticity, increasing GABAergic tone globally seems to

limit the efficacy of extinction-based therapies by mechanisms outlined above. Therefore, it is

unlikely that drugs broadly targeting the GABA system will be useful in this respect. Pharmacological

adjuncts to exposure therapy targeting the GABA system would rather need to strike a balance

between driving and maintaining relevant GABA activity without over-activating the system. The

evidence so far suggests that subunit-selective or allosteric (distinct from BZD) modulation of GABA, receptor signaling may hold promise in this regard.

Table 5 GABAergic signaling in fear extinction (preclinical studies)



GABAa Agonists GABA-binding site (aß interface)

muscimol +# no ^ effect ,1,7 ns BLA (Akirav et al., 2006)

ns # ns ns BLA (Laurent et al., 2008; Laurent & Westbrook, 2008)

ns 1 ns BLA (Laurent & Westbrook, 2008)

(+)# - ns BLA (Sierra-Mercado et al., 2011)

- - ns mPFC (Laurent & Westbrook, 2008)

ns 1 ns mPFC (Laurent & Westbrook, 2008)

ns no effect1, ns IL (Akirav et al., 2006)

+# (+) ns IL (Akirav et al., 2006)

- - ns IL (Sierra-Mercado et al., 2011)

no effect - ns IL (Laurent & Westbrook, 2009)

(+)# no effect ns PL (Laurent & Westbrook, 2009; Sierra-Mercado et al., 2011)

ns ns + (Ren-A)8 dHPC (Corcoran et al., 2005)

no effect (Ren-A)

- - dHPC (Corcoran et al., 2005)

(+)# - ns vHPC (Sierra-Mercado et al., 2011)

GA chlordiazepoxide IBAa-' Ag jonists BZ ns D-binding si ns te ay interf ip ace) (Goldman, 1977)

ns - ns ip (Bouton et al., 1990)

diazepam ns - ns ip (Pereira et al., 1989)

ns - ns ip (Bouton et al., 1990)

midazolam ns 1 ns ip (Bustos et al., 2009)

##6 - ns ip (Hart et al., 2009, 2010; Hart et al., 2014)

#6 - ns BLA (Hart et al., 2009, 2010; Hart et

al., 2014)

GABAB receptor agonists

baclofen ns - ns ip (Heaney et al., 2012)

GS39783 (positive modulator GABAb) ns no effect ns Po (Sweeney et al., 2013)



GAD67 KD in BLA - ns ns no drug (Heldt et al., 2012)

no drug

GAD65 KO - 2 - 2 ns (Sangha et al., 2009)

a5 KD in HPC ns 3 ns no drug (Yee et al., 2004)

no drug

al KO in CRF+ cells ns (Gafford et al., 2012)

ns + .4 ns iP (McGaugh et al., 1990)

picrotoxin ns ns +4 +* ns ns PL (Thompson et al., 2010) (Thompson et al., 2010) iFit7ffprn1rl pt ni 901 4M

bicuculline ns +1 ns BLA (Berlau & McGaugh, 2006)

bicuculline + propanolol ns no effect1 ns BLA (Berlau & McGaugh, 2006)

FG7142 - - ns iP (Harris & Westbrook, 1998)

ns - ns iP (Kim & Richardson, 2007, 2009)

GABAB receptor antagonism

GABABdb) KO 5 ns ns no drug (Jacobson et al., 2006)

phaclofen ns no effect ns iP (Heaney et al., 2012)

CGP52432 ns no ns Po (Sweeney et al., 2013)


1 drug administration following extinction training; 2 only cued memory, contextual intact, 3 trace conditioning, 4 reconsolidation (injection prior reactivation of memory), 5 conditioned taste aversion, 6 midazolam may not impair fear extinction if initial extinction occurs drug-free [see (Hart et al., 2014)], 7 short extinction training (5 CS presentations), 8 injection prior renewal-testing

# reduced fear expression at start of extinction training; ## enhanced immobility at start of extinction training;

+, improved; -, impaired; (+) or (-), only minor effects; ip, intraperitoneal injection; po,peroral administration; ns, not studied; HPC, intra-hippocampal administration; BLA, intra-basolateral amygdala administration; IL, infralimbic cortex; PL, prelimbic cortex; Ren-A, Fear renewal in conditioning context; ag, agonist; ant, antagonist, KO, knock-out;

4.6 Cannabinoids

A growing body of literature demonstrates that the endogenous cannabinoid (eCB) system modulates neuronal excitability in stressful and fearful situations (de Bitencourt et al., 2013; Gunduz-Cinar et al., 2013a). eCB signaling has been implicated in emotional and cognitive processing of threatening stimuli, for instance during the consolidation of fear and fear extinction memories (for more detailed recent reviews see (Riebe et al., 2012; Gunduz-Cinar et al., 2013b). Upon neuronal activation, an eCB (anandamide) and 2-arachidonoylglycerol (Figure 8) are rapidly synthesized in the postsynaptic neuron (within minutes) and released into the synaptic cleft to modulate presynaptic signaling by the activation of Gi/0-coupled CB-1 receptors (CB-2 receptors are mainly expressed on immune cells, osteoblasts, osteoclasts and hematopoietic cells but also on neuroglia).

Supporting a role of CB signaling in the extinction of aversive memories (see Figure 8 for overview), there are increased eCB levels in the mouse BLA following extinction training (Marsicano et al., 2002). Conversely, PTSD patients show low brain anandamide levels (Neumeister et al., 2013). In rodents, facilitation of eCB signaling by CB-1 receptor agonists or exogenous cannabinoids [cannabidiol, (Bitencourt et al., 2008)], reuptake inhibitors [AM404, (Chhatwal et al., 2005b; Bitencourt et al., 2008; Pamplona et al., 2008)] or anandamide degradation blockers [AM3506, URB 597, (Gunduz-Cinar et al., 2013b)] enhances the formation or consolidation of extinction memories. Blockade or knock-out of CB1-receptors (Marsicano et al., 2002; Cannich et al., 2004; Kamprath et al., 2006; Pamplona et al., 2006; Niyuhire et al., 2007; Reich et al., 2008; Plendl & Wotjak, 2010; Terzian et al., 2011) impairs extinction and blocks the pro-extinction effects of drugs that facilitate eCB transmission (Chhatwal et al., 2005b; Do Monte et al., 2013; Gunduz-Cinar et al., 2013b) (see Table 6). Collectively, these observations point to CB-1 receptor mediated eCB signaling as a powerful modulator of extinction.

Following up on these studies, intra-cerebral infusions of CB1-receptor agonists and antagonists have

revealed a potential role of mPFC-BLA eCB signaling in extinction [see Table 6, (Do Monte et al.,

2013; Ganon-Elazar & Akirav, 2013; Gunduz-Cinar et al., 2013b)]. CB1-receptor activation inhibits both presynaptic glutamate and GABA release. The release of anandamide and concomitant CB1-receptor activation induce long-term depression of inhibitory transmission (LTDi) in the BLA (Azad et al., 2004; Gunduz-Cinar et al., 2013b). In addition, a recent study demonstrated that enhanced inhibitory input via activation of CB1 receptor expressing cholecystokinin (CCK) positive interneurons selectively reduces firing of BLA fear neurons and promotes extinction (Trouche et al., 2013). Of note is the fact that it has also been shown that one potential mechanism for the CB1 effect on extinction within the AMY is via blockade of CCK release, as an intra-AMY CCK antagonist reversed the extinction blockade of systemic CB1 antagonists, and CCK agonists block extinction (Chhatwal et al., 2009).

In summary, current preclinical data suggest that eCB signaling gates BLA excitability through synaptic plasticity changes and inhibition (via reduced presynaptic glutamate release) of BLA pyramidal neurons to modulate BLA output and augment extinction. Initial results from clinical studies in healthy volunteers suggest that exogenous cannabinoid administration strengthens extinction and protects against reinstatement [see Table 6A, (Das et al., 2013; Rabinak et al., 2013)]. Future clinical trials in extinction-impaired PTSD patients will be needed to show whether cannabinoids (or substances which increase endogenous eCB signaling, such as FAAH inhibitors) might prove useful as adjuncts to CBT-based therapy.

Table 6 Cannabinoid signaling in fear extinction (preclinical studies)



cannabidiol + + ns icv (Bitencourt et al., 2008)

+ + ns IL (Do Monte et al., 2013)

anandamide ns +1 ns dCA1 (de Oliveira Alvares et al., 2008)

AM404 (eCB uptake inhibitor) ns + ns ip (Pamplona et al., 2008)

ns + + (Re-in) ip (Chhatwal et al., 2005b)

+ (+) ns icv (Bitencourt et al., 2008)

no training + ns IL (Lin et al., 2009)

AM3506 (FAAH Inhibitor) ns + ns ip (Gunduz-Cinar et al., 2013b)

WIN 55,212-2 (low-dose CB1 Ag) +* no effect2 ns ip (Pamplona et al., 2006)

WIN 55,212-2 (high-dose CB1 Ag) no effect2 ns ip (Pamplona et al., 2006)

WIN 55,212-2 (CB1 Ag) ns + ns nd ip ip (Pamplona et al., 2006) (Pamplona et al., 2008)

WIN 55,212-2 (CB1 Ag) ns +4 ns BLA (Ganon-Elazar & Akirav, 2013)

ns +4 ns HPC (Ganon-Elazar & Akirav, 2013)

ns no effect4 ns mPFC (Ganon-Elazar & Akirav, 2013)

ns + no effect (Re-in, SR3) IL (Lin et al., 2009)

no training + ns IL (Lin et al., 2009)

ns no effect ns PL (Kuhnert et al., 2013)

HU210 no training + ns IL (Lin et al., 2009)

URB597 (AEA hydrolysis inhibitor) no training + ns IL (Lin et al., 2009)

AM3506 (FAAH Inhibitor) + SR141716A (CB1 Ant) ns no effect ns ip + BLA (Gunduz-Cinar et al., 2013b)

AM3506 (FAAH Inhibitor) ns + ns BLA (Gunduz-Cinar et al., 2013b)

no training no effect ns BLA (Gunduz-Cinar et al., 2013b)

cannabidiol + SR141716A (CB1 Ant) no effect no effect ns IL + ip (Do Monte et al., 2013)



CB1 KO - - ns no drug (Cannich et al., 2004)

CB1 KO - ns ns no drug (Marsicano et al., 2002; Kamprath et al., 2006; Dubreucq et al., 2010; Plendl & Wotjak, 2010)

D1-CB1 KO - ns ns no drug (Terzian et al., 2011)

ns no effect1 ns sc (Marsicano et al., 2002)

- ns ns sc, ip (Kamprath et al., 2006; Niyuhire et al., 2007; Plendl & Wotjak, 2010)

SR141716A ns i ns ip (Suzuki et al., 2004)

CB1 ant - no effect ns ip (Pamplona et al., 2006; Pamplona et al., 2008)

ns - ns ip (Chhatwal et al., 2005b)

## no effect ns ip (Bowers & Ressler, 2014)

- ns ns ip (Reich et al., 2008)

AM251 (CB1 inverse ns i ns dCAl (de Oliveira Alvares et al., 2008)

ns - ns IL (Lin et al., 2009)

no training

ag) no effect ns IL (Lin et al., 2009)

ns - ns PL (Kuhnert et al., 2013)

1 drug administration following extinction training; 2 drug-free retrieval of contextual fear memory; 3 5 days, 4 single-prolonged-stress model: injection immediately after trauma

*, Recent memory; remote memory; ##, enhanced immobility at start of extinction training;

+, improved; -, impaired; (+) or (-), only minor effects; ip, intraperitoneal injection; ip, sc, subcutanous injection; ns, not studied; HPC, intra-hippocampal administration; BLA, intra-basolateral amygdala administration; IL, infralimbic cortex; PL, prelimbic cortex; CA1, cornu ammonis 1; Re-in, reinstatement; SR, spontaneous recovery, ag, agonist; ant, antagonist, KO, knock-out;

Table 6A: Human trials: Cannabinoids combined with CBT

Disorder Study Design Outcome (compared to placebo control group) Reference

Healthy volunteers Fear conditioning paradigm, Cannabidiol inhalation prior or following extinction Reduced fear in retrieval Protection against reinstatement (Das et al., 2013)

Healthy volunteers Fear conditioning paradigm, tetrahydrocannabinol prior extinction No effect (Klumpers et al., 2012)

Healthy volunteers Fear conditioning paradigm, Dronabinol prior extinction Reduced fear in retrieval (Rabinak et al., 2013)

4.7 Neuropeptides (Oxytocin, Neuropeptide Y, Neuropeptide S, Opioids)

Various neuropeptides and their corresponding receptors are localized in brain regions mediating emotional behavior and stress response and have been considered as potential anxiolytic drug targets ((Ebner et al., 2009; Bowers et al., 2012; Griebel & Holmes, 2013)). While other neuroptides such as hypocretin/Orexin (Flores et al., 2014) may also be involved in fear extinction, we will here address the role of oxytocin, neuropeptide Y, neuropeptide S and opioids in extinction.

a) Oxytocin

The oxytocin (OXT) system, strongly implicated in social cognition and behavior, is posited to play a role in anxiety disorders with impaired social functioning (Meyer-Lindenberg et al., 2011; Neumann & Landgraf, 2012). OXT is synthesized in the paraventricular (PVN) and supraoptic nuclei of the hypothalamus and processed along the axonal projections to the posterior pituitary gland. Upon neuronal activation OXT is released from secretory vesicles into the peripheral circulation as neurohypophyseal hormone. The central nervous system (CNS) component of OXT is derived from dendritic release of the same cell population (Ludwig & Leng, 2006), as well as from the OXT-synthesizing parvocellular PVN cells sending projections throughout the brain [reviewed in (Gimpl & Fahrenholz, 2001)]. OXT receptors are typically Gq-protein coupled and have potential allosteric binding sites for Mg2+ and steroids like cholesterol. The distribution of OXT receptors has not been fully delineated, but OXT fibers and neurosecretory nerve endings have been described in, among other regions, the AMY [especially CeL (Veinante & Freund-Mercier, 1997; Knobloch et al., 2012)], the dorsal and ventral HPC and the main monoamine nuclei - substantia nigra (dopamine), raphe nuclei (serotonin) and the locus coeruleus (noradrenaline) [see (Gimpl & Fahrenholz, 2001) for review).

Regulatory effects of OXT on stress-induced activation of the hypothalamic-pituitary-adrenal (HPA) axis, as well as direct OXT effects on the brain and specific parts of the extinction circuitry, can affect

fear extinction in various ways. Intracerebroventricular (icv) infusion of OXT prior to fear conditioning does not affect fear learning but facilitates later extinction acquisition and retrieval (Toth et al., 2012a). Conversely, OXT receptor antagonists impair extinction learning and retrieval when administered icv prior to fear acquisition (Toth et al., 2012a). More localized OXY infusions into the central CeA reduce fear expression by inhibiting CeM excitatory output to fear-eliciting brainstem structures (Huber et al., 2005) (Viviani et al., 2011), suggesting one possible mechanism for the effects of icv OXY on extinction.

Another potential mechanism might be OXT-induced dampening of stress-induced activation of the HPA axis (Windle et al., 1997; Heinrichs et al., 2003; Quirin et al., 2011; de Oliveira et al., 2012). As explained in more detail in Section 4.8 Glucocorticoids, glucocorticoid release during an actual learning process facilitates cognitive processing [reviewed in (Bentz et al., 2010)], hence the release of endogenous OXT during traumatic experiences (Zoicas et al., 2014) may interfere with the consolidation of fear memories. Along these lines, OXT-mediated reduction of HPA axis activity and subsequent lower glucocorticoid levels could interfere with fear acquisition, resulting in a weaker fear memory that is more susceptible to extinction training. In this context, OXT administration either icv or intra BLA prior to extinction training disrupts extinction learning [(Toth et al., 2012a) (Lahoud & Maroun, 2013) see Table 7 for summary]. OXT infusions into the dorsolateral septum prior to extinction training have the opposite effect and facilitate extinction learning and retrieval in a social fear conditioning paradigm that may recruit a somewhat different neural circuitry than non-social forms of fear (Zoicas et al., 2014).

Considering that systemically applied neuropeptides do not cross the blood-brain-barrier, clinical use

of neuropeptides would require a direct pathway to the human brain. In the case of OXT, this may be

feasible via intranasal administration (Born et al., 2002). Intranasal OXT administration has been

demonstrated to reduce stress-induced cortisol release in humans (Heinrichs et al., 2003; Quirin et

al., 2011; de Oliveira et al., 2012), and to attenuate AMY hyperactivity as well as AMY-hindbrain

coupling in anxiety patients [(Kirsch et al., 2005; Labuschagne et al., 2010)]. In a recent study

investigating the effects of intranasal OXT treatment on fear extinction in healthy volunteers, OXT increased initial fear expression during extinction training, but this effect was gone by the end of training and there was a lower level of fear in the OXT treated group in extinction retrieval (Acheson et al., 2013). These data raise the prospect of OXT-augmented CBT effectiveness.

b) Neuropeptide Y

Neuropeptide Y (NPY) contains 36 amino acids and is the most widely expressed neuropeptide in the mammalian brain. There are particularly high concentrations of NPY in the limbic system, including in the AMY, the HPC and the periaqueductal gray. Six G-protein coupled NPY receptors (Y1-6) have been identified, among which Y1, Y2, Y4, and Y5 mediate central effects. Y1 mRNA is present at a high level in brain areas involved in memory processing, namely the AMY, HPC, thalamus, hypothalamus, and the cerebral cortex. The AMY, HPC, and hypothalamus are also rich in Y2 receptors, while Y5 receptors can be detected in HPC, cingulate cortex and thalamic and hypothalamic nuclei (Parker & Herzog, 1999) [reviewed in (Holmes et al., 2003)].

Icv administration of NPY facilitates extinction learning (Gutman et al., 2008), while genetic deletion of NPY disrupts extinction acquisition and subsequent retrieval (Verma et al., 2012). Extinction deficits caused by NPY knock-out are rescued by AAV-mediated NPY re-expression in the BLA (Verma et al., 2012), where NPY co-localizes with GABAergic neurons modifying inhibitory control of BLA projection neurons (McDonald & Pearson, 1989). To elucidate which NPY receptors mediate the BLA-associated effects on extinction, the consequences of gene deletion via either deletion of Y1 or Y2 receptors or double Y1/Y2 deletion have been examined. Deletion of Y1 receptors impaired extinction learning, while Y2 receptor deletion had no effect (Verma et al., 2012). Underscoring the importance to extinction of Y1 receptors in the BLA, local infusion of the Y1 agonist Leu31Pro34-NPY prior to extinction training led to stronger extinction retrieval (Gutman et al., 2008; Lach & de Lima,

2013). Further studies are required to further delineate the underlying mechanisms of Y1-mediated facilitation of extinction, and to investigate the potential clinical use of NPY and Y1 receptor agonism as adjunctive therapy to CBT.

c) Neuropeptide S

Neuropeptide S (NPS) is synthesized in neurons located adjacent to the locus coeruleus (Xu et al.,

2007) and binds to G-protein coupled NPS receptors expressed in the BLA among other areas. Intra-BLA infusion of exogenous NPS accelerates extinction learning, while BLA NPS receptor antagonism (via SHA68) impairs extinction learning and retrieval and increases fear renewal (Jungling et al., 2008; Chauveau et al., 2012) (Table 7). NPS treatment also rescues deficient extinction learning in hyperanxious rats (Slattery et al., in press), exhibiting aberrant cortico-AMY activation (Muigg et al.,

2008). The activation of NPS receptors in the BLA increases excitatory input to GABAergic ITCs, thus increasing feed-forward inhibition to CeM neurons and reducing fear expression (Meis et al., 2008; Pape et al., 2010; Meis et al., 2011). Exogenous NPS administration is also associated with enhanced DA release in the mPFC (Si et al., 2010), suggesting another mechanism for strengthening extinction (see Section 4.2 Dopaminergic system).

Underscoring the translational relevance of NPS, healthy human volunteers carrying the NPS receptor polymorphism rs324981, which potentiates NPS efficacy at the receptor, show enhanced extinction in a virtual reality fear potentiated startle paradigm (Glotzbach-Schoon et al., 2013). Additional studies are required to assess whether increasing NPS signaling improves extinction in anxiety patients. This would be aided by the development of small molecule NPS receptor agonists.

d) Opioids

The opioid peptide family comprises different members including endorphins, enkephalins, dynorphins and hemorphins. The 3 classical opioid receptors (MOR), k (KOR) and 5 (DOR)] show heterogeneous expression throughout the brain and are located in extinction-relevant brain areas including the AMY, mPFC and HPC. Typically, MOR, KOR and DORs are coupled to Gi-proteins, reducing (in most cases) net neuronal excitability and reducing neurotransmitter release upon activation [reviewed in (Nutt, 2014)].

There is evidence that morphine application (intended for pain management) following an acute trauma attenuates the incidence of PTSD at later time points (Bryant et al., 2009; Holbrook et al., 2010; Szczytkowski-Thomson et al., 2013; Melcer et al., 2014). Aside from this potential PTSD preventing property of opioids, several studies have tried to determine the importance of opioids in extinction.

Systemic administration of the opioid receptor antagonist naloxone (which has highest affinity to MOR, but also inhibits KOR and DOR) impairs extinction when given prior to extinction training (McNally & Westbrook, 2003; McNally et al., 2004) but not when applied after extinction training or prior to retrieval, see Table 7). Subsequent investigations have demonstrated that extinction-impairing effects are mediated by MORs in the PAG [as shown with the selective MOR antagonist CTAP in the PAG (McNally, 2005; Parsons et al., 2010)].

The AMY ITCs express high levels of MOR (Busti et al., 2011), and lesioning of MOR-expressing neurons in the ITCs following extinction training impairs extinction retrieval (Likhtik et al., 2008), indicating that MOR signaling in the ITCs contributes to extinction consolidates. Probably due to the high addiction potential of MOR agonists, no clinical studies have investigated their potential in CBT. However, treatment with the opioid receptor antagonist naloxone prior to exposure therapy is associated with reduced treatment success (Egan et al., 1988; Arntz et al., 1993), which is in accordance with preclinical results (Table 7).

Another opioid receptor gaining attention in the field of fear extinction is the KOR, activated by endogenous dynorphins (reviewed in (Schwarzer, 2009)). Human volunteers displaying single

nucleotide polymorphisms in the prodynorphin gene showed increased skin conductance (a physiological measure of fear) during fear extinction training and blunted functional connectivity between AMY and mPFC (Bilkei-Gorzo et al., 2012). Along these lines, genetic deletion of dynorphin or systemic antagonism of KORs in rodents impairs extinction learning and reduces neuronal activity in the BLA and mPFC (Bilkei-Gorzo et al., 2012). In contrast to these extinction-impairing effects, systemic administration of KOR antagonists protects against fear renewal (Cole et al., 2011) - an effect mimicked by local infusions into the ventral HPC (Cole et al., 2013). Additional studies will help clarify these effects and their possible relevance to clinical use of opioidergic drugs in conjunction with exposure-based therapies.

Table 7 Neuropeptide signaling in fear extinction (preclinical studies)



oxytocin ns ns icv F>T Q (Toth et al., 2012a)

.*5 -*5 ns ns ULS iP (zoicas et ai., 2014) (Eskandarian et al., 2013)

chronic oxytocin (30d) ns no effect*6 ns in (Bales et al., 2014)

NPY + + ns icv (Gutman et al., 2008)

NPY KO 3*** - ns no drug (Verma et al., 2012)

NPY Y1 KO - no effect ns no drug (Verma et al., 2012)

NPY Y2 KO no effect no effect ns no drug (Verma et al., 2012)

NPY Y1/Y2 KO - - ns no drug (Verma et al., 2012)

Leu31Pro-NPY (Y1 ag) ns + ns BLA (Lach & de Lima, 2013)

BIBO 3304 (Y1 ant) ns - ns BLA (Gutman et al., 2008)

NPS (+)4 no effect no effect BLA (Jungling et al., 2008)

+ ns ns icv (Slattery et al., in press)

SHA68 (NPS-R ant) 4, *** - BLA (Jungling et al., 2008)


naloxone - - ns systemic (McNally & Westbrook, 2003)

ns no effect1 ns systemic (McNally & Westbrook, 2003)

- - ns vlPAG (McNally et al., 2004)

- - ns vlPAG (Parsons et al., 2010)

no effect no effect ns BLA (Parsons et al., 2010)

CTAP (MOR ant) - - ns vlPAG (McNally et al., 2005)

dynorphin KO 3 - ns no drug (Bilkei-Gorzo et al., 2012)

nor-BNI (KOR ant) ns 1 ns systemic (Bilkei-Gorzo et al., 2012)

1 drug administration following extinction training; 2 social fear conditioning;3 animals show accelerated fear learning; 4 administration 2h prior extinction training; 5 single prolonged stress model; 6 BTBR mouse autism model and C57BL6J

*** enhanced fear expression at the beginning of extinction training, # reduced fear expression at the beginning of extinction training

+, improved; -, impaired; (+) or (-), only minor effects; ip, intraperitoneal injection; icv, intra-cerebroventricular injection; ns, not studied; HPC, intra-hippocampal administration; BLA, intra-basolateral amygdala administration; DLS, dorsolateral septum; vlPAG, ventrolateral periaqueductal gray; Ren-A, fear renewal in conditioning context; ag, agonist; ant, antagonist, KO, knock-out;

4.8 Glucocorticoids

Emotionally arousing experiences activate the HPA axis and the release of glucocorticoids (GCs) into the bloodstream. GCs which include cortisol in humans, and corticosterone in rodents are lipophilic and readily cross the blood-brain-barrier to interact with glucocorticoid (GR) and mineralocorticoid receptors (MR) in the brain. GRs are widely expressed throughout the brain including the AMY, HPC and PFC (Bentz et al., 2010). Early pioneering studies reported that extinction-memory formation is disrupted by adrenalectomy (Silva, 1973), as well as, more recently, by compounds that antagonize GRs, such as mifepristone (Yang et al., 2006), or that inhibit corticosterone synthesis [metapyrone, (Harrison et al., 1990; Barrett & Gonzalez-Lima, 2004; Yang et al., 2006; Yang et al., 2007; Blundell et al., 2011)] (see Table 8). Conversely, systemic administration of corticosterone (Blundell et al., 2011) or the GR agonists dexamethasone or RU28362 (Yang et al., 2006; Yang et al., 2007; Ninomiya et al., 2010) facilitate the consolidation of aversive and appetitive extinction memories (see Table 8).

How can stress hormones promote the formation of extinction memories? Cytosolic GRs induce genomic responses by binding to glucocorticoid responsive elements within promoter regions of GC-responsive genes, and act as transcription factors inducing the expression of learning-related genes. In addition, membrane-bound GRs can induce non-genomic actions of relevance to extinction, including the synthesis of eCBs (see Section 4.6 Cannabinoids) from membrane phospholipids (Di et al., 2003; Hill et al., 2005; Hill et al., 2011). Further supporting a link between GRs and eCBs, and possibly of importance in GC-augmented extinction consolidation, adrenalectomy leads to reduced CB-1 receptor expression (Mailleux & Vanderhaeghen, 1993) and GC-mediated memory consolidation is prevented by CB-1 receptor antagonists (Campolongo et al., 2009).

GRs can also induce indirect learning-relevant genomic actions via activation of intracellular signaling

cascades such as the ERK/MAPK pathway [reviewed in (Reul, 2014)] in cooperation with other

neurotransmitter systems or ion channels including P-adrenoceptors (Roozendaal et al., 2008), and L-

type calcium channels (Karst et al., 2002). These interrelated effects are functionally relevant, given

that the infusion of P-adrenoceptor antagonists into the BLA blocks the memory-facilitating effects of systemically administered glucocorticoids (Quirarte et al., 1997; Roozendaal et al., 2002).

Another important functional interaction occurs between GCs and the glutamate system. GCs potentiate glutamatergic signaling via genomic and non-genomic mechanisms, by (i) increasing the readily releasable pool of presynaptic glutamate vesicles, and (ii) enhancing NMDA and AMPA receptor surface expression through increased receptor trafficking [reviewed in (Popoli et al., 2012)]. The concomitant activation of GC and NMDA receptors, which can occur during emotionally arousing experiences, induces downstream nuclear mechanisms that result in histone modifications [reviewed in (Reul, 2014)], an epigenetic mechanism implicated in extinction (see Section 4.10: Epigenetics for details). Underscoring the potential importance of emotional arousal and thus of GC release in this process, pretreatment with the anxiolytic BZD lorazepam (resulting in reduced arousal in response to the stressor) blocked epigenetic modifications on Histone H3, while application of the anxiogenic BZD inverse agonist FG7142 (Singewald et al., 2003) induced transcription facilitating acetylation and phosphorylation on histone tails (Papadopoulos et al., 2011). These epigenetic effects could contribute to the aforementioned extinction impairing effects of BZDs (see Section 4.5: y-aminobutyric acid (GABA) and Table 5).

In contrast to the effects of acute GC elevations, chronic high levels of corticosterone reduce cell-surface NMDA and AMPA receptor expression (Gourley et al., 2009). This loss of critical plasticity mechanisms might be one explanation as to why anxiety patients with a history of repeated traumatic events, such as combat veterans, show greater resistance to treatment. However, a considerable proportion of PTSD patients have reduced cortisol levels (Yehuda et al., 2004 and small case studies suggest that there are beneficial effects of CBT and adjunctive cortisol administration in PTSD patients (Yehuda et al., 2010). A number of larger studies are under way to extend this work (NCT01108146, NCT00751855, NCT01525680). In addition, it has been found that cortisol-augmented CBT has efficacy in acrophobia (de Quervain et al., 2011), arachnophobia (Soravia et al.,

2006; Soravia et al., 2014) and social phobia [(Soravia et al., 2006) see Table 8A for a summary].

Whether cortisol augmented CBT for non-phobic anxiety disorders, including also GAD, facilitates fear inhibition is currently being investigated in ongoing clinical studies (see (Cain et al., 2012). Furthermore, future studies may implement more selective GC agonists than cortisol (which is also acting on MRs) to avoid nonspecific side effects.

Table 8 Glucocorticoid signaling in fear extinction (preclinical studies)



no effect

ns +1 ip (Blundell et al., 2011)

corticosterone (GR/MR ag) (Re-in)

ns 2 ns ip (Den et al., 2014)

(Yang et al., 2006; Yang et

dexamethasone (GR ag) ns + ns ip al., 2007; Ninomiya et al.,

RU28362 (GR ag) ganoxolone (allopregnanolone analog) ns +*3 +*3 ns ns ip ( Yang et al., 2006) (Pinna & Rasmusson, 2014)


metyrapone (CORT/cortisol synthesis inhibitor) no effect - -* sc (Barrett & Gonzalez-Lima, 2004; Clay et al., 2011)

ns - ns sc (Yang et al., 2006; Yang et al., 2007; Blundell et al., 2011)

mifepristone (GR and progesterone ant) ns - ns AMY (Yang et al., 2006)

1 drug administration following extinction training; 2 in adolescent but not adult rats if exposed to CORT one week prior to (drugfree) testing; adults also show impaired extinction retrieval if they were exposed to one week of CORT in their adolescence; 3 socially isolated mice, CAVE ganoxolone was administered following a reactivation session 24h prior extinction training

+, improved; -, impaired; ip, intraperitoneal injection; sc, subcutaneous injection; ns, not studied; AMY, intra-amygdala administration; Re-in, reinstatement; ag, agonist; ant, antagonist; GR, glucocorticoid receptor; MR, mineralocorticoid receptor; CORT, corticosteroid

Table 8A: Human trials: Glucocorticoids combined with CBT

Disorder Study Design Outcome (compared to placebo control group) Reference

Social phobia Cortisone or placebo administered orally 1 h before a socio-evaluative stressor Reduced self-reported fear during anticipation and exposure (Soravia et al., 2006)

Spider phobia Cortisol or placebo administered orally 1 h before exposure to a spider Progressive reduction of stimulus-induced fear (Soravia et al., 2006)

photograph in 6 sessions distributed over 2 weeks Reduction of fear was maintained also 2 days following session ending (OFF-drug)

Spider phobia Cortisol or placebo administered orally 1 h before 2 exposure therapy sessions Follow-up after 1 month Significant decrease in phobic symptoms assessed with the Fear of Spiders Questionnaire Cortisol-treated patients reported significantly less anxiety during exposure to living spiders at follow-up (Soravia et al., 2014)

Acrophobia Cortisol or placebo was administered orally 1 h before virtual reality exposure to heights Follow-up after 1 month Greater reduction in fear of heights measured with the acrophobia questionnaire both at post-treatment and at follow-up (de Quervain et al., 2011)

PTSD (combat-related ) Memory reactivation task followed by intravenous administration of cortisol or saline Follow-up after 1 month Reduced PTSD symptomatic in cortisol-treated patients No differences between cortisol and saline treated patients (initial improvement was lost after 1 month) (Suris et al., 2010)

PTSD 10 weekly sessions of prolonged exposure therapy, cortisol or placebo 30min prior session 3-10 Accelerated and greater decline in PTSD symptoms Caveat - includes only 2 patients (1 cortisol / 1 placebo) (Yehuda et al., 2010)

4.9 Neurotrophins and miscellaneous targets

a) Fibroblast growth factor-2

Fibroblast growth factor-2 (FGF2) is a multi-functional growth factor involved in brain development and learning-related molecular signaling cascades (reviewed in (Graham & Richardson, 2011a). FGF2 signaling is associated with glutamate-mediated synaptic plasticity (Numakawa et al., 2002), L-type voltage gated calcium channel expression and activation (Shitaka et al., 1996) and phosphorylation of both MAPK (Abe & Saito, 2000) and CREB (Sung et al., 2001). FGF2 also promotes LTP in the HPC (Terlau & Seifert, 1990). Hence, FGF2 interacts with the molecular tools required for the formation and consolidation of extinction memories. FGF receptors are tyrosine kinase receptors expressed widely throughout the brain, including in areas within the extinction circuitry such as the HPC and the CeA, and FGF2 expression in the HPC and the mPFC is induced under stress (Molteni et al., 2001), thus suggesting that emotionally arousing situations requiring new learning generate increased FGF2 signaling which supports the formation of emotional memories.

FGF2 has been shown to cross the blood-brain barrier (Deguchi et al., 2000) and pioneering work demonstrates that systemic administration of FGF2 prior to or following extinction training facilitates the consolidation of extinction memories (Graham & Richardson, 2009, 2010). Local infusion into the BLA replicates the extinction-facilitating effects of systemic FGF2 (Table 9), demonstrating at least one key site of this neurotrophins action (Graham & Richardson, 2011b). Of significant importance, is the fact that FGF2-augmented extinction has been associated with enhanced protection against return of fear phenomena including renewal and reinstatement [(Graham & Richardson, 2009, 2010, 2011b), see Table 9 for details] making it an interesting candidate for future clinical applications. Clinical studies investigating the potential of FGF2 in CBT could be implemented in the near future as human trials investigating FGF2 for angiogenesis have already been shown to be safe (Laham et al., 2000).

b) Brain-derived neurotrophic factor

Brain-derived neurotrophic factor (BDNF) is the most abundant neurotrophin in the CNS and a key player in synaptic plasticity [reviewed in (Andero & Ressler, 2012)]. BDNF binds with high affinity to the tropomyosin-related kinase B (TrkB) receptor and with low affinity to the p75NTR, a receptor for multiple neurotrophins (Reichardt, 2006). BDNF and TrkB are present in the HPC, AMY, PFC and the hypothalamus, and are integral components of fear extinction mechanisms as blunted activity of BDNF-TrkB signaling is associated with deficient extinction retrieval in rats (Kabir et al., 2013). Conversely, increased levels of BDNF mRNA are observed in the BLA (Chhatwal et al., 2006), mPFC (Bredy et al., 2007) following successful fear extinction. The potential utility of BDNF-TrkB signaling as cognitive enhancing target is underscored by the findings that stimulating TrkB signaling by administering the TrkB agonist 7,8-dihydroxyflavone (DHF) facilitates LTP induction in the AMY (Li et al., 2011) and can augment fear extinction (Peters et al., 2010; Rosas-Vidal et al., 2014b).

Haploinsufficiency of BDNF leads to deficits in extinction learning and retrieval (Psotta et al., 2013), while inhibition of the BDNF-evoked signaling cascade via transfection of a dominant negative form of the TrkB receptor specifically disrupts extinction consolidation in a fear potentiated startle paradigm (Chhatwal et al., 2006). Conversely, systemic injection of the TrkB agonist DHF promoted extinction in a stress model of impaired fear extinction and protected against the reinstatement of fear (Andero et al., 2011) (for an overview, see Table 9). In mice and humans, a single nucleotide polymorphism (SNP) in the BDNF gene (Val66Met), causing inefficient BDNF trafficking and reduced activity-dependent BDNF secretion, is associated with poor extinction (Table 9) and abnormal fronto-AMY activity (Soliman et al., 2010). Moreover, human carriers of the BDNF Val66Met SNP show reduced responsivity to exposure-based therapies [reviewed in (McGuire et al., 2014)], underscoring the potential role of BDNF in deficient fear extinction.

Studies aimed at identifying the site of BDNF-induced effects on extinction showed that deletion of BDNF in the HPC, but not in the PL (Choi et al., 2010), impairs fear extinction learning (Heldt et al., 2007). In addition, injection of BDNF antibodies (anti-BDNF) in the IL prior to extinction training disrupts acquisition and retrieval of extinction memories while anti-BDNF infusions in the PL cortex do not affect extinction (Rosas-Vidal et al., 2014a) (Table 9). These findings indicate that BDNF signaling in the HPC and the IL support the formation and maintenance of fear extinction memories. In fact, local BDNF injections in the IL produced fear inhibition for recent as well as remote fear memories even in the absence of extinction training (Peters et al., 2010; Rosas-Vidal et al., 2014a). Given the possibility that BDNF infusions into the IL could reinstate fear by using the aforementioned extinction-independent paradigm (Peters et al., 2010), BDNF seems to induce signaling cascades crucial for the formation of extinction memories rather than decreasing the stability of the original fear memory. Overall these effects are consistent with a model in which the effects of BDNF are brain-region dependent, and BDNF appears to enhance synaptic plasticity of the most robust form of learning occurring in a time- and region-dependent manner.

Various targets described in this review may mediate their effects on extinction via interactions with BDNF. For example, chronic treatment with the SSRI fluoxetine (Section 4.1: Serotonergic system) facilitates extinction and enhances BDNF levels in the AMY and the HPC (Karpova et al., 2011). Valproate, an extinction-promoting inhibitor of histone deacetylation (see Section 4.10: Epigenetics), increases BDNF mRNA in the mPFC (Bredy et al., 2007). Furthermore, TrkB activation triggers the release of eCBs (Lemtiri-Chlieh & Levine, 2010) and increases the expression of CB1 receptors (Maison et al., 2009), hence potentially contributing to extinction memory formation (see Section 4.6: Cannabinoids). Finally, BDNF Met66 knock-in mice exhibit dysfunctional NMDA receptor-dependent synaptic plasticity in addition to reduced extinction acquisition (Ninan et al., 2010) that is rescued by systemic administration of d-cycloserine (Yu et al., 2009), underscoring an additional strong interaction between BDNF and the glutamatergic system [see (Andero & Ressler, 2012) for more details].

These findings suggest that BDNF signaling may be an important common signaling pathway for various systems involved in extinction. Although poor blood-brain-barrier permeability (Wu, 2005) ) limits the therapeutic potential of BDNF itself, TrkB receptor agonists such as DHF (see above) or LM22A-4 (Massa et al., 2010) may hold promise for CBT-adjunctive therapy in anxiety.

c) Nitric oxide and methylene blue

Nitric oxide (NO) signaling has received considerable attention in terms of its effect on fear learning and has been shown, for example, to be implicated in the formation of LTP at thalamic input synapses in the LA (Shin et al., 2013). One recent study did demonstrate that reducing NO signaling via inhibition of nitric oxide synthase (e.g. via L-NAME) impairs extinction learning and retrieval (Luo et al., 2014), indicating that NO signaling may also be involved in the formation and maintenance of fear extinction memories.

More work has been done on the brain penetrant methylene blue, which is an inhibitor of NO synthase, as well as a central monoamine oxidase (MAO) inhibitor and a cerebral metabolic enhancer (reviewed in (Rojas et al., 2012)). A contribution of nitric oxide to the behavioral effects of this and related compounds was suggested in relation to their observed antidepressant-like activity (Harvey et al., 2010).

In rodents, subchronic administration of methylene blue facilitates extinction retrieval (GonzalezLima & Bruchey, 2004) (Table 9) and increases metabolic activity in the IL subdivision of the mPFC. Methylene blue administration also rendered extinction memories resistant to fear renewal when administered following extinction training in a learned helplessness model exhibiting impaired extinction (Wrubel et al., 2007). ). Because methylene blue is used to treat metemoglobinemia and has a well-described safety profile (Ohlow & Moosmann, 2011), these preclinical data could be quickly moved forward to clinical investigations. Indeed, the first clinical study has recently reported

that methylene blue treatment during CBT led to greater fear inhibition that was persistent for at least one month [(Telch et al., 2014) see Table 9A for details]. However, similar to the profile of DCS discussed earlier, only those patients capable of showing some extinction benefited from the methylene blue treatment. A clinical trial investigating the potential of methylene blue in PTSD (NCT01188694) is now under way.

d) Histamine

The tuberomammillary nucleus is the main source of histamine in the brain. Histaminergic projections innervate main monoaminergic nuclei, such as raphe nuclei and locus coeruleus (Lee et al., 2005), as well as extinction relevant brain areas, including the AMY, mPFC and hippocampus (Kohler et al., 1985). To date, 4 histamine receptor subtypes (H1-4) have been identified - H1-3 are expressed in the CNS, while H4 is involved in chemotactic processes of the immune system. Local histamine infusions into the CA1 region of the HPC have been associated with improved extinction consolidation (Bonini et al., 2011). This effect is H2 receptor mediated, since the H2 agonist dimaprit facilitates extinction consolidation while the histamine H2 antagonist ranitidine impairs it, when injected into the CA1, BLA or IL following extinction training (Bonini et al., 2011; Fiorenza et al., 2012). Furthermore, both histamine and the H2 agonist dimaprit facilitate extinction-induced phosphorylation of Erk1, suggesting a possible molecular pathway mediating the augmenting effects of H2 receptor agonism on extinction consolidation (Bonini et al., 2011). However, although the H1 antagonist hydroxyzine has been used in some anxiety therapies (Guaiana et al., 2010), the potential clinical use of histaminergic drugs in particular targeting the H2 receptor for CBT augmentation has not been investigated.

e) Voltage gated calcium channels

Voltage-gated calcium channels (VGCCs) are classified into L-, P/Q-, R-, N- and T-type VGCCs [for a review see (Catterall et al., 2005)]. A rise in intracellular calcium via NMDA receptor or VGCC activation initiates various second messenger signaling cascades that play a role in LTP formation. Due to their neuronal expression as well as their association with gene transcription the L-type calcium channels (LTCCs) Cav1.2 and Cav1.3 (Striessnig et al., 2006; Striessnig et al., 2014) have attracted most attention in the fear conditioning field.

Early studies have shown that systemic injections of LTCC blockers, e.g. nifedipine (that inhibits Cav1.2 and Cav1.3 channels), impair fear extinction acquisition (Cain et al., 2002). However, whole-brain gene knockout of Cav1.3 channels (McKinney & Murphy, 2006; Busquet et al., 2008) as well as conditional knockout of Cav1.2 on CaMKII-expressing principal neurons (McKinney et al., 2008) failed to replicate deleterious effects of LTCC blockers on extinction training. Pre-training icv infusion of nifedipine has revealed no effect on extinction learning (Busquet et al., 2008), suggesting that the extinction-impairing effects of systemic nifedipine may be due to peripheral actions (Waltereit et al., 2008).

However, pre-training intra-BLA or intra-HPC infusion of nifedipine, or of another LTCC blocker, verapamil, impairs extinction retrieval 24h later (Davis & Bauer, 2012; de Carvalho Myskiw et al., 2014), indicating a role for LTCCs within these regions in the consolidation of extinction. This effect could be related to Cav1.3 mediation of synaptic plasticity and neuronal excitability in the AMY (McKinney et al., 2009) or to altered neuronal firing in the CA1 region of the HPC (Gamelli et al., 2011). However, the effect on extinction consolidation of selective Cav1.3 activation has not been assessed so far.

While activation of Cav1.2 channels produces severe neurological effects and germline gain of Cav1.3 function is deleterious (Scholl et al., 2013), selective Cav1.3 activation in adulthood has been shown to be tolerated at least in mice (Sinnegger-Brauns et al., 2004; Hetzenauer et al., 2006). Hence, short term use of such compounds, as would typically be required in combination with exposure therapy,

should be possible. Taken together, these preclinical findings raise the prospect of targeting LTCCs, and Cav1.3 in particular, for the treatment of anxiety.

Table 9 Neurotrophins and miscellaneous targets in fear extinction (preclinical studies)



FGF2 (+)# + ns sc (Graham & Richardson, 2009)

ns +1 + (Re-in) (Ren-A) sc (Graham & Richardson, 2009, 2010)

ns +1 + (Ren-A) BLA (Graham & Richardson, 2011b)

BDNF no training +**2 no effect (Re-in) IL (Peters et al., 2010; Rosas-Vidal et al., 2014a)

no training no effect2 ns PL (Rosas-Vidal et al., 2014a)

7.8-dihydroxyflavone (+)* no effect (+) (Re-in) ip (Andero et al., 2011)

no effect no effect* + (Ren-A) ip (Baker-Andresen et al., 2013)

Lentiviral transfected dominant negative form of TrkB no effect - ns BLA (Chhatwal et al., 2006)

BDNF KD in HPC - ns ns no drug (Heldt et al., 2007)

Val66Met BDNF SNP - ns ns no drug (Soliman et al., 2010)

no drug

BDNF +/- KO ns (Psotta et al., 2013)

BDNF antibody - - ns IL (Rosas-Vidal et al., 2014a)

no effect no effect ns PL (Rosas-Vidal et al., 2014a)

BDNF KO in forebrain ns no effect# ns PL (Choi et al., 2010)

1 drug administration following extinction training; 2 drug administration 24h prior to extinction retrieval

3 drug administration 30 min prior to extinction retrieval 4 ABA scheme, 40mg/kg



methylene blue ns +1 ns ip (Gonzalez-Lima & Bruchey, 2004)

ns ns +1* (Ren-A) ip (Wrubel et al., 2007)

Histamine ns +1 ns CA1 (Bonini et al., 2011)

dimaprit (H2 ag) ns +1 ns CA1 (Bonini et al., 2011)

ranitidine (H2 ant) ns i i ns CA1 rt a (Fiorenza et al., 2012)

ns ns i ns ns BLA PFC (Fiorenza et al., 2012) (Fiorenza et al., 2012)

SKF9188 (histamine methyl-transferase inhibitor) ns +1 ns CA1 (Fiorenza et al., 2012)

ns +1 ns BLA (Fiorenza et al., 2012)

ns +1 ns PFC (Fiorenza et al., 2012)

L-NAME (nNOS inhibitor)4 - - ns iP (Luo et al., 2014)

CamKII-Cre Cav1.2 KO no effect ns ns no drug (McKinney et al., 2008)

Cav1.3 KO no effect ns ns no drug (Busquet et al., 2008)

no effect ns ns no drug (McKinney & Murphy, 2006)

Nifedipine (LTCC ant) - ns ns iP (Cain et al., 2002)

no effect ns ns icv (Busquet et al., 2008)

no effect - ns BLA (Davis & Bauer, 2012)

ns 1 ns HPC (de Carvalho Myskiw et al., 2014)

Verapamil (VGCC ant) no effect - ns BLA (Davis & Bauer, 2012)

1 drug administration following extinction training; 2 drug administration 24h prior extinction retrieval 3 drug administration 30 min prior extinction retrieval 4 ABA scheme, 40mg/kg

* facilitates rescue of impaired fear extinction; ** facilitates extinction of remote memories, *** only in older animals (7 months), younger ones (2 months) are not affected, # reduced fear expression at the beginning of extinction training

+, improved; -, impaired; (+) or (-), only minor effects; ip, intraperitoneal injection; sc, subcutanous injection; icv, intracerebroventricular injection; ns, not studied; HPC, intra-hippocampal administration; BLA, intra-basolateral amygdala administration; IL, infralimbic cortex; PL, prelimbic cortex; CA1, cornu ammonis 1; Ren-A, Fear renewal in conditioning context; SR, spontaneous recovery; Re-in, reinstatement; ag, agonist; ant, antagonist, KO, knock-out;

4.10 Epigenetics

The formation of extinction memories requires an intricate regulatory network of signal transduction, gene transcription and translation. A key step in this process involves the coordinated transcription of specific genes coding for learning-associated transcription factors, synaptic plasticity factors, neurotransmitter receptors, cytoskeletal proteins and other cellular substrates [reviewed in (Monti, 2013; Whittle & Singewald, 2014)]. Gene transcription is in turn tightly controlled by epigenetic mechanisms (Callinan & Feinberg, 2006). Epigenetic mechanisms regulate the accessibility of deoxyribonucleic acid (DNA) to transcription-initiating machinery via certain molecular events including histone tail post-translational modifications and DNA methylation. In this section we will focus on histone acetylation and DNA methylation, with emphasis on their dynamic interactions within the chromatin environment that orchestrate the regulation of genes at the molecular level, and review accumulating evidence that modulation of extinction-relevant receptors at the synapse can initiate epigenetic programs within the nucleus and modulate extinction in a persistent and context-independent manner. We will also review data showing that drugs targeting epigenetic mechanisms may serve to strengthen extinction.

a) Histone modifications

To date, a main focus of research is on understanding the interaction between histone modifications and the strengthening of fear extinction memories. In eukaryotic cells, DNA is organized in a highly conserved structural polymer, termed chromatin. The basic building block of chromatin is the nucleosome, which consists of 146 base pairs (bp) of DNA wrapped around an octamer consisting of (dimers of) core histone proteins (H2A, H2B, H3, and H4) held together by a H1 linker protein (Kornberg & Lorch, 1999). Histones contain a globular domain with a covalently modifiable N-terminal tail consisting of lysine and/or arginine residues. Histone modifications constitute a signal that is read alone or, in combination with other modifications and interactions with neighboring histones - a 'histone code' (Kouzarides, 2007). At least 9 different posttranslational modifications,

including acetylation, phosphorylation, methylation, biotinylation, SUMOylation, ADP ribosylation, and ubiquitination, influence chromatin condensation, resulting in gene transcription by coordinating protein and enzyme complex accessibility to DNA (Ruthenburg et al., 2007). Here, we focus primarily on the most well-studied histone modification in extinction - acetylation of histone proteins.

Histone acetylation on lysine (K) residues leads to transcriptional activation by neutralizing the positive charge of the K e-amino group of histone tails, which in-turn relaxes chromatin by reducing the electrostatic bonding of histone with negatively charged DNA (Grayson et al., 2010). The enzymes involved in regulating this process are 1) histone acetyltransferases (HATs), also known as lysine acetyltransferases (KATs) (Allis et al., 2007) or 'writers' (Monti, 2013) and 2) histone deacetylases (HDACs), also known as lysine deacetylases (KDACs) (Choudhary et al., 2009) or 'erasers' (Monti, 2013). HATs acetylate K residues to promote gene transcription, whereas HDACs, which are present in co-repressor complexes, remove K residues to impair gene transcription [for greater detail, see (Fischer et al., 2010)].

There is some evidence that extinction is associated with alterations in HAT activity and that drugs increasing HAT activity could constitute a novel approach to augmenting extinction. Following extinction, there is increased expression of the HAT p300/CBP-associated factor (PCAF) in the rodent IL, and intra-IL infusion of the PCAF activator, SPV106, facilitates extinction and protects against fear renewal (Wei et al., 2012). However, inhibiting, rather than activating, the activity of another HAT, p300, in the IL also strengthens extinction (Marek et al., 2011). One possible explanation of this finding is that rather than strengthening extinction, p300 may bolster fear memory reconsolidation via transcription of genes including nuclear factor kB (NF-kB) (Perkins et al., 1997; Furia et al., 2002) and yin-yang 1 (YY1) (Yao et al., 2001), known to be involved in reconsolidation (Lubin & Sweatt, 2007; Gao et al., 2010). These two studies that demonstrate how targeting HATs affects fear in different ways indicate the need for additional work to determine the optimal approach to facilitate extinction with HAT modulators.

There is an increasing amount of evidence to suggest that histone acetylation is an important mechanism promoting successful fear extinction (reviewed in (Whittle & Singewald, 2014)]. An important early study found that histone extinction is associated with increased acetylation of histone H4 in the promoter region of bdnf exon IV (Bredy et al., 2007). Subsequent work showed that administration of various HDAC inhibitors including TSA (trichostatin A), sodium butyrate, entinostat (MS-275), vorinostat (SAHA, suberoylanilide hydroxamic acid), VPA (valproic acid) and Cl-944 can augment fear extinction (Table 10). The potential clinical utility of using HDAC inhibitors has been further strengthened by showing that Cl-944, MS-275 and SAHA rescue extinction deficits in various rodent models (Matsumoto et al., 2013; Whittle et al., 2013; Graff et al., 2014; Hait et al., 2014) (see Table 10).

An additional attribute of HDAC inhibitors is their ability to extinguish remote (aged) fear memories that are normally resistant to extinction. Extinction of recent fear memories (1 day after conditioning), using a memory update-consolidation paradigm, increases HDAC2 nitrosylation (Graff et al., 2014), which facilitates the dissociation of HDAC2 from chromatin (Nott et al., 2008)], leading to histone hyper-acetylation and HPC expression of extinction-relevant genes including c-Fos. By contrast, nitrosylation of HDAC2 and c-Fos expression do not increase after extinction training of remote (1 month post conditioning) fear memories (Graff et al., 2014). Systemic administration of the HDAC inhibitor Cl-994 was able to rescue remote extinction and the associated gene expression deficits. Rescue of impaired remote extinction has been observed with dietary zinc restriction, which inhibits HDAC in addition to affecting other systems (Whittle et al., 2010; Holmes & Singewald, 2013). Collectively, these two studies support the potential clinical utility of HDAC inhibitors as adjuncts to CBT treatment of fearful memories that started long after the exposure to trauma.

Further supporting a role of HDAC activity in the modulation of fear extinction mechanisms is the

observation that enhanced HDAC activity is associated with improvements in fear extinction (Hait et

al., 2014). At present 18 different mammalian HDAC isoforms have been identified, and they are

divided into four classes (Classes I—IV). Targeting individual HDAC isoforms is an important aim of

drug development (Grayson et al., 2010). The majority of currently available HDAC inhibitors target multiple isoforms of the HDAC family (e.g. classes I, II, and IV), while some of the HDAC inhibitors that have proved to be successful in augmenting fear extinction (Table 10) exhibit preferential selectivity towards class-I HDACs (encompassing HDAC1, HDAC2, HDAC3 and HDAC8) (Haggarty & Tsai, 2011).

Studies using gene knockdown or over-expression suggest that targeting specific HDAC isoforms could indeed be a promising approach to modulating extinction [reviewed in (Whittle & Singewald, 2014)]. This is exemplified by the recent finding that gene silencing of HDAC2, but not HDAC1, in forebrain neurons promotes extinction (Morris et al., 2013). However, the effect of specifically inhibiting other HDAC isoforms, including HDAC3 [recently shown to facilitate the extinction of drug-seeking memories (Malvaez et al., 2013)], remains to be tested.

It is likely that the extinction-facilitating effects of HDAC inhibitors are due to activation of extinction-related gene transcription programs. The HDAC inhibitors SAHA and VPA increase, respectively histone acetylation in the promoter region of grin2b (NMDA receptor subunit 2B) (Fujita et al., 2012), and histone H4 acetylation in promoter IV of bdnf, leading to increased BDNF exon IV mRNA expression (Bredy et al., 2007). In addition, the HDAC inhibitor Cl-994 increases histone H3 acetylation in the promoter region of plasticity associated genes including igf2, adcy6, c-Fos, npas4, and arc (Graff et al., 2014). Indeed, a range of neurotransmitter/neuromodulator systems that are known to mediate extinction, induce transcription of relevant genes via enhancement of histone acetylation, including histone H3 acetylation in the promoter region of bdnf, camk2a, creb and the NMDA receptor subunit genes grin2a and grin2b (Tsankova et al., 2006; Tian et al., 2009; Tian et al., 2010; Shibasaki et al., 2011). Concerning a possible convergent downstream mechanism for these effects, serotonin via activation of PKA signaling pathways (Guan et al., 2002), L-type calcium channel activation (Dolmetsch et al., 2001) and BDNF/TrkB activation (Correa et al., 2012) all activate the MAPK/ERK signaling pathway, which is crucial for fear extinction (Pape & Pare, 2010) (see also Figure 3). MAPK/ERK signaling to the nucleus could increase histone acetylation by enhancing activity of the HAT CREB-binding protein (CBP) (Chrivia et al., 1993).

b) DNA methylation

DNA methylation is a crucial mechanism for controlling chromatin remodeling in the adult mammalian nervous system (Levenson et al., 2006; Nelson et al., 2008) and can occur at multiple sites within a gene. DNA methylation is a direct chemical modification of a cytosine side-chain that adds a methyl (-CH3) group through a covalent bond, catalyzed by a class of enzymes known as DNA methyltransferases (DNMTs) (Okano et al., 1998). The DNMTs transfer methyl groups to cytosine residues within a continuous stretch of DNA, specifically at the 5'-position of the pyrimidine ring (5-methylcytosine) (Chen et al., 1991). Not all cytosines can be methylated; typically, cytosines are followed by a guanine in order to be methylated (Day & Sweatt, 2011). However, given the recent finding that methylation can occur outside CpG islands and in CpH (where H = adenine/cytosine/thymine) islands and that these CpH islands can repress (Guo et al., 2014) substantially expands and adds further complexity to how methylation can regulate gene transcription in the central nervous system. Furthermore, this finding raises the open question of whether CpH methylation is a molecular mechanism regulating fear extinction.

In a landmark study, linking DNA methylation and extinction, extinction-resistant female mice were found to exhibit increased DNA methylation of Bdnf exon IV and a concomitant decrease in BDNF mRNA expression in the PFC (Baker-Andresen et al., 2013). The fact that DNA methylation is reversible suggests that enhancement of gene transcription by DNA demethylation could represent a novel mechanism for strengthening extinction that has the potential to be pharmaceutically exploited. Along these lines, the ten-eleven translocation (Tet) family of methylcytosine dioxygenases, which includes Tet1, Tet2, and Tet3 enzymes, catalyze oxidation of 5-methylcytosine to 5-hydroxymethylcytosine and thereby promotes DNA demethylation (Tahiliani et al., 2009; Ito et al., 2011).

Two recent studies demonstrate the importance of these Tet enzymes in extinction. Extinction leads to a genome-wide redistribution of 5-hydroxymethylcytosine and Tet3 occupancy to extinction-

relevant genes including the GABAa clustering protein, gephyrin (see Section 4.5: Y-aminobutyric acid (GABA)), and to enhanced gephyrin mRNA expression in the IL (Li et al., 2014). Furthermore, gene knockdown of Tet1 impairs extinction (Rudenko et al., 2013). While agents targeting Tet enzymes are not currently available, these emerging preclinical findings may provide the impetus to develop such compounds.

c) Non-coding RNA

In addition to histone modifications and DNA methylation, gene expression is also regulated by non-coding RNAs including micro-RNAs (miRNAs) (Spadaro & Bredy, 2012). miRNAs represent classes of non-coding RNAs that mediate post-transcriptional regulation of gene expression, including genes associated with synaptic plasticity, learning and memory (Barry, 2014). Although miRNAs are usually associated with preventing mRNA translation and thereby with suppressing new protein synthesis, a specific miRNA was recently shown to augment fear extinction. Fear extinction enhanced the expression of miR-128b in the IL associated with down-regulation of plasticity-related genes including creb1 and sp1 in tandem with inhibition of the original fear memory (Lin et al., 2011). Clearly, further clarification of the role of non-coding RNAs during fear extinction is warranted, including through the development of tools by which specific non-coding RNAs can be modulated.

Table 10: Studies showing that HDAC inhibitors augment exposure-based fear extinction and rescue extinction learning deficits


nUAtl KO (HPC) HDAC2 KO in forebrain CamKII neurons ns ns + *# lis ns no drug no drug (Banan-javan et al., 2012) (Morris et al., 2013)

ns + ns ip (Fujita et al., 2012)

Vorinostat/SAHA ns + ** ns ip (Matsumoto et al., 2013)

ns + ** ns ip (Hait et al., 2014)

TSA (Trichostatin A) ns + * ns ip, HPC (Lattal et al., 2007)

- + + (SR) ip, HPC (Stafford et al., 2012)

Sodium Butyrate ns + ns ip (Itzhak et al., 2012)

ns + ns ip, HPC (Lattal et al., 2007)

Valproic Acid - / + * ns ip (Bredy et al., 2007)

+ * + (Ren-A) ip (Bredy & Barad, 2008)

+ ** + ** + (SR, Ren-N) ip (Whittle et al., 2013)

MS-275 (Entinostat) - + ** + (SR, Ren-N) ip (Whittle et al., 2013)

Cl-994 ns + *** + (SR) ip (Graff et al., 2014)

FTY720 (Fingolimod) - + ** ns ip (Hait et al., 2014)

* partial extinction training: reduction of fear during the extinction training session was not to preconditioning levels, ** facilitates rescue of impaired fear extinction; *** facilitate remote memories combined with memory re-consolidation update paradigm; # extinction protocol based on a reconsolidation/update paradigm

+, improved; -, impaired; ip, intraperitoneal injection; ns, not studied; HPC, intra-hippocampal administration; Ren-A, Fear renewal in the conditioning context; Ren-N, Fear renewal in a novel context; SR, spontaneous recovery; # reduced freezing levels at the beginning of extinction training

5 Discussion and final conclusions

In this review we aimed to summarize (druggable) systems involved in fear extinction and how pharmacological compounds have been utilized to augment fear extinction in preclinical and small-scale clinical studies. It is anticipated that these findings are paving the way for clinical use of such approaches given that extinction training is procedurally similar to exposure-based psychotherapy and the underlying fear/extinction circuitries and molecular mechanisms are well conserved across species (Milad & Quirk, 2012). As mentioned in the introduction, the main problems with current exposure based CBT treatment of fear, anxiety and trauma-related disorders are that a significant proportion of patients either: 1) have difficulties bearing the demanding and exhausting process of this therapy, 2) do not, or not sufficiently, respond to the therapy - failing to substantially reduce their fear response, or 3) responds initially, but suffer from return of fear phenomena hampering remission and full recovery. In this review we summarize the pharmacological approaches that have been investigated and utilized to improve these shortcomings. Initial attempts to combine exposure-based CBT with pharmacotherapy included benzodiazepines that dampened anxiety but also reduced the learning effects of this procedure hence provoking return of fear symptoms upon discontinuation (Otto et al., 2002; Otto et al., 2010a; Hofmann, 2012). A complicating issue is the observation that the interoceptive state induced by such anxiolytics can form part of a "context", and consequently may promote fear in subsequent testing in an "off drug state", leading to state-dependent learning due to a change in interoceptive context (Maren et al., 2013). However, there is evidence that targeting novel anxiolytic systems such as the NPS system or fibroblast growth factor-2 may elicit acute anxiolytic effects without producing sedation, state-dependency and/or interference with the formation of extinction memories. These findings are particularly exciting as they are beginning to address one of the important problems associated with CBT (i.e. intolerability to CBT exposure). However, more research is necessary to prove the utility of such approaches. As well as improving tolerability to exposure, improvements concerning onset, magnitude and duration of the therapeutic

effect of exposure-based CBT are also in the main focus of drug development in this field. As outlined in this review, the augmentation of fear extinction/exposure therapy with a range of different drugs acting as cognitive enhancers to strengthen extinction memories represents an important approach to enhancing therapy efficacy. This has been made possible by revealing the neurochemical/neurobiological responses within the neural circuitry whose activity is required for fear extinction and, by extension, to rescue fear extinction deficits.

Considerable progress has been made in defining the neural basis of fear extinction and fear extinction deficits (for recent reviews see (Milad & Quirk, 2012; Holmes & Singewald, 2013; Parsons & Ressler, 2013). The steadily growing knowledge concerning where and how fear extinction is processed and how it can be pharmacologically augmented is an essential platform from which to identify promising candidates for extinction-promoting therapeutics. Indeed, by successfully translating findings from animal models, progress has been made in enhancing the outcomes of exposure-based CBT using compounds such as DCS, yohimbine and glucocorticoids as cognitive enhancers in the treatment of patients with anxiety disorders, PTSD and OCD (Hofmann & Smits, 2008; Norberg et al., 2008; McGuire et al., 2014).

As outlined in this review, an impressive number of additional extinction augmenting drugs, acting on

a wide variety of pharmacological targets, have indeed been identified. Data arising from the use of

animal models displaying deficient fear extinction, reflecting patients resistant to exposure therapy,

indicate that different neurotransmitter/neurobiological signaling pathways are involved in different

temporal phases of extinction. Hence, it is likely that different pharmacological approaches will be

required to either induce fear reductions during extinction training or rescue/boost the consolidation

of fear extinction (reviewed in (Holmes & Singewald, 2013)). The important finding that within-

session fear fear reduction/habituation favors drug-augmented extinction rather than facilitating

reconsolidation of existing fear memories (Graham et al., 2011; Merlo et al., 2014) has also been

demonstrated in clinical trials using DCS ((Hofmann, 2014) and yohimbine (Smits et al., 2014).

Moreover, multi-target approaches that simultaneously modulate the activity of diverse

neurotransmitter/neurobiological systems seem to be an important option to pursue, in particular for individuals with severe extinction deficit/resistance to exposure therapy. Interestingly, in the much more well established medical fields of infectious disease, hypertension, oncology, and similar areas, targeting multiple different mechanisms of action is also the norm, not the exception and it is also considered promising in other fields of psychiatry (Millan, 2014).

One of the most important aspects of extinction-promoting drugs is their ability to bolster extinction by enhancing memory consolidation. It is likely that this extinction enhancement occurs via the enhancement of cortico-AMY synaptic plasticity through multiple mechanisms (reviewed in (Myers & Davis, 2007; Sierra-Mercado et al., 2011; Orsini & Maren, 2012; Duvarci & Pare, 2014)), ultimately providing lasting effects and better protection from return of fear phenomena. If translated into clinical use, these effects would support sustained symptom remission and recovery. Some of the drug targets outlined in this review [e.g. epigenetic targets including histone modification, BDNF and facilitated dopaminergic and fibroblast-growth-factor-2 signaling) and also cholinergic targets -see (Zelikowsky et al., 2013)] seem to be promising in this respect, as they promote long-term and context-independent fear inhibition when combined with fear extinction. Context-independent extinction learning (extinction generalization) offering enhanced protection against fear return phenomena such as renewal, may be supported not only by targeting specific pharmacological mechanisms, but also by behavioral approaches (see below). Fortunately, some of the promising substances in that respect are approved for human use (e.g. Valproate, L-DOPA, FGF2) and thus, their extinction-augmenting capacity could be immediately examined in anxiety and trauma-focused clinical trials. It seems clear that there are a number of different pharmacological pathways to access the circuits that underlie fear extinction learning and memory (see Figure 3), although some of the discussed agents may share important common downstream signaling pathways, which will enables even more specific targeting of the essential extinction-promoting mechanisms in the future.

Despite this clear progress there remain major challenges for the development of medications to

improve the effectiveness of exposure-based therapies, including challenges related to the design of

safe, brain-penetrant molecules with limited adverse side-effects. Individual differences in treatment tolerability and efficacy, caused by genetic variation, and prior medication history are further complicating concerns. For example, the careful dissection of the brain regions mediating fear extinction including the AMY, PFC, HPC and other regions has also shown that some systems can promote both extinction-facilitating and extinction-impairing effects depending on the brain area/cellular substrate they are acting on. An example is the G-adrenoceptor, blockade of which interferes with extinction when restricted to the IL, but promotes extinction when the BLA is targeted - hence it is difficult to predict the net effect of medicating a patient with a G-adrenoceptor blocker or agonist during exposure therapy. The targeting of specific intracellular signaling cascades might be a solution for future, more selective approaches in this direction. Research in the last few years has revealed that the ligand structure can bias the signal output of G-protein coupled receptors by stabilizing the receptor structure in a distinct way to the natural ligand. By providing a means to produce functional selectivity, biased agonists and antagonists may be utilized to activate preferential, even unnatural, signaling cascades mediating the therapeutically favored downstream biological consequences [for a recent review see (Luttrell, 2014)].

Another important aspect for future clinical implementation of drug-induced facilitation of exposure therapy outcome concerns the time course of drug administration. While current drug treatment for anxiety and trauma-related disorders involves mainly chronic treatment (e.g. with SSRIs, SNRIs, TCA, MAOI) the compounds discussed in this review are (with the exception of antidepressants) recommended to be applied acutely in combination with psychotherapeutic interventions for a limited number of exposure trials. This strategy includes several advantages: First, chronic application of drugs can induce very different biological effects from those observed with acute administration. It is extremely challenging to predict how and at which stage (recall of fear memory, learning, reconsolidation, consolidation, retrieval of extinction memory) chronically applied drugs will enhance/interfere with fear extinction. For example, it is likely that facilitation of extinction and disruption of fear reconsolidation, both leading to fear reduction, depend on opposing molecular

processes, such that chronic administration of the same drug may lead to very different therapeutic outcomes depending on which process (i.e. extinction or reconsolidation) it enhances (Graham et al., 2011). Second, acute administration implies a reduced side effect potential. One example is the addiction potential of some of the compounds currently examined for extinction augmentation (e.g. MDMA). Indeed, first clinical trials reported that none of the involved patients developed a substance abuse problem when MDMA was administered acutely to assist psychotherapy (Mithoefer et al., 2013).

In addition to pharmacological parameters, the efficacy and duration of exposure therapy in humans may also depend (as shown in animal studies) on manipulation of specific behavioral extinction training parameters [see also e.g. (Schiller et al., 2012; de Carvalho Myskiw et al., 2014)] such as providing sufficient extinction training, enhancing the number of contexts for such training, trial spacing, and other approaches (reviewed in (Herry et al., 2010; Fitzgerald et al., 2014a)). It will be an important future line of research to test the optimal combinations between such behavioral approaches and the outlined pharmacological approaches in order to maximize treatment outcome. It is also important to note that thought needs to be given to a variety of factors concerning how to optimally utilize adjunctive and novel treatments. Such factors include consideration of monotherapy vs. add-on adjunctive treatment; use of medications in drug-naive vs. first medicated subjects; combined use of medication explicitly with exposure/extinction psychotherapy vs. medication taken without explicit psychotherapy; timing of medication - e.g. at night to aid memory consolidation during sleep vs. immediately before or after exposure; and use of medications in countries with well-developed vs. poorly developed health systems. As the field of psychopharmacotherapy matures beyond the models that it has followed for decades, all of these considerations are important for new drug development. For example some medications may not be as efficacious in subjects with a history of antidepressant use, as has been suggested for d-cycloserine (Werner-Seidler & Richardson, 2007). Furthermore, as sleep is increasingly thought to be associated with extinction learning, targeting medication to enhance the memory consolidation process during sleep may be important

(Pace-Schott et al., 2012). Finally, medications which are available readily in generic form and that do not require specialized adjunctive psychotherapy may be more readily disseminated to locations with less well-developed mental health care systems than those that are novel, or more expensive, or that may require specialized combined therapy. Taken together, these considerations remind us that identifying molecular mechanisms and novel drug approaches to fear regulation is only part of the challenge, and that the context of the dissemination of such new therapeutics is also of critical concern.

In summary, based on the evidence summarized in this review, the next few years promise to produce several novel clinical approaches to treating trauma- and anxiety-related disorders in a more efficient and persistent way that will most likely lead to enhanced symptom remission. Progress will depend on translational research approaches and a close interaction between preclinical and clinical researchers. Fig. 10 outlines how the different levels of understanding, from genetics to epigenetics to neural circuits, can inform each other as well as how they can be informed across species due to the high level of convergence of shared fear-related processing across mammals. This research and the considerable number of compounds to choose from in the growing pharmacological tool box in this field, many of which display minimal side effects, may enable psychiatrists/psychologists to individualize drug treatment according to specific symptoms of anxiety disorders, PTSD and OCD. Such options are expected to further improve treatment outcome and to reduce the amount, of psychotherapy sessions needed, or the duration or intensity that is required for long-lasting treatment success. As outlined above, evidence is beginning to shape the hypothesis that specific classes of compounds and cognitive enhancers may be superior to others in their ability to support long-term fear-inhibiting effects. There is evidence that the efficacy of different classes of drugs may be distinctly influenced by a number of factors including age, gender and other examples of individual differences. Hence, future research is warranted in order to investigate whether specific drugs used as cognitive enhancers in this field are more or less appropriate for specific individuals, conditions and treatment durations. In conclusion, cognitive enhancers present a promising option to

safely augment extinction-based anxiety and trauma therapy and to reduce treatment duration, thereby facilitating treatment coherence and outcomes.

Conflict of interest statement

Drs. Singewald, Schmuckermair, Whittle and Holmes declare no conflict of interest. Dr. Ressler is a founding member of Extinction Pharmaceuticals / Therapade Technologies. He has received no equity or income from this relationship within the last 5 years. The terms of these arrangements have been reviewed and approved by Emory University in accordance with its conflict of interest policies.


We acknowledge the Austrian Science Fund [FWF grant numbers SFB F4410 and P25375-B24] for funding our research related to this review (NS).

6 References

Abe, K., Saito, H. (2000). Neurotrophic effect of basic fibroblast growth factor is mediated by the

p42/p44 mitogen-activated protein kinase cascade in cultured rat cortical neurons. Brain Res Dev Brain Res 122, 81-85.

Abraham, A. D., Cunningham, C. L., Lattal, K. M. (2012). Methylphenidate enhances extinction of contextual fear. Learn Mem 19, 67-72.

Abraham, A. D., Neve, K. A., Lattal, K. M. (2014). Dopamine and extinction: a convergence of theory with fear and reward circuitry. Neurobiol Learn Mem 108, 65-77.

Abumaria, N., Yin, B., Zhang, L., Li, X. Y., Chen, T., Descalzi, G., Zhao, L., Ahn, M., Luo, L., Ran, C., Zhuo, M., Liu, G. (2011). Effects of elevation of brain magnesium on fear conditioning, fear extinction, and synaptic plasticity in the infralimbic prefrontal cortex and lateral amygdala. J Neurosci 31, 14871-14881.

Acheson, D., Feifel, D., de Wilde, S., McKinney, R., Lohr, J., Risbrough, V. (2013). The effect of

intranasal oxytocin treatment on conditioned fear extinction and recall in a healthy human sample. Psychopharmacology (Berl) 229, 199-208.

Aghajanian, G. K., Marek, G. J. (1999). Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Res 825, 161-171.

Akirav, I., Raizel, H., Maroun, M. (2006). Enhancement of conditioned fear extinction by infusion of

the GABA(A) agonist muscimol into the rat prefrontal cortex and amygdala. Eur J Neurosci 23, 758-764.

Akirav, I., Segev, A., Motanis, H., Maroun, M. (2009). D-cycloserine into the BLA reverses the impairing effects of exposure to stress on the extinction of contextual fear, but not conditioned taste aversion. Learn Mem 16, 682-686.

Allis, C. D., Berger, S. L., Cote, J., Dent, S., Jenuwien, T., Kouzarides, T., Pillus, L., Reinberg, D., Shi, Y., Shiekhattar, R., Shilatifard, A., Workman, J., Zhang, Y. (2007). New nomenclature for chromatin-modifying enzymes. Cell 131, 633-636.

Amir, A., Amano, T., Pare, D. (2011). Physiological identification and infralimbic responsiveness of rat intercalated amygdala neurons. J Neurophysiol 105, 3054-3066.

Amstadter, A. B., Nugent, N. R., Koenen, K. C. (2009). Genetics of PTSD: Fear Conditioning as a Model for Future Research. Psychiatr Ann 39, 358-367.

Andero, R., Ressler, K. J. (2012). Fear extinction and BDNF: translating animal models of PTSD to the clinic. Genes Brain Behav 11, 503-512.

Andero, R., Dias, B. G., Ressler, K. J. (2014). A Role for Tac2, NkB, and Nk3 Receptor in Normal and Dysregulated Fear Memory Consolidation. Neuron 83, 444-454.

Andero, R., Heldt, S. A., Ye, K., Liu, X., Armario, A., Ressler, K. J. (2011). Effect of 7,8-dihydroxyflavone, a small-molecule TrkB agonist, on emotional learning. Am J Psychiatry 168, 163-172.

Arntz, A., Merckelbach, H., de Jong, P. (1993). Opioid antagonist affects behavioral effects of exposure in vivo. J Consult Clin Psychol 61, 865-870.

Arvanov, V. L., Liang, X., Magro, P., Roberts, R., Wang, R. Y. (1999). A pre- and postsynaptic

modulatory action of 5-HT and the 5-HT2A, 2C receptor agonist DOB on NMDA-evoked responses in the rat medial prefrontal cortex. Eur J Neurosci 11, 2917-2934.

Azad, S. C., Monory, K., Marsicano, G., Cravatt, B. F., Lutz, B., Zieglgansberger, W., Rammes, G. (2004). Circuitry for associative plasticity in the amygdala involves endocannabinoid signaling. J Neurosci 24, 9953-9961.

Bagdy, G., Graf, M., Anheuer, Z. E., Modos, E. A., Kantor, S. (2001). Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int J Neuropsychopharmacol 4, 399-408.

Bahari-Javan, S., Maddalena, A., Kerimoglu, C., Wittnam, J., Held, T., Bahr, M., Burkhardt, S., Delalle, I., Kugler, S., Fischer, A., Sananbenesi, F. (2012). HDAC1 regulates fear extinction in mice. J Neurosci 32, 5062-5073.

Bai, Y., Zhou, L., Wu, X., Dong, Z. (2014). d-Serine enhances fear extinction by increasing GluA2-containing AMPA receptor endocytosis. Behav Brain Res 270, 223-227.

Baker-Andresen, D., Flavell, C. R., Li, X., Bredy, T. W. (2013). Activation of BDNF signaling prevents the return of fear in female mice. Learn Mem 20, 237-240.

Baker, J. D., Azorlosa, J. L. (1996). The NMDA antagonist MK-801 blocks the extinction of Pavlovian fear conditioning. Behav Neurosci 110, 618-620.

Bales, K. L., Solomon, M., Jacob, S., Crawley, J. N., Silverman, J. L., Larke, R. H., Sahagun, E., Puhger, K. R., Pride, M. C., Mendoza, S. P. (2014). Long-term exposure to intranasal oxytocin in a mouse autism model. Transl Psychiatry 4, e480.

Bandelow, B., Seidler-Brandler, U., Becker, A., Wedekind, D., Ruther, E. (2007). Meta-analysis of

randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatry 8, 175-187.

Bandelow, B., Sher, L., Bunevicius, R., Hollander, E., Kasper, S., Zohar, J., Moller, H. J., Care, W. T. F. o. M. D. i. P., Wfsbp Task Force on Anxiety Disorders, O. C. D., Ptsd (2012). Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract 16, 77-84.

Banke, T. G., Dravid, S. M., Traynelis, S. F. (2005). Protons trap NR1/NR2B NMDA receptors in a nonconducting state. J Neurosci 25, 42-51.

Barrett, D., Gonzalez-Lima, F. (2004). Behavioral effects of metyrapone on Pavlovian extinction. Neurosci Lett 371, 91-96.

Barry, G. (2014). Integrating the roles of long and small non-coding RNA in brain function and disease. Mol Psychiatry 19, 410-416.

Bentz, D., Michael, T., de Quervain, D. J., Wilhelm, F. H. (2010). Enhancing exposure therapy for anxiety disorders with glucocorticoids: from basic mechanisms of emotional learning to clinical applications. J Anxiety Disord 24, 223-230.

Berlau, D. J., McGaugh, J. L. (2006). Enhancement of extinction memory consolidation: the role of the noradrenergic and GABAergic systems within the basolateral amygdala. Neurobiol Learn Mem 86, 123-132.

Bilkei-Gorzo, A., Erk, S., Schurmann, B., Mauer, D., Michel, K., Boecker, H., Scheef, L., Walter, H.,

Zimmer, A. (2012). Dynorphins regulate fear memory: from mice to men. J Neurosci 32, 93359343.

Bissiere, S., Humeau, Y., Luthi, A. (2003). Dopamine gates LTP induction in lateral amygdala by suppressing feedforward inhibition. Nat Neurosci 6, 587-592.

Bitencourt, R. M., Pamplona, F. A., Takahashi, R. N. (2008). Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats. Eur Neuropsychopharmacol 18, 849-859.

Blomhoff, S., Haug, T. T., Hellstrom, K., Holme, I., Humble, M., Madsbu, H. P., Wold, J. E. (2001).

Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 179, 23-30.

Blundell, J., Blaiss, C. A., Lagace, D. C., Eisch, A. J., Powell, C. M. (2011). Block of glucocorticoid

synthesis during re-activation inhibits extinction of an established fear memory. Neurobiol Learn Mem 95, 453-460.

Bolkan, S. S., Lattal, K. M. (2013). Opposing effects of d-cycloserine on fear despite a common

extinction duration: Interactions between brain regions and behavior. Neurobiol Learn Mem.

Bonini, J. S., Da Silva, W. C., Da Silveira, C. K., Kohler, C. A., Izquierdo, I., Cammarota, M. (2011).

Histamine facilitates consolidation of fear extinction. Int J Neuropsychopharmacol 14, 12091217.

Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., Fehm, H. L. (2002). Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 5, 514-516.

Borowski, T. B., Kokkinidis, L. (1998). The effects of cocaine, amphetamine, and the dopamine D1 receptor agonist SKF 38393 on fear extinction as measured with potentiated startle: implications for psychomotor stimulant psychosis. Behav Neurosci 112, 952-965.

Bouton, M. E., Kenney, F. A., Rosengard, C. (1990). State-dependent fear extinction with two benzodiazepine tranquilizers. Behav Neurosci 104, 44-55.

Bouton, M. E., Vurbic, D., Woods, A. M. (2008). D-cycloserine facilitates context-specific fear extinction learning. Neurobiol Learn Mem 90, 504-510.

Bowers, M. E., Ressler, K. J. (2014). Interaction between the Cholecystokinin and Endogenous Cannabinoid Systems in Cued Fear Expression and Extinction Retention. Neuropsychopharmacology.

Bowers, M. E., Choi, D. C., Ressler, K. J. (2012). Neuropeptide regulation of fear and anxiety:

Implications of cholecystokinin, endogenous opioids, and neuropeptide Y. Physiol Behav 107, 699-710.

Bredy, T. W., Barad, M. (2008). The histone deacetylase inhibitor valproic acid enhances acquisition, extinction, and reconsolidation of conditioned fear. Learn Mem 15, 39-45.

Bredy, T. W., Wu, H., Crego, C., Zellhoefer, J., Sun, Y. E., Barad, M. (2007). Histone modifications

around individual BDNF gene promoters in prefrontal cortex are associated with extinction of conditioned fear. Learn Mem 14, 268-276.

Bryant, R. A., Creamer, M., O'Donnell, M., Silove, D., Clark, C. R., McFarlane, A. C. (2009). Posttraumatic amnesia and the nature of post-traumatic stress disorder after mild traumatic brain injury. J Int Neuropsychol Soc 15, 862-867.

Bui, E., Orr, S. P., Jacoby, R. J., Keshaviah, A., LeBlanc, N. J., Milad, M. R., Pollack, M. H., Simon, N. M. (2013). Two weeks of pretreatment with escitalopram facilitates extinction learning in healthy individuals. Hum Psychopharmacol 28, 447-456.

Bukalo, O., Pinard, C., Holmes, A. (2014). Mechanisms to medicines: elucidating neural and molecular substrates of fear extinction to identify novel treatments for anxiety disorders. Br J Pharmacol.

Burghardt, N. S., Bauer, E. P. (2013). Acute and chronic effects of selective serotonin reuptake inhibitor treatment on fear conditioning: implications for underlying fear circuits. Neuroscience 247, 253-272.

Burghardt, N. S., Sigurdsson, T., Gorman, J. M., McEwen, B. S., LeDoux, J. E. (2013). Chronic

antidepressant treatment impairs the acquisition of fear extinction. Biol Psychiatry 73, 10781086.

Burgos-Robles, A., Vidal-Gonzalez, I., Santini, E., Quirk, G. J. (2007). Consolidation of fear extinction requires NMDA receptor-dependent bursting in the ventromedial prefrontal cortex. Neuron 53, 871-880.

Busquet, P., Hetzenauer, A., Sinnegger-Brauns, M. J., Striessnig, J., Singewald, N. (2008). Role of L-type Ca2+ channel isoforms in the extinction of conditioned fear. Learn Mem 15, 378-386.

Busti, D., Geracitano, R., Whittle, N., Dalezios, Y., Manko, M., Kaufmann, W., Satzler, K., Singewald, N., Capogna, M., Ferraguti, F. (2011). Different fear states engage distinct networks within the intercalated cell clusters of the amygdala. J Neurosci 31, 5131-5144.

Bustos, S. G., Maldonado, H., Molina, V. A. (2009). Disruptive effect of midazolam on fear memory reconsolidation: decisive influence of reactivation time span and memory age. Neuropsychopharmacology 34, 446-457.

Cain, C. K., Blouin, A. M., Barad, M. (2002). L-type voltage-gated calcium channels are required for extinction, but not for acquisition or expression, of conditional fear in mice. J Neurosci 22, 9113-9121.

Cain, C. K., Blouin, A. M., Barad, M. (2004). Adrenergic transmission facilitates extinction of conditional fear in mice. Learn Mem 11, 179-187.

Cain, C. K., Maynard, G. D., Kehne, J. H. (2012). Targeting memory processes with drugs to prevent or cure PTSD. Expert Opin Investig Drugs 21, 1323-1350.

Callaerts-Vegh, Z., Beckers, T., Ball, S. M., Baeyens, F., Callaerts, P. F., Cryan, J. F., Molnar, E., D'Hooge, R. (2006). Concomitant deficits in working memory and fear extinction are functionally dissociated from reduced anxiety in metabotropic glutamate receptor 7-deficient mice. J Neurosci 26, 6573-6582.

Callinan, P. A., Feinberg, A. P. (2006). The emerging science of epigenomics. Hum Mol Genet 15 Spec No 1, R95-101.

Camp, M. C., Macpherson, K. P., Lederle, L., Graybeal, C., Gaburro, S., Debrouse, L. M., Ihne, J. L.,

Bravo, J. A., O'Connor, R. M., Ciocchi, S., Wellman, C. L., Luthi, A., Cryan, J. F., Singewald, N., Holmes, A. (2012). Genetic strain differences in learned fear inhibition associated with variation in neuroendocrine, autonomic, and amygdala dendritic phenotypes. Neuropsychopharmacology 37, 1534-1547.

Campbell, B. M., Merchant, K. M. (2003). Serotonin 2C receptors within the basolateral amygdala induce acute fear-like responses in an open-field environment. Brain Res 993, 1-9.

Campolongo, P., Roozendaal, B., Trezza, V., Hauer, D., Schelling, G., McGaugh, J. L., Cuomo, V. (2009). Endocannabinoids in the rat basolateral amygdala enhance memory consolidation and enable glucocorticoid modulation of memory. Proc Natl Acad Sci U S A 106, 4888-4893.

Cannich, A., Wotjak, C. T., Kamprath, K., Hermann, H., Lutz, B., Marsicano, G. (2004). CB1 cannabinoid receptors modulate kinase and phosphatase activity during extinction of conditioned fear in mice. Learn Mem 11, 625-632.

Carmack, S. A., Wood, S. C., Anagnostaras, S. G. (2010). Amphetamine and extinction of cued fear. Neurosci Lett 468, 18-22.

Catlow, B. J., Song, S., Paredes, D. A., Kirstein, C. L., Sanchez-Ramos, J. (2013). Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning. Exp Brain Res 228, 481491.

Catterall, W. A., Perez-Reyes, E., Snutch, T. P., Striessnig, J. (2005). International Union of

Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev 57, 411-425.

Cestari, V., Rossi-Arnaud, C., Saraulli, D., Costanzi, M. (2014). The MAP(K) of fear: from memory consolidation to memory extinction. Brain Res Bull 105, 8-16.

Chalmers, D. T., Watson, S. J. (1991). Comparative anatomical distribution of 5-HT1A receptor mRNA and 5-HT1A binding in rat brain--a combined in situ hybridisation/in vitro receptor autoradiographic study. Brain Res 561, 51-60.

Chan, W. Y., McNally, G. P. (2009). Conditioned stimulus familiarity determines effects of MK-801 on fear extinction. Behav Neurosci 123, 303-314.

Chasson, G. S., Buhlmann, U., Tolin, D. F., Rao, S. R., Reese, H. E., Rowley, T., Welsh, K. S., Wilhelm, S. (2010). Need for speed: evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine. Behav Res Ther 48, 675-679.

Chauveau, F., Lange, M. D., Jungling, K., Lesting, J., Seidenbecher, T., Pape, H. C. (2012). Prevention of stress-impaired fear extinction through neuropeptide s action in the lateral amygdala. Neuropsychopharmacology 37, 1588-1599.

Chen, L., MacMillan, A. M., Chang, W., Ezaz-Nikpay, K., Lane, W. S., Verdine, G. L. (1991). Direct identification of the active-site nucleophile in a DNA (cytosine-5)-methyltransferase. Biochemistry 30, 11018-11025.

Chhatwal, J. P., Myers, K. M., Ressler, K. J., Davis, M. (2005a). Regulation of gephyrin and GABAA receptor binding within the amygdala after fear acquisition and extinction. J Neurosci 25, 502-506.

Chhatwal, J. P., Davis, M., Maguschak, K. A., Ressler, K. J. (2005b). Enhancing cannabinoid

neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology 30, 516-524.

Chhatwal, J. P., Stanek-Rattiner, L., Davis, M., Ressler, K. J. (2006). Amygdala BDNF signaling is required for consolidation but not encoding of extinction. Nat Neurosci 9, 870-872.

Chhatwal, J. P., Gutman, A. R., Maguschak, K. A., Bowser, M. E., Yang, Y., Davis, M., Ressler, K. J.

(2009). Functional interactions between endocannabinoid and CCK neurotransmitter systems may be critical for extinction learning. Neuropsychopharmacology 34, 509-521.

Choi, D. C., Maguschak, K. A., Ye, K., Jang, S. W., Myers, K. M., Ressler, K. J. (2010). Prelimbic cortical BDNF is required for memory of learned fear but not extinction or innate fear. Proc Natl Acad Sci U S A 107, 2675-2680.

Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., Mann, M. (2009). Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-840.

Choy, Y., Fyer, A. J., Lipsitz, J. D. (2007). Treatment of specific phobia in adults. Clin Psychol Rev 27, 266-286.

Chrivia, J. C., Kwok, R. P., Lamb, N., Hagiwara, M., Montminy, M. R., Goodman, R. H. (1993).

Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 365, 855-859.

Ciocchi, S., Herry, C., Grenier, F., Wolff, S. B., Letzkus, J. J., Vlachos, I., Ehrlich, I., Sprengel, R.,

Deisseroth, K., Stadler, M. B., Muller, C., Luthi, A. (2010). Encoding of conditioned fear in central amygdala inhibitory circuits. Nature 468, 277-282.

Clark, R. E., Xie, H., Brunette, M. F. (2004). Benzodiazepine prescription practices and substance abuse in persons with severe mental illness. J Clin Psychiatry 65, 151-155.

Clay, R., Hebert, M., Gill, G., Stapleton, L. A., Pridham, A., Coady, M., Bishop, J., Adamec, R. E.,

Blundell, J. J. (2011). Glucocorticoids are required for extinction of predator stress-induced hyperarousal. Neurobiol Learn Mem 96, 367-377.

Cole, S., Richardson, R., McNally, G. P. (2011). Kappa opioid receptors mediate where fear is expressed following extinction training. Learn Mem 18, 88-95.

Cole, S., Richardson, R., McNally, G. P. (2013). Ventral hippocampal kappa opioid receptors mediate the renewal of fear following extinction in the rat. PLoS One 8, e58701.

Corcoran, K. A., Desmond, T. J., Frey, K. A., Maren, S. (2005). Hippocampal inactivation disrupts the acquisition and contextual encoding of fear extinction. J Neurosci 25, 8978-8987.

Cornea-Hebert, V., Riad, M., Wu, C., Singh, S. K., Descarries, L. (1999). Cellular and subcellular

distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat. J Comp Neurol 409, 187-209.

Correa, S. A., Hunter, C. J., Palygin, O., Wauters, S. C., Martin, K. J., McKenzie, C., McKelvey, K.,

Morris, R. G., Pankratov, Y., Arthur, J. S., Frenguelli, B. G. (2012). MSK1 regulates homeostatic and experience-dependent synaptic plasticity. J Neurosci 32, 13039-13051.

Dalton, G. L., Wang, Y. T., Floresco, S. B., Phillips, A. G. (2008). Disruption of AMPA receptor endocytosis impairs the extinction, but not acquisition of learned fear. Neuropsychopharmacology 33, 2416-2426.

Dalton, G. L., Wu, D. C., Wang, Y. T., Floresco, S. B., Phillips, A. G. (2012). NMDA GluN2A and GluN2B receptors play separate roles in the induction of LTP and LTD in the amygdala and in the acquisition and extinction of conditioned fear. Neuropharmacology 62, 797-806.

Das, R. K., Kamboj, S. K., Ramadas, M., Yogan, K., Gupta, V., Redman, E., Curran, H. V., Morgan, C. J. (2013). Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology (Berl) 226, 781-792.

Davidson, J. R., Foa, E. B., Huppert, J. D., Keefe, F. J., Franklin, M. E., Compton, J. S., Zhao, N., Connor, K. M., Lynch, T. R., Gadde, K. M. (2004). Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry 61, 1005-1013.

Davis, A. R., Shields, A. D., Brigman, J. L., Norcross, M., McElligott, Z. A., Holmes, A., Winder, D. G.

(2008). Yohimbine impairs extinction of cocaine-conditioned place preference in an alpha2-adrenergic receptor independent process. Learn Mem 15, 667-676.

Davis, M. J., Iancu, O. D., Acher, F. C., Stewart, B. M., Eiwaz, M. A., Duvoisin, R. M., Raber, J. (2013).

Role of mGluR4 in acquisition of fear learning and memory. Neuropharmacology 66, 365-372.

Davis, S. E., Bauer, E. P. (2012). L-type voltage-gated calcium channels in the basolateral amygdala are necessary for fear extinction. J Neurosci 32, 13582-13586.

Day, J. J., Sweatt, J. D. (2011). Epigenetic mechanisms in cognition. Neuron 70, 813-829.

Dayan, L., Finberg, J. P. (2003). L-DOPA increases noradrenaline turnover in central and peripheral nervous systems. Neuropharmacology 45, 524-533.

de Beurs, E., van Balkom, A. J., Lange, A., Koele, P., van Dyck, R. (1995). Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. Am J Psychiatry 152, 683-691.

de Bitencourt, R. M., Pamplona, F. A., Takahashi, R. N. (2013). A current overview of cannabinoids and glucocorticoids in facilitating extinction of aversive memories: potential extinction enhancers. Neuropharmacology 64, 389-395.

de Carvalho Myskiw, J., Furini, C. R., Benetti, F., Izquierdo, I. (2014). Hippocampal molecular

mechanisms involved in the enhancement of fear extinction caused by exposure to novelty. Proc Natl Acad Sci U S A 111, 4572-4577.

de Kleine, R. A., Hendriks, G. J., Kusters, W. J., Broekman, T. G., van Minnen, A. (2012). A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biol Psychiatry 71, 962-968.

de Oliveira Alvares, L., Pasqualini Genro, B., Diehl, F., Molina, V. A., Quillfeldt, J. A. (2008). Opposite action of hippocampal CB1 receptors in memory reconsolidation and extinction. Neuroscience 154, 1648-1655.

de Oliveira, D. C., Zuardi, A. W., Graeff, F. G., Queiroz, R. H., Crippa, J. A. (2012). Anxiolytic-like effect of oxytocin in the simulated public speaking test. J Psychopharmacol 26, 497-504.

de Quervain, D. J., Bentz, D., Michael, T., Bolt, O. C., Wiederhold, B. K., Margraf, J., Wilhelm, F. H.

(2011). Glucocorticoids enhance extinction-based psychotherapy. Proc Natl Acad Sci U S A 108, 6621-6625.

Debiec, J., Ledoux, J. E. (2004). Disruption of reconsolidation but not consolidation of auditory fear conditioning by noradrenergic blockade in the amygdala. Neuroscience 129, 267-272.

Deguchi, Y., Naito, T., Yuge, T., Furukawa, A., Yamada, S., Pardridge, W. M., Kimura, R. (2000). Blood-brain barrier transport of 125I-labeled basic fibroblast growth factor. Pharm Res 17, 63-69.

Den, M. L., Altmann, S. R., Richardson, R. (2014). A Comparison of the Short- and Long-Term Effects of Corticosterone Exposure on Extinction in Adolescence Versus Adulthood. Behav Neurosci.

Deschaux, O., Spennato, G., Moreau, J. L., Garcia, R. (2011). Chronic treatment with fluoxetine

prevents the return of extinguished auditory-cued conditioned fear. Psychopharmacology (Berl) 215, 231-237.

Deschaux, O., Zheng, X., Lavigne, J., Nachon, O., Cleren, C., Moreau, J. L., Garcia, R. (2013). Postextinction fluoxetine treatment prevents stress-induced reemergence of extinguished fear. Psychopharmacology (Berl) 225, 209-216.

Deupree, J. D., Montgomery, M. D., Bylund, D. B. (2007). Pharmacological properties of the active

metabolites of the antidepressants desipramine and citalopram. Eur J Pharmacol 576, 55-60.

Di, S., Malcher-Lopes, R., Halmos, K. C., Tasker, J. G. (2003). Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J Neurosci 23, 4850-4857.

Difede, J., Cukor, J., Wyka, K., Olden, M., Hoffman, H., Lee, F. S., Altemus, M. (2014). D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial. Neuropsychopharmacology 39, 1052-1058.

Do-Monte, F. H., Allensworth, M., Carobrez, A. P. (2010a). Impairment of contextual conditioned fear extinction after microinjection of alpha-1-adrenergic blocker prazosin into the medial prefrontal cortex. Behav Brain Res 211, 89-95.

Do-Monte, F. H., Kincheski, G. C., Pavesi, E., Sordi, R., Assreuy, J., Carobrez, A. P. (2010b). Role of beta-adrenergic receptors in the ventromedial prefrontal cortex during contextual fear extinction in rats. Neurobiol Learn Mem 94, 318-328.

Do Monte, F. H., Souza, R. R., Bitencourt, R. M., Kroon, J. A., Takahashi, R. N. (2013). Infusion of

cannabidiol into infralimbic cortex facilitates fear extinction via CB1 receptors. Behav Brain Res 250, 23-27.

Dobi, A., Sartori, S. B., Busti, D., Van der Putten, H., Singewald, N., Shigemoto, R., Ferraguti, F. (2013). Neural substrates for the distinct effects of presynaptic group III metabotropic glutamate receptors on extinction of contextual fear conditioning in mice. Neuropharmacology 66, 274289.

Dolmetsch, R. E., Pajvani, U., Fife, K., Spotts, J. M., Greenberg, M. E. (2001). Signaling to the nucleus by an L-type calcium channel-calmodulin complex through the MAP kinase pathway. Science 294, 333-339.

DSM-5 (2013). Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition APA Press: Washington, DC.

Dubreucq, S., Koehl, M., Abrous, D. N., Marsicano, G., Chaouloff, F. (2010). CB1 receptor deficiency decreases wheel-running activity: consequences on emotional behaviours and hippocampal neurogenesis. Exp Neurol 224, 106-113.

Dubrovina, N. I., Zinov'eva, D. V. (2010). Effects of activation and blockade of dopamine receptors on the extinction of a passive avoidance reaction in mice with a depressive-like state. Neurosci Behav Physiol 40, 55-59.

Dunlop, B. W., Mansson, E., Gerardi, M. (2012). Pharmacological innovations for posttraumatic stress disorder and medication- enhanced psychotherapy. Curr Pharm Des 18, 5645-5658.

Duvarci, S., Pare, D. (2014). Amygdala Microcircuits Controlling Learned Fear. Neuron 82, 966-980.

Ebner, K., Sartori, S. B., Singewald, N. (2009). Tachykinin receptors as therapeutic targets in stress-related disorders. Curr Pharm Des 15, 1647-1674.

Effting, M., Kindt, M. (2007). Contextual control of human fear associations in a renewal paradigm. Behav Res Ther 45, 2002-2018.

Egan, K. J., Carr, J. E., Hunt, D. D., Adamson, R. (1988). Endogenous opiate system and systematic desensitization. J Consult Clin Psychol 56, 287-291.

Ehrlich, I., Humeau, Y., Grenier, F., Ciocchi, S., Herry, C., Luthi, A. (2009). Amygdala inhibitory circuits and the control of fear memory. Neuron 62, 757-771.

El-Ghundi, M., O'Dowd, B. F., George, S. R. (2001). Prolonged fear responses in mice lacking dopamine D1 receptor. Brain Res 892, 86-93.

Eriksson, T. M., Holst, S., Stan, T. L., Hager, T., Sjogren, B., Ogren, S. O., Svenningsson, P., Stiedl, O. (2012). 5-HT1A and 5-HT7 receptor crosstalk in the regulation of emotional memory: implications for effects of selective serotonin reuptake inhibitors. Neuropharmacology 63, 1150-1160.

Eskandarian, S., Vafaei, A. A., Vaezi, G. H., Taherian, F., Kashefi, A., Rashidy-Pour, A. (2013). Effects of systemic administration of oxytocin on contextual fear extinction in a rat model of posttraumatic stress disorder. Basic Clin Neurosci 4, 315-322.

Falls, W. A., Miserendino, M. J., Davis, M. (1992). Extinction of fear-potentiated startle: blockade by infusion of an NMDA antagonist into the amygdala. J Neurosci 12, 854-863.

Farrell, L. J., Waters, A. M., Boschen, M. J., Hattingh, L., McConnell, H., Milliner, E. L., Collings, N.,

Zimmer-Gembeck, M., Shelton, D., Ollendick, T. H., Testa, C., Storch, E. A. (2013). Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and preliminary results of a randomized pilot trial of D-cycloserine-augmented behavior therapy. Depress Anxiety 30, 723-731.

Felder, C. C., Jose, P. A., Axelrod, J. (1989). The dopamine-1 agonist, SKF 82526, stimulates

phospholipase-C activity independent of adenylate cyclase. J Pharmacol Exp Ther 248, 171175.

Fendt, M., Fanselow, M. S. (1999). The neuroanatomical and neurochemical basis of conditioned fear. Neurosci Biobehav Rev 23, 743-760.

Fendt, M., Imobersteg, S., Peterlik, D., Chaperon, F., Mattes, C., Wittmann, C., Olpe, H. R.,

Mosbacher, J., Vranesic, I., van der Putten, H., McAllister, K. H., Flor, P. J., Gee, C. E. (2013).

Differential roles of mGlu(7) and mGlu(8) in amygdala-dependent behavior and physiology. Neuropharmacology 72, 215-223.

Fendt, M., Schmid, S., Thakker, D. R., Jacobson, L. H., Yamamoto, R., Mitsukawa, K., Maier, R., Natt, F., Husken, D., Kelly, P. H., McAllister, K. H., Hoyer, D., van der Putten, H., Cryan, J. F., Flor, P. J. (2008). mGluR7 facilitates extinction of aversive memories and controls amygdala plasticity. Mol Psychiatry 13, 970-979.

Fernandez Espejo, E. (2003). Prefrontocortical dopamine loss in rats delays long-term extinction of contextual conditioned fear, and reduces social interaction without affecting short-term social interaction memory. Neuropsychopharmacology 28, 490-498.

Fiorelli, R., Rudolph, U., Straub, C. J., Feldon, J., Yee, B. K. (2008). Affective and cognitive effects of global deletion of alpha3-containing gamma-aminobutyric acid-A receptors. Behav Pharmacol 19, 582-596.

Fiorenza, N. G., Rosa, J., Izquierdo, I., Myskiw, J. C. (2012). Modulation of the extinction of two different fear-motivated tasks in three distinct brain areas. Behav Brain Res.

Fischer, A., Sananbenesi, F., Mungenast, A., Tsai, L. H. (2010). Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol Sci 31, 605-617.

Fischer, A., Radulovic, M., Schrick, C., Sananbenesi, F., Godovac-Zimmermann, J., Radulovic, J. (2007). Hippocampal Mek/Erk signaling mediates extinction of contextual freezing behavior. Neurobiol Learn Mem 87, 149-158.

Fitzgerald, P. J., Seemann, J. R., Maren, S. (2014a). Can fear extinction be enhanced? A review of pharmacological and behavioral findings. Brain Res Bull 105, 46-60.

Fitzgerald, P. J., Whittle, N., Flynn, S. M., Graybeal, C., Pinard, C. R., Gunduz-Cinar, O., Kravitz, A. V., Singewald, N., Holmes, A. (2014b). Prefrontal single-unit firing associated with deficient extinction in mice. Neurobiol Learn Mem 113, 69-81.

Flores, A., Valls-Comamala, V., Costa, G., Saravia, R., Maldonado, R., Berrendero, F. (2014). The hypocretin/orexin system mediates the extinction of fear memories. Neuropsychopharmacology 39, 2732-2741.

Fontanez-Nuin, D. E., Santini, E., Quirk, G. J., Porter, J. T. (2011). Memory for fear extinction requires mGluR5-mediated activation of infralimbic neurons. Cereb Cortex 21, 727-735.

Fritschy, J. M., Meskenaite, V., Weinmann, O., Honer, M., Benke, D., Mohler, H. (1999). GABAB-receptor splice variants GB1a and GB1b in rat brain: developmental regulation, cellular distribution and extrasynaptic localization. Eur J Neurosci 11, 761-768.

Fujita, Y., Morinobu, S., Takei, S., Fuchikami, M., Matsumoto, T., Yamamoto, S., Yamawaki, S. (2012). Vorinostat, a histone deacetylase inhibitor, facilitates fear extinction and enhances expression of the hippocampal NR2B-containing NMDA receptor gene. J Psychiatr Res.

Furia, B., Deng, L., Wu, K., Baylor, S., Kehn, K., Li, H., Donnelly, R., Coleman, T., Kashanchi, F. (2002). Enhancement of nuclear factor-kappa B acetylation by coactivator p300 and HIV-1 Tat proteins. J Biol Chem 277, 4973-4980.

Furini, C. R., Rossato, J. I., Bitencourt, L. L., Medina, J. H., Izquierdo, I., Cammarota, M. (2010). Beta-adrenergic receptors link NO/sGC/PKG signaling to BDNF expression during the consolidation of object recognition long-term memory. Hippocampus 20, 672-683.

Gafford, G. M., Guo, J. D., Flandreau, E. I., Hazra, R., Rainnie, D. G., Ressler, K. J. (2012). Cell-type specific deletion of GABA(A)alpha1 in corticotropin-releasing factor-containing neurons enhances anxiety and disrupts fear extinction. Proc Natl Acad Sci U S A 109, 16330-16335.

Gamelli, A. E., McKinney, B. C., White, J. A., Murphy, G. G. (2011). Deletion of the L-type calcium channel Ca(V) 1.3 but not Ca(V) 1.2 results in a diminished sAHP in mouse CA1 pyramidal neurons. Hippocampus 21, 133-141.

Ganon-Elazar, E., Akirav, I. (2013). Cannabinoids and traumatic stress modulation of contextual fear extinction and GR expression in the amygdala-hippocampal-prefrontal circuit. Psychoneuroendocrinology 38, 1675-1687.

Gao, J., Wang, W. Y., Mao, Y. W., Graff, J., Guan, J. S., Pan, L., Mak, G., Kim, D., Su, S. C., Tsai, L. H.

(2010). A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature 466, 1105-1109.

Gass, J. T., Olive, M. F. (2009). Positive allosteric modulation of mGluR5 receptors facilitates extinction of a cocaine contextual memory. Biol Psychiatry 65, 717-720.

Gelinas, J. N., Nguyen, P. V. (2005). Beta-adrenergic receptor activation facilitates induction of a

protein synthesis-dependent late phase of long-term potentiation. J Neurosci 25, 3294-3303.

Gimpl, G., Fahrenholz, F. (2001). The oxytocin receptor system: structure, function, and regulation. Physiol Rev 81, 629-683.

Glotzbach-Schoon, E., Andreatta, M., Reif, A., Ewald, H., Troger, C., Baumann, C., Deckert, J.,

Muhlberger, A., Pauli, P. (2013). Contextual fear conditioning in virtual reality is affected by 5HTTLPR and NPSR1 polymorphisms: effects on fear-potentiated startle. Front Behav Neurosci 7, 31.

Goddyn, H., Callaerts-Vegh, Z., Stroobants, S., Dirikx, T., Vansteenwegen, D., Hermans, D., van der

Putten, H., D'Hooge, R. (2008). Deficits in acquisition and extinction of conditioned responses in mGluR7 knockout mice. Neurobiol Learn Mem 90, 103-111.

Gogolla, N., Caroni, P., Luthi, A., Herry, C. (2009). Perineuronal nets protect fear memories from erasure. Science 325, 1258-1261.

Goldman, M. S. (1977). Effect of chlordiazepoxide administered early in extinction on subsequent extinction of a conditioned emotional response in rats: implications for human clinical use. Psychol Rep 40, 783-786.

Gomes, G. M., Mello, C. F., da Rosa, M. M., Bochi, G. V., Ferreira, J., Barron, S., Rubin, M. A. (2010). Polyaminergic agents modulate contextual fear extinction in rats. Neurobiol Learn Mem 93, 589-595.

Gonzalez-Lima, F., Bruchey, A. K. (2004). Extinction memory improvement by the metabolic enhancer methylene blue. Learn Mem 11, 633-640.

Gourley, S. L., Kedves, A. T., Olausson, P., Taylor, J. R. (2009). A history of corticosterone exposure

regulates fear extinction and cortical NR2B, GluR2/3, and BDNF. Neuropsychopharmacology 34, 707-716.

Graff, J., Joseph, N. F., Horn, M. E., Samiei, A., Meng, J., Seo, J., Rei, D., Bero, A. W., Phan, T. X.,

Wagner, F., Holson, E., Xu, J., Sun, J., Neve, R. L., Mach, R. H., Haggarty, S. J., Tsai, L. H. (2014). Epigenetic priming of memory updating during reconsolidation to attenuate remote fear memories. Cell 156, 261-276.

Graham, B. M., Richardson, R. (2009). Acute systemic fibroblast growth factor-2 enhances long-term extinction of fear and reduces reinstatement in rats. Neuropsychopharmacology 34, 18751882.

Graham, B. M., Richardson, R. (2010). Fibroblast growth factor-2 enhances extinction and reduces renewal of conditioned fear. Neuropsychopharmacology 35, 1348-1355.

Graham, B. M., Richardson, R. (2011a). Memory of fearful events: the role of fibroblast growth factor-2 in fear acquisition and extinction. Neuroscience 189, 156-169.

Graham, B. M., Richardson, R. (2011b). Intraamygdala infusion of fibroblast growth factor 2 enhances extinction and reduces renewal and reinstatement in adult rats. J Neurosci 31, 14151-14157.

Graham, B. M., Langton, J. M., Richardson, R. (2011). Pharmacological enhancement of fear reduction: preclinical models. Br J Pharmacol 164, 1230-1247.

Grayson, D. R., Kundakovic, M., Sharma, R. P. (2010). Is there a future for histone deacetylase

inhibitors in the pharmacotherapy of psychiatric disorders? Mol Pharmacol 77, 126-135.

Griebel, G., Holmes, A. (2013). 50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov 12, 667-687.

Guaiana, G., Barbui, C., Cipriani, A. (2010). Hydroxyzine for generalised anxiety disorder. Cochrane Database Syst Rev CD006815.

Guan, Z., Giustetto, M., Lomvardas, S., Kim, J. H., Miniaci, M. C., Schwartz, J. H., Thanos, D., Kandel, E. R. (2002). Integration of long-term-memory-related synaptic plasticity involves bidirectional regulation of gene expression and chromatin structure. Cell 111, 483-493.

Guastella, A. J., Lovibond, P. F., Dadds, M. R., Mitchell, P., Richardson, R. (2007). A randomized

controlled trial of the effect of D-cycloserine on extinction and fear conditioning in humans. Behav Res Ther 45, 663-672.

Guastella, A. J., Richardson, R., Lovibond, P. F., Rapee, R. M., Gaston, J. E., Mitchell, P., Dadds, M. R.

(2008). A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry 63, 544-549.

Guedea, A. L., Schrick, C., Guzman, Y. F., Leaderbrand, K., Jovasevic, V., Corcoran, K. A., Tronson, N.

C., Radulovic, J. (2011). ERK-associated changes of AP-1 proteins during fear extinction. Mol Cell Neurosci 47, 137-144.

Guerra, G. P., Mello, C. F., Sauzem, P. D., Berlese, D. B., Furian, A. F., Tabarelli, Z., Rubin, M. A. (2006). Nitric oxide is involved in the memory facilitation induced by spermidine in rats. Psychopharmacology (Berl) 186, 150-158.

Gunduz-Cinar, O., Hill, M. N., McEwen, B. S., Holmes, A. (2013a). Amygdala FAAH and anandamide: mediating protection and recovery from stress. Trends Pharmacol Sci 34, 637-644.

Gunduz-Cinar, O., MacPherson, K. P., Cinar, R., Gamble-George, J., Sugden, K., Williams, B.,

Godlewski, G., Ramikie, T. S., Gorka, A. X., Alapafuja, S. O., Nikas, S. P., Makriyannis, A., Poulton, R., Patel, S., Hariri, A. R., Caspi, A., Moffitt, T. E., Kunos, G., Holmes, A. (2013b). Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry 18, 813-823.

Gunn, B. G., Cunningham, L., Mitchell, S. G., Swinny, J. D., Lambert, J. J., Belelli, D. (2014). GABA receptor-acting neurosteroids: A role in the development and regulation of the stress response. Front Neuroendocrinol.

Guo, J. U., Su, Y., Shin, J. H., Shin, J., Li, H., Xie, B., Zhong, C., Hu, S., Le, T., Fan, G., Zhu, H., Chang, Q., Gao, Y., Ming, G. L., Song, H. (2014). Distribution, recognition and regulation of non-CpG methylation in the adult mammalian brain. Nat Neurosci 17, 215-222.

Gupta, S. C., Hillman, B. G., Prakash, A., Ugale, R. R., Stairs, D. J., Dravid, S. M. (2013). Effect of D-cycloserine in conjunction with fear extinction training on extracellular signal-regulated kinase activation in the medial prefrontal cortex and amygdala in rat. Eur J Neurosci 37, 18111822.

Gustavsson, A. et al. (2011). Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21, 718-779.

Gutman, A. R., Yang, Y., Ressler, K. J., Davis, M. (2008). The role of neuropeptide Y in the expression and extinction of fear-potentiated startle. J Neurosci 28, 12682-12690.

Gutner, C. A., Weinberger, J., Hofmann, S. G. (2012). The effect of D-cycloserine on subliminal cue exposure in spider fearful individuals. Cogn Behav Ther 41, 335-344.

Haaker, J., Gaburro, S., Sah, A., Gartmann, N., Lonsdorf, T. B., Meier, K., Singewald, N., Pape, H. C., Morellini, F., Kalisch, R. (2013). Single dose of L-dopa makes extinction memories context-independent and prevents the return of fear. Proc Natl Acad Sci U S A 110, E2428-2436.

Haggarty, S. J., Tsai, L. H. (2011). Probing the role of HDACs and mechanisms of chromatin-mediated neuroplasticity. Neurobiol Learn Mem 96, 41-52.

Hait, N. C., Wise, L. E., Allegood, J. C., O'Brien, M., Avni, D., Reeves, T. M., Knapp, P. E., Lu, J., Luo, C., Miles, M. F., Milstien, S., Lichtman, A. H., Spiegel, S. (2014). Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory. Nat Neurosci.

Harrell, A. V., Allan, A. M. (2003). Improvements in hippocampal-dependent learning and

decremental attention in 5-HT(3) receptor overexpressing mice. Learn Mem 10, 410-419.

Harris, J. A., Westbrook, R. F. (1998). Evidence that GABA transmission mediates context-specific extinction of learned fear. Psychopharmacology (Berl) 140, 105-115.

Harrison, S. A., Buxton, J. M., Clancy, B. M., Czech, M. P. (1990). Insulin regulation of hexose transport in mouse 3T3-L1 cells expressing the human HepG2 glucose transporter. Journal of Biological Chemistry 265, 20106-20116.

Hart, G., Harris, J. A., Westbrook, R. F. (2009). Systemic or intra-amygdala injection of a

benzodiazepine (midazolam) impairs extinction but spares re-extinction of conditioned fear responses. Learn Mem 16, 53-61.

Hart, G., Harris, J. A., Westbrook, R. F. (2010). Systemic or intra-amygdala infusion of the

benzodiazepine, midazolam, impairs learning, but facilitates re-learning to inhibit fear responses in extinction. Learn Mem 17, 210-220.

Hart, G., Panayi, M. C., Harris, J. A., Westbrook, R. F. (2014). Benzodiazepine treatment can impair or spare extinction, depending on when it is given. Behav Res Ther 56, 22-29.

Hartley, C. A., McKenna, M. C., Salman, R., Holmes, A., Casey, B. J., Phelps, E. A., Glatt, C. E. (2012). Serotonin transporter polyadenylation polymorphism modulates the retention of fear extinction memory. Proc Natl Acad Sci U S A 109, 5493-5498.

Harvey, B. H., Duvenhage, I., Viljoen, F., Scheepers, N., Malan, S. F., Wegener, G., Brink, C. B., Petzer, J. P. (2010). Role of monoamine oxidase, nitric oxide synthase and regional brain monoamines in the antidepressant-like effects of methylene blue and selected structural analogues. Biochem Pharmacol 80, 1580-1591.

Haubensak, W., Kunwar, P. S., Cai, H., Ciocchi, S., Wall, N. R., Ponnusamy, R., Biag, J., Dong, H. W., Deisseroth, K., Callaway, E. M., Fanselow, M. S., Luthi, A., Anderson, D. J. (2010). Genetic dissection of an amygdala microcircuit that gates conditioned fear. Nature 468, 270-276.

Haug, T. T., Blomhoff, S., Hellstrom, K., Holme, I., Humble, M., Madsbu, H. P., Wold, J. E. (2003).

Exposure therapy and sertraline in social phobia: I-year follow-up of a randomised controlled trial. Br J Psychiatry 182, 312-318.

Hauner, K. K., Mineka, S., Voss, J. L., Paller, K. A. (2012). Exposure therapy triggers lasting reorganization of neural fear processing. Proc Natl Acad Sci U S A 109, 9203-9208.

Heaney, C. F., Bolton, M. M., Murtishaw, A. S., Sabbagh, J. J., Magcalas, C. M., Kinney, J. W. (2012).

Baclofen administration alters fear extinction and GABAergic protein levels. Neurobiol Learn Mem 98, 261-271.

Hefner, K., Whittle, N., Juhasz, J., Norcross, M., Karlsson, R. M., Saksida, L. M., Bussey, T. J.,

Singewald, N., Holmes, A. (2008). Impaired fear extinction learning and cortico-amygdala circuit abnormalities in a common genetic mouse strain. J Neurosci 28, 8074-8085.

Heinrichs, M., Baumgartner, T., Kirschbaum, C., Ehlert, U. (2003). Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol Psychiatry 54, 13891398.

Heldt, S. A., Ressler, K. J. (2007). Training-induced changes in the expression of GABAA-associated genes in the amygdala after the acquisition and extinction of Pavlovian fear. Eur J Neurosci 26, 3631-3644.

Heldt, S. A., Mou, L., Ressler, K. J. (2012). In vivo knockdown of GAD67 in the amygdala disrupts fear extinction and the anxiolytic-like effect of diazepam in mice. Transl Psychiatry 2, e181.

Heldt, S. A., Stanek, L., Chhatwal, J. P., Ressler, K. J. (2007). Hippocampus-specific deletion of BDNF in adult mice impairs spatial memory and extinction of aversive memories. Mol Psychiatry 12, 656-670.

Heresco-Levy, U., Kremer, I., Javitt, D. C., Goichman, R., Reshef, A., Blanaru, M., Cohen, T. (2002).

Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder. Int J Neuropsychopharmacol 5, 301-307.

Herry, C., Trifilieff, P., Micheau, J., Luthi, A., Mons, N. (2006). Extinction of auditory fear conditioning requires MAPK/ERK activation in the basolateral amygdala. Eur J Neurosci 24, 261-269.

Herry, C., Ciocchi, S., Senn, V., Demmou, L., Muller, C., Luthi, A. (2008). Switching on and off fear by distinct neuronal circuits. Nature 454, 600-606.

Herry, C., Ferraguti, F., Singewald, N., Letzkus, J. J., Ehrlich, I., Luthi, A. (2010). Neuronal circuits of fear extinction. Eur J Neurosci 31, 599-612.

Hetzenauer, A., Sinnegger-Brauns, M. J., Striessnig, J., Singewald, N. (2006). Brain activation pattern induced by stimulation of L-type Ca2+-channels: contribution of Ca(V)1.3 and Ca(V)1.2 isoforms. Neuroscience 139, 1005-1015.

Hikind, N., Maroun, M. (2008). Microinfusion of the D1 receptor antagonist, SCH23390 into the IL but not the BLA impairs consolidation of extinction of auditory fear conditioning. Neurobiol Learn Mem 90, 217-222.

Hill, M. N., Ho, W. S., Meier, S. E., Gorzalka, B. B., Hillard, C. J. (2005). Chronic corticosterone

treatment increases the endocannabinoid 2-arachidonylglycerol in the rat amygdala. Eur J Pharmacol 528, 99-102.

Hill, M. N., McLaughlin, R. J., Pan, B., Fitzgerald, M. L., Roberts, C. J., Lee, T. T., Karatsoreos, I. N., Mackie, K., Viau, V., Pickel, V. M., McEwen, B. S., Liu, Q. S., Gorzalka, B. B., Hillard, C. J. (2011). Recruitment of prefrontal cortical endocannabinoid signaling by glucocorticoids contributes to termination of the stress response. J Neurosci 31, 10506-10515.

Hoffman, E. J., Mathew, S. J. (2008). Anxiety disorders: a comprehensive review of pharmacotherapies. Mt Sinai J Med 75, 248-262.

Hofmann, S. G. (2012). Psychobiological approaches for anxiety disorders: Treament combination strategies. Wiley series in Clincial Psychology.

Hofmann, S. G. (2014). D-cycloserine for treating anxiety disorders: making good exposures better and bad exposures worse. Depress Anxiety 31, 175-177.

Hofmann, S. G., Smits, J. A. (2008). Cognitive-behavioral therapy for adult anxiety disorders: a metaanalysis of randomized placebo-controlled trials. J Clin Psychiatry 69, 621-632.

Hofmann, S. G., Wu, J. Q., Boettcher, H. (2013a). D-Cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders. Biol Mood Anxiety Disord 3, 11.

Hofmann, S. G., Meuret, A. E., Smits, J. A., Simon, N. M., Pollack, M. H., Eisenmenger, K., Shiekh, M., Otto, M. W. (2006). Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 63, 298-304.

Hofmann, S. G., Smits, J. A., Rosenfield, D., Simon, N., Otto, M. W., Meuret, A. E., Marques, L., Fang, A., Tart, C., Pollack, M. H. (2013b). D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am J Psychiatry 170, 751-758.

Holbrook, T. L., Galarneau, M. R., Dye, J. L., Quinn, K., Dougherty, A. L. (2010). Morphine use after combat injury in Iraq and post-traumatic stress disorder. N Engl J Med 362, 110-117.

Holmes, A., Quirk, G. J. (2010). Pharmacological facilitation of fear extinction and the search for

adjunct treatments for anxiety disorders--the case of yohimbine. Trends Pharmacol Sci 31, 27.

Holmes, A., Singewald, N. (2013). Individual differences in recovery from traumatic fear. Trends Neurosci 36, 23-31.

Holmes, A., Heilig, M., Rupniak, N. M., Steckler, T., Griebel, G. (2003). Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol Sci 24, 580-588.

Holst, B., Egerod, K. L., Schild, E., Vickers, S. P., Cheetham, S., Gerlach, L. O., Storjohann, L., Stidsen, C. E., Jones, R., Beck-Sickinger, A. G., Schwartz, T. W. (2007). GPR39 signaling is stimulated by zinc ions but not by obestatin. Endocrinology 148, 13-20.

Holtzman-Assif, O., Laurent, V., Westbrook, R. F. (2010). Blockade of dopamine activity in the nucleus accumbens impairs learning extinction of conditioned fear. Learn Mem 17, 71-75.

Huang, F., Yang, Z., Liu, X., Li, C. Q. (2014). Melatonin facilitates extinction, but not acquisition or expression, of conditional cued fear in rats. BMC Neurosci 15, 86.

Huber, D., Veinante, P., Stoop, R. (2005). Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. Science 308, 245-248.

Hugues, S., Garcia, R., Lena, I. (2007). Time course of extracellular catecholamine and glutamate levels in the rat medial prefrontal cortex during and after extinction of conditioned fear. Synapse 61, 933-937.

ICD-10 (1994). World Health Organisation International classification of diseases.

Irwin, R. P., Lin, S. Z., Rogawski, M. A., Purdy, R. H., Paul, S. M. (1994). Steroid potentiation and inhibition of N-methyl-D-aspartate receptor-mediated intracellular Ca++ responses: structure-activity studies. J Pharmacol Exp Ther 271, 677-682.

Ishikawa, S., Saito, Y., Yanagawa, Y., Otani, S., Hiraide, S., Shimamura, K., Matsumoto, M., Togashi, H. (2012). Early postnatal stress alters extracellular signal-regulated kinase signaling in the corticolimbic system modulating emotional circuitry in adult rats. Eur J Neurosci 35, 135-145.

Ito, S., Shen, L., Dai, Q., Wu, S. C., Collins, L. B., Swenberg, J. A., He, C., Zhang, Y. (2011). Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333, 13001303.

Itzhak, Y., Anderson, K. L., Kelley, J. B., Petkov, M. (2012). Histone acetylation rescues contextual fear conditioning in nNOS KO mice and accelerates extinction of cued fear conditioning in wild type mice. Neurobiol Learn Mem 97, 409-417.

Izumi, T., Ohmura, Y., Futami, Y., Matsuzaki, H., Kubo, Y., Yoshida, T., Yoshioka, M. (2012). Effects of serotonergic terminal lesion in the amygdala on conditioned fear and innate fear in rats. Eur J Pharmacol 696, 89-95.

Jacobson, L. H., Kelly, P. H., Bettler, B., Kaupmann, K., Cryan, J. F. (2006). GABA(B(1)) receptor

isoforms differentially mediate the acquisition and extinction of aversive taste memories. J Neurosci 26, 8800-8803.

Janak, P. H., Corbit, L. H. (2011). Deepened extinction following compound stimulus presentation: noradrenergic modulation. Learn Mem 18, 1-10.

Jasnow, A. M., Ehrlich, D. E., Choi, D. C., Dabrowska, J., Bowers, M. E., McCullough, K. M., Rainnie, D.

G., Ressler, K. J. (2013). Thy1-expressing neurons in the basolateral amygdala may mediate fear inhibition. J Neurosci 33, 10396-10404.

Johnson, D. M., Baker, J. D., Azorlosa, J. L. (2000). Acquisition, extinction, and reinstatement of

Pavlovian fear conditioning: the roles of the NMDA receptor and nitric oxide. Brain Res 857, 66-70.

Jovanovic, T., Kazama, A., Bachevalier, J., Davis, M. (2012). Impaired safety signal learning may be a biomarker of PTSD. Neuropharmacology 62, 695-704.

Jungling, K., Seidenbecher, T., Sosulina, L., Lesting, J., Sangha, S., Clark, S. D., Okamura, N., Duangdao, D. M., Xu, Y. L., Reinscheid, R. K., Pape, H. C. (2008). Neuropeptide S-mediated control of fear expression and extinction: role of intercalated GABAergic neurons in the amygdala. Neuron 59, 298-310.

Kabir, Z. D., Katzman, A. C., Kosofsky, B. E. (2013). Molecular mechanisms mediating a deficit in recall of fear extinction in adult mice exposed to cocaine in utero. PLoS One 8, e84165.

Kamprath, K., Marsicano, G., Tang, J., Monory, K., Bisogno, T., Di Marzo, V., Lutz, B., Wotjak, C. T.

(2006). Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. J Neurosci 26, 6677-6686.

Karpova, N. N., Pickenhagen, A., Lindholm, J., Tiraboschi, E., Kulesskaya, N., Agustsdottir, A., Antila,

H., Popova, D., Akamine, Y., Bahi, A., Sullivan, R., Hen, R., Drew, L. J., Castren, E. (2011). Fear erasure in mice requires synergy between antidepressant drugs and extinction training. Science 334, 1731-1734.

Karst, H., Nair, S., Velzing, E., Rumpff-van Essen, L., Slagter, E., Shinnick-Gallagher, P., Joels, M.

(2002). Glucocorticoids alter calcium conductances and calcium channel subunit expression in basolateral amygdala neurons. Eur J Neurosci 16, 1083-1089.

Kawahara, H., Yoshida, M., Yokoo, H., Nishi, M., Tanaka, M. (1993). Psychological stress increases

serotonin release in the rat amygdala and prefrontal cortex assessed by in vivo microdialysis. Neurosci Lett 162, 81-84.

Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., Walters, E. E. (2005). Lifetime

prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62, 593-602.

Kessler, R. C., Avenevoli, S., McLaughlin, K. A., Green, J. G., Lakoma, M. D., Petukhova, M., Pine, D. S., Sampson, N. A., Zaslavsky, A. M., Merikangas, K. R. (2012). Lifetime co-morbidity of DSM-IV

disorders in the US National Comorbidity Survey Replication Adolescent Supplement (NCS-A). Psychol Med 42, 1997-2010.

Kim, J., Lee, S., Park, H., Song, B., Hong, I., Geum, D., Shin, K., Choi, S. (2007). Blockade of amygdala metabotropic glutamate receptor subtype 1 impairs fear extinction. Biochem Biophys Res Commun 355, 188-193.

Kim, J. H., Richardson, R. (2007). A developmental dissociation of context and GABA effects on extinguished fear in rats. Behav Neurosci 121, 131-139.

Kim, J. H., Richardson, R. (2009). Expression of renewal is dependent on the extinction-test interval rather than the acquisition-extinction interval. Behav Neurosci 123, 641-649.

Kindt, M., Soeter, M., Vervliet, B. (2009). Beyond extinction: erasing human fear responses and preventing the return of fear. Nat Neurosci 12, 256-258.

Kirsch, P., Esslinger, C., Chen, Q., Mier, D., Lis, S., Siddhanti, S., Gruppe, H., Mattay, V. S., Gallhofer, B., Meyer-Lindenberg, A. (2005). Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci 25, 11489-11493.

Klumpers, F., Denys, D., Kenemans, J. L., Grillon, C., van der Aart, J., Baas, J. M. (2012). Testing the effects of Delta9-THC and D-cycloserine on extinction of conditioned fear in humans. J Psychopharmacol 26, 471-478.

Knapska, E., Macias, M., Mikosz, M., Nowak, A., Owczarek, D., Wawrzyniak, M., Pieprzyk, M., Cymerman, I. A., Werka, T., Sheng, M., Maren, S., Jaworski, J., Kaczmarek, L. (2012). Functional anatomy of neural circuits regulating fear and extinction. Proc Natl Acad Sci U S A 109, 17093-17098.

Knobloch, H. S., Charlet, A., Hoffmann, L. C., Eliava, M., Khrulev, S., Cetin, A. H., Osten, P., Schwarz, M. K., Seeburg, P. H., Stoop, R., Grinevich, V. (2012). Evoked axonal oxytocin release in the central amygdala attenuates fear response. Neuron 73, 553-566.

Kohler, C., Swanson, L. W., Haglund, L., Wu, J. Y. (1985). The cytoarchitecture, histochemistry and projections of the tuberomammillary nucleus in the rat. Neuroscience 16, 85-110.

Kondo, M., Nakamura, Y., Ishida, Y., Yamada, T., Shimada, S. (2014). The 5-HT3A receptor is essential for fear extinction. Learn Mem 21, 1-4.

Kong, E., Monje, F. J., Hirsch, J., Pollak, D. D. (2014). Learning not to fear: neural correlates of learned safety. Neuropsychopharmacology 39, 515-527.

Kornberg, R. D., Lorch, Y. (1999). Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 98, 285-294.

Koszycki, D., Taljaard, M., Segal, Z., Bradwejn, J. (2011). A randomized trial of sertraline, self-

administered cognitive behavior therapy, and their combination for panic disorder. Psychol Med 41, 373-383.

Kouzarides, T. (2007). Chromatin modifications and their function. Cell 128, 693-705.

Kroner, S., Rosenkranz, J. A., Grace, A. A., Barrionuevo, G. (2005). Dopamine modulates excitability of basolateral amygdala neurons in vitro. J Neurophysiol 93, 1598-1610.

Kuhnert, S., Meyer, C., Koch, M. (2013). Involvement of cannabinoid receptors in the amygdala and prefrontal cortex of rats in fear learning, consolidation, retrieval and extinction. Behav Brain Res 250, 274-284.

Kuriyama, K., Honma, M., Soshi, T., Fujii, T., Kim, Y. (2011). Effect of D-cycloserine and valproic acid on the extinction of reinstated fear-conditioned responses and habituation of fear conditioning in healthy humans: a randomized controlled trial. Psychopharmacology (Berl) 218, 589-597.

Kushner, M. G., Kim, S. W., Donahue, C., Thuras, P., Adson, D., Kotlyar, M., McCabe, J., Peterson, J., Foa, E. B. (2007). D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry 62, 835-838.

Laborda, M. A., Miller, R. R. (2013). Preventing return of fear in an animal model of anxiety: additive effects of massive extinction and extinction in multiple contexts. Behav Ther 44, 249-261.

Labuschagne, I., Phan, K. L., Wood, A., Angstadt, M., Chua, P., Heinrichs, M., Stout, J. C., Nathan, P. J.

(2010). Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. Neuropsychopharmacology 35, 2403-2413.

Lach, G., de Lima, T. C. (2013). Role of NPY Y1 receptor on acquisition, consolidation and extinction on contextual fear conditioning: dissociation between anxiety, locomotion and nonemotional memory behavior. Neurobiol Learn Mem 103, 26-33.

Laham, R. J., Chronos, N. A., Pike, M., Leimbach, M. E., Udelson, J. E., Pearlman, J. D., Pettigrew, R. I., Whitehouse, M. J., Yoshizawa, C., Simons, M. (2000). Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. J Am Coll Cardiol 36, 2132-2139.

Lahoud, N., Maroun, M. (2013). Oxytocinergic manipulations in corticolimbic circuit differentially affect fear acquisition and extinction. Psychoneuroendocrinology 38, 2184-2195.

Langton, J. M., Richardson, R. (2008). D-cycloserine facilitates extinction the first time but not the second time: an examination of the role of NMDA across the course of repeated extinction sessions. Neuropsychopharmacology 33, 3096-3102.

Langton, J. M., Richardson, R. (2010). The effect of D-cycloserine on immediate vs. delayed extinction of learned fear. Learn Mem 17, 547-551.

Langton, J. M., Kim, J. H., Nicholas, J., Richardson, R. (2007). The effect of the NMDA receptor

antagonist MK-801 on the acquisition and extinction of learned fear in the developing rat. Learn Mem 14, 665-668.

Lattal, K. M., Radulovic, J., Lukowiak, K. (2006). Extinction: [corrected] does it or doesn't it? The

requirement of altered gene activity and new protein synthesis. Biol Psychiatry 60, 344-351.

Lattal, K. M., Barrett, R. M., Wood, M. A. (2007). Systemic or intrahippocampal delivery of histone deacetylase inhibitors facilitates fear extinction. Behav Neurosci 121, 1125-1131.

Laurent, V., Westbrook, R. F. (2008). Distinct contributions of the basolateral amygdala and the

medial prefrontal cortex to learning and relearning extinction of context conditioned fear. Learn Mem 15, 657-666.

Laurent, V., Westbrook, R. F. (2009). Inactivation of the infralimbic but not the prelimbic cortex impairs consolidation and retrieval of fear extinction. Learn Mem 16, 520-529.

Laurent, V., Marchand, A. R., Westbrook, R. F. (2008). The basolateral amygdala is necessary for

learning but not relearning extinction of context conditioned fear. Learn Mem 15, 304-314.

Leaderbrand, K., Corcoran, K. A., Radulovic, J. (2014). Co-activation of NR2A and NR2B subunits induces resistance to fear extinction. Neurobiol Learn Mem 113, 35-40.

Lebron-Milad, K., Tsareva, A., Ahmed, N., Milad, M. R. (2013). Sex differences and estrous cycle in female rats interact with the effects of fluoxetine treatment on fear extinction. Behav Brain Res 253, 217-222.

Ledgerwood, L., Richardson, R., Cranney, J. (2003). Effects of D-cycloserine on extinction of conditioned freezing. Behav Neurosci 117, 341-349.

Ledgerwood, L., Richardson, R., Cranney, J. (2004). D-cycloserine and the facilitation of extinction of conditioned fear: consequences for reinstatement. Behav Neurosci 118, 505-513.

Ledgerwood, L., Richardson, R., Cranney, J. (2005). D-cycloserine facilitates extinction of learned fear: effects on reacquisition and generalized extinction. Biol Psychiatry 57, 841-847.

LeDoux, J. E., Iwata, J., Cicchetti, P., Reis, D. J. (1988). Different projections of the central amygdaloid nucleus mediate autonomic and behavioral correlates of conditioned fear. J Neurosci 8, 2517-2529.

Lee, H., Kim, J. J. (1998). Amygdalar NMDA receptors are critical for new fear learning in previously fear-conditioned rats. J Neurosci 18, 8444-8454.

Lee, H. S., Lee, B. Y., Waterhouse, B. D. (2005). Retrograde study of projections from the

tuberomammillary nucleus to the dorsal raphe and the locus coeruleus in the rat. Brain Res 1043, 65-75.

Lee, J. L., Milton, A. L., Everitt, B. J. (2006). Reconsolidation and extinction of conditioned fear: inhibition and potentiation. J Neurosci 26, 10051-10056.

Lee, S. P., So, C. H., Rashid, A. J., Varghese, G., Cheng, R., Lanca, A. J., O'Dowd, B. F., George, S. R. (2004). Dopamine D1 and D2 receptor Co-activation generates a novel phospholipase C-mediated calcium signal. Journal of Biological Chemistry 279, 35671-35678.

Lehner, M., Wislowska-Stanek, A., Taracha, E., Maciejak, P., Szyndler, J., Skorzewska, A., Turzynska, D., Sobolewska, A., Hamed, A., Bidzinski, A., Plaznik, A. (2010). The effects of midazolam and D-cycloserine on the release of glutamate and GABA in the basolateral amygdala of low and high anxiety rats during extinction trial of a conditioned fear test. Neurobiol Learn Mem 94, 468-480.

Lemtiri-Chlieh, F., Levine, E. S. (2010). BDNF evokes release of endogenous cannabinoids at layer 2/3 inhibitory synapses in the neocortex. J Neurophysiol 104, 1923-1932.

Levenson, J. M., Roth, T. L., Lubin, F. D., Miller, C. A., Huang, I. C., Desai, P., Malone, L. M., Sweatt, J. D. (2006). Evidence that DNA (cytosine-5) methyltransferase regulates synaptic plasticity in the hippocampus. J Biol Chem 281, 15763-15773.

Li, C., Dabrowska, J., Hazra, R., Rainnie, D. G. (2011). Synergistic activation of dopamine D1 and TrkB receptors mediate gain control of synaptic plasticity in the basolateral amygdala. PLoS One 6, e26065.

Li, S. H., Westbrook, R. F. (2008). Massed extinction trials produce better short-term but worse long-term loss of context conditioned fear responses than spaced trials. J Exp Psychol Anim Behav Process 34, 336-351.

Li, X., Wei, W., Zhao, Q. Y., Widagdo, J., Baker-Andresen, D., Flavell, C. R., D'Alessio, A., Zhang, Y., Bredy, T. W. (2014). Neocortical Tet3-mediated accumulation of 5-hydroxymethylcytosine promotes rapid behavioral adaptation. Proc Natl Acad Sci U S A 111, 7120-7125.

Likhtik, E., Popa, D., Apergis-Schoute, J., Fidacaro, G. A., Pare, D. (2008). Amygdala intercalated neurons are required for expression of fear extinction. Nature 454, 642-645.

Lin, C. H., Lee, C. C., Gean, P. W. (2003a). Involvement of a calcineurin cascade in amygdala depotentiation and quenching of fear memory. Mol Pharmacol 63, 44-52.

Lin, C. H., Yeh, S. H., Lu, H. Y., Gean, P. W. (2003b). The similarities and diversities of signal pathways leading to consolidation of conditioning and consolidation of extinction of fear memory. J Neurosci 23, 8310-8317.

Lin, H. C., Mao, S. C., Su, C. L., Gean, P. W. (2009). The role of prefrontal cortex CB1 receptors in the modulation of fear memory. Cereb Cortex 19, 165-175.

Lin, H. C., Mao, S. C., Su, C. L., Gean, P. W. (2010). Alterations of excitatory transmission in the lateral amygdala during expression and extinction of fear memory. Int J Neuropsychopharmacol 13, 335-345.

Lin, Q., Wei, W., Coelho, C. M., Li, X., Baker-Andresen, D., Dudley, K., Ratnu, V. S., Boskovic, Z., Kobor, M. S., Sun, Y. E., Bredy, T. W. (2011). The brain-specific microRNA miR-128b regulates the formation of fear-extinction memory. Nat Neurosci 14, 1115-1117.

Litz, B. T., Salters-Pedneault, K., Steenkamp, M. M., Hermos, J. A., Bryant, R. A., Otto, M. W.,

Hofmann, S. G. (2012). A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder. J Psychiatr Res 46, 1184-1190.

Liu, J. L., Li, M., Dang, X. R., Wang, Z. H., Rao, Z. R., Wu, S. X., Li, Y. Q., Wang, W. (2009). A NMDA receptor antagonist, MK-801 impairs consolidating extinction of auditory conditioned fear responses in a Pavlovian model. PLoS One 4, e7548.

Llado-Pelfort, L., Santana, N., Ghisi, V., Artigas, F., Celada, P. (2012). 5-HT1A receptor agonists

enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons. Cereb Cortex 22, 1487-1497.

Loretan, K., Bissiere, S., Luthi, A. (2004). Dopaminergic modulation of spontaneous inhibitory network activity in the lateral amygdala. Neuropharmacology 47, 631-639.

Lu, K. T., Walker, D. L., Davis, M. (2001). Mitogen-activated protein kinase cascade in the basolateral nucleus of amygdala is involved in extinction of fear-potentiated startle. J Neurosci 21, RC162.

Lubin, F. D., Sweatt, J. D. (2007). The IkappaB kinase regulates chromatin structure during reconsolidation of conditioned fear memories. Neuron 55, 942-957.

Ludwig, M., Leng, G. (2006). Dendritic peptide release and peptide-dependent behaviours. Nat Rev Neurosci 7, 126-136.

Luo, H., Han, L., Tian, S. (2014). Effect of nitric oxide synthase inhibitor l-NAME on fear extinction in rats: A task-dependent effect. Neurosci Lett.

Luttrell, L. M. (2014). Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery. Mol Endocrinol 28, 281-294.

Macaluso, M., Kalia, R., Ali, F., Khan, A. Y. (2010). The role of benzodiazepines in the treatment of anxiety disorders: a clinical review. Psychiatric Annuals 40, 605-610.

Mailleux, P., Vanderhaeghen, J. J. (1993). Glucocorticoid regulation of cannabinoid receptor

messenger RNA levels in the rat caudate-putamen. An in situ hybridization study. Neurosci Lett 156, 51-53.

Maison, P., Walker, D. J., Walsh, F. S., Williams, G., Doherty, P. (2009). BDNF regulates neuronal sensitivity to endocannabinoids. Neurosci Lett 467, 90-94.

Makkar, S. R., Zhang, S. Q., Cranney, J. (2010). Behavioral and neural analysis of GABA in the acquisition, consolidation, reconsolidation, and extinction of fear memory. Neuropsychopharmacology 35, 1625-1652.

Malvaez, M., McQuown, S. C., Rogge, G. A., Astarabadi, M., Jacques, V., Carreiro, S., Rusche, J. R., Wood, M. A. (2013). HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner. Proc Natl Acad Sci U S A 110, 2647-2652.

Manko, M., Geracitano, R., Capogna, M. (2011). Functional connectivity of the main intercalated nucleus of the mouse amygdala. J Physiol 589, 1911-1925.

Mao, S. C., Lin, H. C., Gean, P. W. (2008). Augmentation of fear extinction by D-cycloserine is blocked by proteasome inhibitors. Neuropsychopharmacology 33, 3085-3095.

Mao, S. C., Chang, C. H., Wu, C. C., Orejarena, M. J., Manzoni, O. J., Gean, P. W. (2013). Inhibition of spontaneous recovery of fear by mGluR5 after prolonged extinction training. PLoS One 8, e59580.

Marek, R., Coelho, C. M., Sullivan, R. K., Baker-Andresen, D., Li, X., Ratnu, V., Dudley, K. J., Meyers, D., Mukherjee, C., Cole, P. A., Sah, P., Bredy, T. W. (2011). Paradoxical enhancement of fear extinction memory and synaptic plasticity by inhibition of the histone acetyltransferase p300. J Neurosci 31, 7486-7491.

Maren, S. (2001). Neurobiology of Pavlovian fear conditioning. Annu Rev Neurosci 24, 897-931.

Maren, S., Phan, K. L., Liberzon, I. (2013). The contextual brain: implications for fear conditioning, extinction and psychopathology. Nat Rev Neurosci 14, 417-428.

Marks, I. M., Swinson, R. P., Basoglu, M., Kuch, K., Noshirvani, H., O'Sullivan, G., Lelliott, P. T., Kirby, M., McNamee, G., Sengun, S., et al. (1993). Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. Br J Psychiatry 162, 776-787.

Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgansberger, W., Di Marzo, V., Lutz, B. (2002). The endogenous cannabinoid system controls extinction of aversive memories. Nature 418, 530-534.

Massa, S. M., Yang, T., Xie, Y., Shi, J., Bilgen, M., Joyce, J. N., Nehama, D., Rajadas, J., Longo, F. M. (2010). Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents. J Clin Invest 120, 1774-1785.

Mataix-Cols, D., Turner, C., Monzani, B., Isomura, K., Murphy, C., Krebs, G., Heyman, I. (2014).

Cognitive-behavioural therapy with post-session D-cycloserine augmentation for paediatric obsessive-compulsive disorder: pilot randomised controlled trial. Br J Psychiatry 204, 77-78.

Matsuda, S., Matsuzawa, D., Nakazawa, K., Sutoh, C., Ohtsuka, H., Ishii, D., Tomizawa, H., Iyo, M., Shimizu, E. (2010). d-serine enhances extinction of auditory cued fear conditioning via ERK1/2 phosphorylation in mice. Prog Neuropsychopharmacol Biol Psychiatry 34, 895-902.

Matsumoto, M., Togashi, H., Konno, K., Koseki, H., Hirata, R., Izumi, T., Yamaguchi, T., Yoshioka, M.

(2008). Early postnatal stress alters the extinction of context-dependent conditioned fear in adult rats. Pharmacol Biochem Behav 89, 247-252.

Matsumoto, Y., Morinobu, S., Yamamoto, S., Matsumoto, T., Takei, S., Fujita, Y., Yamawaki, S. (2013). Vorinostat ameliorates impaired fear extinction possibly via the hippocampal NMDA-CaMKII pathway in an animal model of posttraumatic stress disorder. Psychopharmacology (Berl) 229, 51-62.

McDonald, A. J., Pearson, J. C. (1989). Coexistence of GABA and peptide immunoreactivity in nonpyramidal neurons of the basolateral amygdala. Neurosci Lett 100, 53-58.

McGaugh, J. L. (2000). Memory--a century of consolidation. Science 287, 248-251.

McGaugh, J. L., Castellano, C., Brioni, J. (1990). Picrotoxin enhances latent extinction of conditioned fear. Behav Neurosci 104, 264-267.

McGuire, J. F., Lewin, A. B., Storch, E. A. (2014). Enhancing exposure therapy for anxiety disorders, obsessive-compulsive disorder and post-traumatic stress disorder. Expert Rev Neurother 118.

McKinney, B. C., Murphy, G. G. (2006). The L-Type voltage-gated calcium channel Cav1.3 mediates consolidation, but not extinction, of contextually conditioned fear in mice. Learn Mem 13, 584-589.

McKinney, B. C., Sze, W., White, J. A., Murphy, G. G. (2008). L-type voltage-gated calcium channels in conditioned fear: a genetic and pharmacological analysis. Learn Mem 15, 326-334.

McKinney, B. C., Sze, W., Lee, B., Murphy, G. G. (2009). Impaired long-term potentiation and

enhanced neuronal excitability in the amygdala of Ca(V)1.3 knockout mice. Neurobiol Learn Mem 92, 519-528.

McNally, G. P. (2005). Facilitation of fear extinction by midbrain periaqueductal gray infusions of RB101(S), an inhibitor of enkephalin-degrading enzymes. Behav Neurosci 119, 1672-1677.

McNally, G. P., Westbrook, R. F. (2003). Opioid receptors regulate the extinction of Pavlovian fear conditioning. Behav Neurosci 117, 1292-1301.

McNally, G. P., Westbrook, R. F. (2006). Predicting danger: the nature, consequences, and neural mechanisms of predictive fear learning. Learn Mem 13, 245-253.

McNally, G. P., Pigg, M., Weidemann, G. (2004). Opioid receptors in the midbrain periaqueductal gray regulate extinction of pavlovian fear conditioning. J Neurosci 24, 6912-6919.

McNally, G. P., Lee, B. W., Chiem, J. Y., Choi, E. A. (2005). The midbrain periaqueductal gray and fear extinction: opioid receptor subtype and roles of cyclic AMP, protein kinase A, and mitogen-activated protein kinase. Behav Neurosci 119, 1023-1033.

Meis, S., Stork, O., Munsch, T. (2011). Neuropeptide S-mediated facilitation of synaptic transmission enforces subthreshold theta oscillations within the lateral amygdala. PLoS One 6, e18020.

Meis, S., Bergado-Acosta, J. R., Yanagawa, Y., Obata, K., Stork, O., Munsch, T. (2008). Identification of a neuropeptide S responsive circuitry shaping amygdala activity via the endopiriform nucleus. PLoS One 3, e2695.

Melcer, T., Walker, J., Sechriest, V. F., 2nd, Lebedda, M., Quinn, K., Galarneau, M. (2014). Glasgow Coma Scores, early opioids, and posttraumatic stress disorder among combat amputees. J Trauma Stress 27, 152-159.

Merlo, A. B., Izquierdo, I. (1967). The effect of catecholamines on learning in rats. Med Pharmacol Exp Int J Exp Med 16, 343-349.

Merlo, E., Milton, A. L., Goozee, Z. Y., Theobald, D. E., Everitt, B. J. (2014). Reconsolidation and extinction are dissociable and mutually exclusive processes: behavioral and molecular evidence. J Neurosci 34, 2422-2431.

Meyer-Lindenberg, A., Domes, G., Kirsch, P., Heinrichs, M. (2011). Oxytocin and vasopressin in the

human brain: social neuropeptides for translational medicine. Nat Rev Neurosci 12, 524-538.

Meyerbroeker, K., Powers, M. B., van Stegeren, A., Emmelkamp, P. M. (2012). Does yohimbine hydrochloride facilitate fear extinction in virtual reality treatment of fear of flying? A randomized placebo-controlled trial. Psychother Psychosom 81, 29-37.

Michael, T., Blechert, J., Vriends, N., Margraf, J., Wilhelm, F. H. (2007). Fear conditioning in panic disorder: Enhanced resistance to extinction. J Abnorm Psychol 116, 612-617.

Mickley, G. A., Hoxha, N., Luchsinger, J. L., Rogers, M. M., Wiles, N. R. (2013). Chronic dietary magnesium-L-threonate speeds extinction and reduces spontaneous recovery of a conditioned taste aversion. Pharmacol Biochem Behav 106, 16-26.

Milad, M. R., Quirk, G. J. (2012). Fear extinction as a model for translational neuroscience: ten years of progress. Annu Rev Psychol 63, 129-151.

Milad, M. R., Furtak, S. C., Greenberg, J. L., Keshaviah, A., Im, J. J., Falkenstein, M. J., Jenike, M., Rauch, S. L., Wilhelm, S. (2013). Deficits in conditioned fear extinction in obsessive-compulsive disorder and neurobiological changes in the fear circuit. JAMA Psychiatry 70, 608618; quiz 554.

Milad, M. R., Pitman, R. K., Ellis, C. B., Gold, A. L., Shin, L. M., Lasko, N. B., Zeidan, M. A., Handwerger, K., Orr, S. P., Rauch, S. L. (2009). Neurobiological basis of failure to recall extinction memory in posttraumatic stress disorder. Biol Psychiatry 66, 1075-1082.

Millan, M. J. (2014). On 'polypharmacy' and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal. Int J Neuropsychopharmacol 17, 1009-1037.

Milton, A. L., Merlo, E., Ratano, P., Gregory, B. L., Dumbreck, J. K., Everitt, B. J. (2013). Double

dissociation of the requirement for GluN2B- and GluN2A-containing NMDA receptors in the destabilization and restabilization of a reconsolidating memory. J Neurosci 33, 1109-1115.

Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., Doblin, R. (2011). The safety and

efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol 25, 439-452.

Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., Martin, S. F., Yazar-Klosinski, B., Michel, Y., Brewerton, T. D., Doblin, R. (2013). Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol 27, 28-39.

Molteni, R., Fumagalli, F., Magnaghi, V., Roceri, M., Gennarelli, M., Racagni, G., Melcangi, R. C., Riva, M. A. (2001). Modulation of fibroblast growth factor-2 by stress and corticosteroids: from developmental events to adult brain plasticity. Brain Res Brain Res Rev 37, 249-258.

Monti, B. (2013). Histone post-translational modifications to target memory-related diseases. Curr Pharm Des 19, 5065-5075.

Morawska, M. M., Fendt, M. (2012). The effects of muscimol and AMN082 injections into the medial prefrontal cortex on the expression and extinction of conditioned fear in mice. J Exp Biol 215, 1394-1398.

Morris, M. J., Mahgoub, M., Na, E. S., Pranav, H., Monteggia, L. M. (2013). Loss of histone deacetylase 2 improves working memory and accelerates extinction learning. J Neurosci 33, 6401-6411.

Morris, R. W., Bouton, M. E. (2007). The effect of yohimbine on the extinction of conditioned fear: a role for context. Behav Neurosci 121, 501-514.

Morrow, B. A., Elsworth, J. D., Rasmusson, A. M., Roth, R. H. (1999). The role of mesoprefrontal dopamine neurons in the acquisition and expression of conditioned fear in the rat. Neuroscience 92, 553-564.

Mueller, D., Cahill, S. P. (2010). Noradrenergic modulation of extinction learning and exposure therapy. Behav Brain Res 208, 1-11.

Mueller, D., Porter, J. T., Quirk, G. J. (2008). Noradrenergic signaling in infralimbic cortex increases cell excitability and strengthens memory for fear extinction. J Neurosci 28, 369-375.

Mueller, D., Bravo-Rivera, C., Quirk, G. J. (2010). Infralimbic D2 receptors are necessary for fear extinction and extinction-related tone responses. Biol Psychiatry 68, 1055-1060.

Mueller, D., Olivera-Figueroa, L. A., Pine, D. S., Quirk, G. J. (2009). The effects of yohimbine and

amphetamine on fear expression and extinction in rats. Psychopharmacology (Berl) 204, 599606.

Muigg, P., Hetzenauer, A., Hauer, G., Hauschild, M., Gaburro, S., Frank, E., Landgraf, R., Singewald, N. (2008). Impaired extinction of learned fear in rats selectively bred for high anxiety--evidence of altered neuronal processing in prefrontal-amygdala pathways. Eur J Neurosci 28, 22992309.

Myers, K. M., Davis, M. (2007). Mechanisms of fear extinction. Mol Psychiatry 12, 120-150.

Myers, K. M., Carlezon, W. A., Jr., Davis, M. (2011). Glutamate receptors in extinction and extinction-based therapies for psychiatric illness. Neuropsychopharmacology 36, 274-293.

Nader, K., LeDoux, J. E. (1999). Inhibition of the mesoamygdala dopaminergic pathway impairs the retrieval of conditioned fear associations. Behav Neurosci 113, 891-901.

Nader, K., Schafe, G. E., Le Doux, J. E. (2000). Fear memories require protein synthesis in the amygdala for reconsolidation after retrieval. Nature 406, 722-726.

Nave, A. M., Tolin, D. F., Stevens, M. C. (2012). Exposure therapy, D-cycloserine, and functional

magnetic resonance imaging in patients with snake phobia: a randomized pilot study. J Clin Psychiatry 73, 1179-1186.

Nelson, E. D., Kavalali, E. T., Monteggia, L. M. (2008). Activity-dependent suppression of miniature neurotransmission through the regulation of DNA methylation. J Neurosci 28, 395-406.

Neumann, I. D., Landgraf, R. (2012). Balance of brain oxytocin and vasopressin: implications for anxiety, depression, and social behaviors. Trends Neurosci 35, 649-659.

Neumeister, A., Normandin, M. D., Pietrzak, R. H., Piomelli, D., Zheng, M. Q., Gujarro-Anton, A.,

Potenza, M. N., Bailey, C. R., Lin, S. F., Najafzadeh, S., Ropchan, J., Henry, S., Corsi-Travali, S., Carson, R. E., Huang, Y. (2013). Elevated brain cannabinoid CB1 receptor availability in posttraumatic stress disorder: a positron emission tomography study. Mol Psychiatry 18, 10341040.

Ninan, I., Bath, K. G., Dagar, K., Perez-Castro, R., Plummer, M. R., Lee, F. S., Chao, M. V. (2010). The BDNF Val66Met polymorphism impairs NMDA receptor-dependent synaptic plasticity in the hippocampus. J Neurosci 30, 8866-8870.

Ninomiya, E. M., Martynhak, B. J., Zanoveli, J. M., Correia, D., da Cunha, C., Andreatini, R. (2010). Spironolactone and low-dose dexamethasone enhance extinction of contextual fear conditioning. Prog Neuropsychopharmacol Biol Psychiatry 34, 1229-1235.

Niyuhire, F., Varvel, S. A., Thorpe, A. J., Stokes, R. J., Wiley, J. L., Lichtman, A. H. (2007). The disruptive effects of the CB1 receptor antagonist rimonabant on extinction learning in mice are task-specific. Psychopharmacology (Berl) 191, 223-231.

Norberg, M. M., Krystal, J. H., Tolin, D. F. (2008). A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry 63, 1118-1126.

Nott, A., Watson, P. M., Robinson, J. D., Crepaldi, L., Riccio, A. (2008). S-Nitrosylation of histone deacetylase 2 induces chromatin remodelling in neurons. Nature 455, 411-415.

Numakawa, T., Yokomaku, D., Kiyosue, K., Adachi, N., Matsumoto, T., Numakawa, Y., Taguchi, T., Hatanaka, H., Yamada, M. (2002). Basic fibroblast growth factor evokes a rapid glutamate release through activation of the MAPK pathway in cultured cortical neurons. Journal of Biological Chemistry 277, 28861-28869.

Nutt, D. J. (2014). The role of the opioid system in alcohol dependence. J Psychopharmacol 28, 8-22.

Oehrberg, S., Christiansen, P. E., Behnke, K., Borup, A. L., Severin, B., Soegaard, J., Calberg, H., Judge, R., Ohrstrom, J. K., Manniche, P. M. (1995). Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry 167, 374-379.

Ogden, K. K., Khatri, A., Traynelis, S. F., Heldt, S. A. (2014). Potentiation of GluN2C/D NMDA receptor subtypes in the amygdala facilitates the retention of fear and extinction learning in mice. Neuropsychopharmacology 39, 625-637.

Ohlow, M. J., Moosmann, B. (2011). Phenothiazine: the seven lives of pharmacology's first lead structure. Drug Discov Today 16, 119-131.

Okano, M., Xie, S., Li, E. (1998). Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet 19, 219-220.

Orsini, C. A., Maren, S. (2012). Neural and cellular mechanisms of fear and extinction memory formation. Neurosci Biobehav Rev 36, 1773-1802.

Otto, M. W., Hong, J. J., Safren, S. A. (2002). Benzodiazepine discontinuation difficulties in panic

disorder: conceptual model and outcome for cognitive-behavior therapy. Curr Pharm Des 8, 75-80.

Otto, M. W., McHugh, R., Kantak, K. M. (2010a). Combined Pharmacotherapy and Cognitive-Behavioral Therapy for Anxiety Disorders: Medication Effects, Glucocorticoids, and Attenuated Treatment Outcomes. Clinical Psychology Science and Practice 12, 72-86.

Otto, M. W., McHugh, R. K., Simon, N. M., Farach, F. J., Worthington, J. J., Pollack, M. H. (2010b).

Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: Further evaluation. Behav Res Ther 48, 720-727.

Otto, M. W., Tolin, D. F., Simon, N. M., Pearlson, G. D., Basden, S., Meunier, S. A., Hofmann, S. G.,

Eisenmenger, K., Krystal, J. H., Pollack, M. H. (2010c). Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry 67, 365-370.

Owens, M. J., Morgan, W. N., Plott, S. J., Nemeroff, C. B. (1997). Neurotransmitter receptor and

transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 283, 1305-1322.

Pace-Schott, E. F., Verga, P. W., Bennett, T. S., Spencer, R. M. (2012). Sleep promotes consolidation and generalization of extinction learning in simulated exposure therapy for spider fear. J Psychiatr Res 46, 1036-1044.

Pamplona, F. A., Bitencourt, R. M., Takahashi, R. N. (2008). Short- and long-term effects of

cannabinoids on the extinction of contextual fear memory in rats. Neurobiol Learn Mem 90, 290-293.

Pamplona, F. A., Prediger, R. D., Pandolfo, P., Takahashi, R. N. (2006). The cannabinoid receptor agonist WIN 55,212-2 facilitates the extinction of contextual fear memory and spatial memory in rats. Psychopharmacology (Berl) 188, 641-649.

Paoletti, P., Ascher, P., Neyton, J. (1997). High-affinity zinc inhibition of NMDA NR1-NR2A receptors. J Neurosci 17, 5711-5725.

Paoletti, P., Bellone, C., Zhou, Q. (2013). NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci 14, 383-400.

Papadopoulos, A., Chandramohan, Y., Collins, A., Droste, S. K., Nutt, D. J., Reul, J. M. (2011).

GABAergic control of novelty stress-responsive epigenetic and gene expression mechanisms in the rat dentate gyrus. Eur Neuropsychopharmacol 21, 316-324.

Pape, H. C., Pare, D. (2010). Plastic synaptic networks of the amygdala for the acquisition, expression, and extinction of conditioned fear. Physiol Rev 90, 419-463.

Pape, H. C., Jungling, K., Seidenbecher, T., Lesting, J., Reinscheid, R. K. (2010). Neuropeptide S: a

transmitter system in the brain regulating fear and anxiety. Neuropharmacology 58, 29-34.

Park, S. M., Williams, C. L. (2012). Contribution of serotonin type 3 receptors in the successful

extinction of cued or contextual fear conditioned responses: interactions with GABAergic signaling. Rev Neurosci 23, 555-569.

Parker, R. M., Herzog, H. (1999). Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur J Neurosci 11, 1431-1448.

Parnas, A. S., Weber, M., Richardson, R. (2005). Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats. Neurobiol Learn Mem 83, 224-231.

Parsons, R. G., Ressler, K. J. (2013). Implications of memory modulation for post-traumatic stress and fear disorders. Nat Neurosci 16, 146-153.

Parsons, R. G., Gafford, G. M., Helmstetter, F. J. (2010). Regulation of extinction-related plasticity by opioid receptors in the ventrolateral periaqueductal gray matter. Front Behav Neurosci 4.

Pavlov, I. P. (1927). Conditioned Reflexes. Oxford University Press.

Pearce, J. M., Bouton, M. E. (2001). Theories of associative learning in animals. Annu Rev Psychol 52, 111-139.

Pereira, M. E., Rosat, R., Huang, C. H., Godoy, M. G., Izquierdo, I. (1989). Inhibition by diazepam of the effect of additional training and of extinction on the retention of shuttle avoidance behavior in rats. Behav Neurosci 103, 202-205.

Perez de la Mora, M., Gallegos-Cari, A., Crespo-Ramirez, M., Marcellino, D., Hansson, A. C., Fuxe, K.

(2012). Distribution of dopamine D(2)-like receptors in the rat amygdala and their role in the modulation of unconditioned fear and anxiety. Neuroscience 201, 252-266.

Perkins, N. D., Felzien, L. K., Betts, J. C., Leung, K., Beach, D. H., Nabel, G. J. (1997). Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. Science 275, 523527.

Peters, J., Dieppa-Perea, L. M., Melendez, L. M., Quirk, G. J. (2010). Induction of fear extinction with hippocampal-infralimbic BDNF. Science 328, 1288-1290.

Pfeiffer, U. J., Fendt, M. (2006). Prefrontal dopamine D4 receptors are involved in encoding fear extinction. Neuroreport 17, 847-850.

Pinard, C. R., Muller, J. F., Mascagni, F., McDonald, A. J. (2008). Dopaminergic innervation of interneurons in the rat basolateral amygdala. Neuroscience 157, 850-863.

Pinna, G., Rasmusson, A. M. (2014). Ganaxolone improves behavioral deficits in a mouse model of post-traumatic stress disorder. Front Cell Neurosci 8, 256.

Pinto, A., Sesack, S. R. (2008). Ultrastructural analysis of prefrontal cortical inputs to the rat

amygdala: spatial relationships to presumed dopamine axons and D1 and D2 receptors. Brain Struct Funct 213, 159-175.

Plendl, W., Wotjak, C. T. (2010). Dissociation of within- and between-session extinction of conditioned fear. J Neurosci 30, 4990-4998.

Ponnusamy, R., Nissim, H. A., Barad, M. (2005). Systemic blockade of D2-like dopamine receptors facilitates extinction of conditioned fear in mice. Learn Mem 12, 399-406.

Popoli, M., Yan, Z., McEwen, B. S., Sanacora, G. (2012). The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci 13, 22-37.

Popova, D., Agustsdottir, A., Lindholm, J., Mazulis, U., Akamine, Y., Castren, E., Karpova, N. N. (2014). Combination of fluoxetine and extinction treatments forms a unique synaptic protein profile that correlates with long-term fear reduction in adult mice. Eur Neuropsychopharmacol 24, 1162-1174.

Powers, M. B., Smits, J. A., Otto, M. W., Sanders, C., Emmelkamp, P. M. (2009). Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: a randomized placebo controlled trial of yohimbine augmentation. J Anxiety Disord 23, 350-356.

Psotta, L., Lessmann, V., Endres, T. (2013). Impaired fear extinction learning in adult heterozygous BDNF knock-out mice. Neurobiol Learn Mem 103, 34-38.

Quartermain, D., Mower, J., Rafferty, M. F., Herting, R. L., Lanthorn, T. H. (1994). Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol 257, 7-12.

Quirarte, G. L., Roozendaal, B., McGaugh, J. L. (1997). Glucocorticoid enhancement of memory

storage involves noradrenergic activation in the basolateral amygdala. Proc Natl Acad Sci U S A 94, 14048-14053.

Quirin, M., Kuhl, J., Dusing, R. (2011). Oxytocin buffers cortisol responses to stress in individuals with impaired emotion regulation abilities. Psychoneuroendocrinology 36, 898-904.

Rabinak, C. A., Angstadt, M., Sripada, C. S., Abelson, J. L., Liberzon, I., Milad, M. R., Phan, K. L. (2013). Cannabinoid facilitation of fear extinction memory recall in humans. Neuropharmacology 64, 396-402.

Railey, A. M., Micheli, T. L., Wanschura, P. B., Flinn, J. M. (2010). Alterations in fear response and spatial memory in pre- and post-natal zinc supplemented rats: remediation by copper. Physiol Behav 100, 95-100.

Rainnie, D. G. (1999). Serotonergic modulation of neurotransmission in the rat basolateral amygdala. J Neurophysiol 82, 69-85.

Reich, C. G., Mohammadi, M. H., Alger, B. E. (2008). Endocannabinoid modulation of fear responses: learning and state-dependent performance effects. J Psychopharmacol 22, 769-777.

Reichardt, L. F. (2006). Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 361, 1545-1564.

Ren, J., Li, X., Zhang, X., Li, M., Wang, Y., Ma, Y. (2013). The effects of intra-hippocampal

microinfusion of D-cycloserine on fear extinction, and the expression of NMDA receptor subunit NR2B and neurogenesis in the hippocampus in rats. Prog Neuropsychopharmacol Biol Psychiatry 44, 257-264.

Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., Davis, M. (2004). Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 61, 1136-1144.

Reul, J. M. (2014). Making memories of stressful events: a journey along epigenetic, gene transcription, and signaling pathways. Front Psychiatry 5, 5.

Rey, C. D., Lipps, J., Shansky, R. M. (2014). Dopamine D1 receptor activation rescues extinction impairments in low-estrogen female rats and induces cortical layer-specific activation changes in prefrontal-amygdala circuits. Neuropsychopharmacology 39, 1282-1289.

Riaza Bermudo-Soriano, C., Perez-Rodriguez, M. M., Vaquero-Lorenzo, C., Baca-Garcia, E. (2012). New perspectives in glutamate and anxiety. Pharmacol Biochem Behav 100, 752-774.

Riebe, C. J., Pamplona, F. A., Kamprath, K., Wotjak, C. T. (2012). Fear relief-toward a new conceptual frame work and what endocannabinoids gotta do with it. Neuroscience 204, 159-185.

Rodrigues, H., Figueira, I., Goncalves, R., Mendlowicz, M., Macedo, T., Ventura, P. (2011). CBT for

pharmacotherapy non-remitters--a systematic review of a next-step strategy. J Affect Disord 129, 219-228.

Rodrigues, S. M., Bauer, E. P., Farb, C. R., Schafe, G. E., LeDoux, J. E. (2002). The group I metabotropic glutamate receptor mGluR5 is required for fear memory formation and long-term potentiation in the lateral amygdala. J Neurosci 22, 5219-5229.

Rodriguez-Romaguera, J., Sotres-Bayon, F., Mueller, D., Quirk, G. J. (2009). Systemic propranolol acts centrally to reduce conditioned fear in rats without impairing extinction. Biol Psychiatry 65, 887-892.

Rogan, M. T., Leon, K. S., Perez, D. L., Kandel, E. R. (2005). Distinct neural signatures for safety and danger in the amygdala and striatum of the mouse. Neuron 46, 309-320.

Rojas, J. C., Bruchey, A. K., Gonzalez-Lima, F. (2012). Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol 96, 32-45.

Roozendaal, B., Quirarte, G. L., McGaugh, J. L. (2002). Glucocorticoids interact with the basolateral amygdala beta-adrenoceptor--cAMP/cAMP/PKA system in influencing memory consolidation. Eur J Neurosci 15, 553-560.

Roozendaal, B., Schelling, G., McGaugh, J. L. (2008). Corticotropin-releasing factor in the basolateral amygdala enhances memory consolidation via an interaction with the beta-adrenoceptor-cAMP pathway: dependence on glucocorticoid receptor activation. J Neurosci 28, 6642-6651.

Rosas-Vidal, L. E., Do-Monte, F. H., Sotres-Bayon, F., Quirk, G. J. (2014a). Hippocampal-Prefrontal BDNF and Memory for Fear Extinction. Neuropsychopharmacology.

Rosas-Vidal, L. E., Do-Monte, F. H., Sotres-Bayon, F., Quirk, G. J. (2014b). Hippocampal-prefrontal BDNF and memory for fear extinction. Neuropsychopharmacology 39, 2161-2169.

Rowe, M. K., Craske, M. G. (1998a). Effects of an expanding-spaced vs massed exposure schedule on fear reduction and return of fear. Behav Res Ther 36, 701-717.

Rowe, M. K., Craske, M. G. (1998b). Effects of varied-stimulus exposure training on fear reduction and return of fear. Behav Res Ther 36, 719-734.

Rudenko, A., Dawlaty, M. M., Seo, J., Cheng, A. W., Meng, J., Le, T., Faull, K. F., Jaenisch, R., Tsai, L. H. (2013). Tet1 is critical for neuronal activity-regulated gene expression and memory extinction. Neuron 79, 1109-1122.

Ruthenburg, A. J., Li, H., Patel, D. J., Allis, C. D. (2007). Multivalent engagement of chromatin modifications by linked binding modules. Nat Rev Mol Cell Biol 8, 983-994.

Saito, Y., Matsumoto, M., Yanagawa, Y., Hiraide, S., Inoue, S., Kubo, Y., Shimamura, K., Togashi, H.

(2013). Facilitation of fear extinction by the 5-HT(1A) receptor agonist tandospirone: possible involvement of dopaminergic modulation. Synapse 67, 161-170.

Salchner, P., Singewald, N. (2006). 5-HT receptor subtypes involved in the anxiogenic-like action and associated Fos response of acute fluoxetine treatment in rats. Psychopharmacology (Berl) 185, 282-288.

Sangha, S., Narayanan, R. T., Bergado-Acosta, J. R., Stork, O., Seidenbecher, T., Pape, H. C. (2009).

Deficiency of the 65 kDa isoform of glutamic acid decarboxylase impairs extinction of cued but not contextual fear memory. J Neurosci 29, 15713-15720.

Santana, N., Bortolozzi, A., Serrats, J., Mengod, G., Artigas, F. (2004). Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex 14, 1100-1109.

Santini, E., Muller, R. U., Quirk, G. J. (2001). Consolidation of extinction learning involves transfer from NMDA-independent to NMDA-dependent memory. J Neurosci 21, 9009-9017.

Scheeringa, M. S., Weems, C. F. (2014). Randomized placebo-controlled D-cycloserine with cognitive behavior therapy for pediatric posttraumatic stress. J Child Adolesc Psychopharmacol 24, 6977.

Schiller, D., Raio, C. M., Phelps, E. A. (2012). Extinction training during the reconsolidation window prevents recovery of fear. J Vis Exp e3893.

Schiller, D., Cain, C. K., Curley, N. G., Schwartz, J. S., Stern, S. A., Ledoux, J. E., Phelps, E. A. (2008).

Evidence for recovery of fear following immediate extinction in rats and humans. Learn Mem 15, 394-402.

Schneier, F. R., Neria, Y., Pavlicova, M., Hembree, E., Suh, E. J., Amsel, L., Marshall, R. D. (2012).

Combined prolonged exposure therapy and paroxetine for PTSD related to the World Trade Center attack: a randomized controlled trial. Am J Psychiatry 169, 80-88.

Scholl, U. I. et al. (2013). Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet 45, 1050-1054.

Schwabe, L., Nader, K., Pruessner, J. C. (2014). Reconsolidation of Human Memory: Brain Mechanisms and Clinical Relevance. Biol Psychiatry 76, 274-280.

Schwarzer, C. (2009). 30 years of dynorphins--new insights on their functions in neuropsychiatric diseases. Pharmacol Ther 123, 353-370.

Senn, V., Wolff, S. B., Herry, C., Grenier, F., Ehrlich, I., Grundemann, J., Fadok, J. P., Muller, C., Letzkus, J. J., Luthi, A. (2014). Long-range connectivity defines behavioral specificity of amygdala neurons. Neuron 81, 428-437.

Sepulveda-Orengo, M. T., Lopez, A. V., Soler-Cedeno, O., Porter, J. T. (2013). Fear extinction induces mGluR5-mediated synaptic and intrinsic plasticity in infralimbic neurons. J Neurosci 33, 71847193.

Sharp, D. M., Power, K. G., Simpson, R. J., Swanson, V., Anstee, J. A. (1997). Global measures of

outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care. Br J Gen Pract 47, 150-155.

Shibasaki, M., Mizuno, K., Kurokawa, K., Ohkuma, S. (2011). L-type voltage-dependent calcium

channels facilitate acetylation of histone H3 through PKCgamma phosphorylation in mice with methamphetamine-induced place preference. J Neurochem 118, 1056-1066.

Shin, R. M., Higuchi, M., Suhara, T. (2013). Nitric oxide signaling exerts bidirectional effects on plasticity inductions in amygdala. PLoS One 8, e74668.

Shitaka, Y., Matsuki, N., Saito, H., Katsuki, H. (1996). Basic fibroblast growth factor increases

functional L-type Ca2+ channels in fetal rat hippocampal neurons: implications for neurite morphogenesis in vitro. J Neurosci 16, 6476-6489.

Si, W., Aluisio, L., Okamura, N., Clark, S. D., Fraser, I., Sutton, S. W., Bonaventure, P., Reinscheid, R. K. (2010). Neuropeptide S stimulates dopaminergic neurotransmission in the medial prefrontal cortex. J Neurochem 115, 475-482.

Siegl, S., Flor, P. J., Fendt, M. (2008). Amygdaloid metabotropic glutamate receptor subtype 7 is involved in the acquisition of conditioned fear. Neuroreport 19, 1147-1150.

Siegmund, A., Golfels, F., Finck, C., Halisch, A., Rath, D., Plag, J., Strohle, A. (2011). D-cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. J Psychiatr Res 45, 1042-1047.

Sierra-Mercado, D., Padilla-Coreano, N., Quirk, G. J. (2011). Dissociable roles of prelimbic and

infralimbic cortices, ventral hippocampus, and basolateral amygdala in the expression and extinction of conditioned fear. Neuropsychopharmacology 36, 529-538.

Silva, M. T. (1973). Extinction of a passive avoidance response in adrenalectomized and demedullated rats. Behav Biol 9, 553-562.

Silvestri, A. J., Root, D. H. (2008). Effects of REM deprivation and an NMDA agonist on the extinction of conditioned fear. Physiol Behav 93, 274-281.

Singewald, N., Philippu, A. (1998). Release of neurotransmitters in the locus coeruleus. Prog Neurobiol 56, 237-267.

Singewald, N., Salchner, P., Sharp, T. (2003). Induction of c-Fos expression in specific areas of the fear circuitry in rat forebrain by anxiogenic drugs. Biol Psychiatry 53, 275-283.

Sinnegger-Brauns, M. J., Hetzenauer, A., Huber, I. G., Renstrom, E., Wietzorrek, G., Berjukov, S.,

Cavalli, M., Walter, D., Koschak, A., Waldschutz, R., Hering, S., Bova, S., Rorsman, P., Pongs, O., Singewald, N., Striessnig, J. J. (2004). Isoform-specific regulation of mood behavior and pancreatic beta cell and cardiovascular function by L-type Ca 2+ channels. J Clin Invest 113, 1430-1439.

Slattery, D. A., Naik, R. R., Yen, Y. C., Sartori, S. B., Fuechsl, A., Grund, T., Finger, B. C., Elfving, B.,

Nordemann, U., Guerrini, R., Calo, G., Wegener, G., Mathe, A. A., Singewald, N., Czibere, L., Landgraf, R., Neumann, I. D. (in press). Selective breeding for high anxiety introduces a synonymous SNP that increases neuropeptide S receptor activity. J Neuroscience.

Smits, J. A., Rosenfield, D., Otto, M. W., Powers, M. B., Hofmann, S. G., Telch, M. J., Pollack, M. H., Tart, C. D. (2013a). D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol Psychiatry 73, 10541058.

Smits, J. A., Rosenfield, D., Otto, M. W., Marques, L., Davis, M. L., Meuret, A. E., Simon, N. M., Pollack, M. H., Hofmann, S. G. (2013b). D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions. J Psychiatr Res 47, 1455-1461.

Smits, J. A., Hofmann, S. G., Rosenfield, D., DeBoer, L. B., Costa, P. T., Simon, N. M., O'Cleirigh, C.,

Meuret, A. E., Marques, L., Otto, M. W., Pollack, M. H. (2013c). D-cycloserine augmentation of cognitive behavioral group therapy of social anxiety disorder: prognostic and prescriptive variables. J Consult Clin Psychol 81, 1100-1112.

Smits, J. A., Rosenfield, D., Davis, M. L., Julian, K., Handelsman, P. R., Otto, M. W., Tuerk, P., Shiekh, M., Rosenfield, B., Hofmann, S. G., Powers, M. B. (2014). Yohimbine enhancement of exposure therapy for social anxiety disorder: a randomized controlled trial. Biol Psychiatry 75, 840-846.

Snyder, G. L., Fienberg, A. A., Huganir, R. L., Greengard, P. (1998). A dopamine/D1 receptor/protein kinase A/dopamine- and cAMP-regulated phosphoprotein (Mr 32 kDa)/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor. J Neurosci 18, 10297-10303.

Soliman, F., Glatt, C. E., Bath, K. G., Levita, L., Jones, R. M., Pattwell, S. S., Jing, D., Tottenham, N., Amso, D., Somerville, L. H., Voss, H. U., Glover, G., Ballon, D. J., Liston, C., Teslovich, T., Van Kempen, T., Lee, F. S., Casey, B. J. (2010). A genetic variant BDNF polymorphism alters extinction learning in both mouse and human. Science 327, 863-866.

Soravia, L. M., Heinrichs, M., Aerni, A., Maroni, C., Schelling, G., Ehlert, U., Roozendaal, B., de

Quervain, D. J. (2006). Glucocorticoids reduce phobic fear in humans. Proc Natl Acad Sci U S A 103, 5585-5590.

Soravia, L. M., Heinrichs, M., Winzeler, L., Fisler, M., Schmitt, W., Horn, H., Dierks, T., Strik, W.,

Hofmann, S. G., de Quervain, D. J. (2014). Glucocorticoids enhance in vivo exposure-based therapy of spider phobia. Depress Anxiety 31, 429-435.

Sotres-Bayon, F., Bush, D. E., LeDoux, J. E. (2007). Acquisition of fear extinction requires activation of NR2B-containing NMDA receptors in the lateral amygdala. Neuropsychopharmacology 32, 1929-1940.

Sotres-Bayon, F., Diaz-Mataix, L., Bush, D. E., LeDoux, J. E. (2009). Dissociable roles for the

ventromedial prefrontal cortex and amygdala in fear extinction: NR2B contribution. Cereb Cortex 19, 474-482.

Spadaro, P. A., Bredy, T. W. (2012). Emerging role of non-coding RNA in neural plasticity, cognitive function, and neuropsychiatric disorders. Front Genet 3, 132.

Stafford, J. M., Raybuck, J. D., Ryabinin, A. E., Lattal, K. M. (2012). Increasing Histone Acetylation in the Hippocampus-Infralimbic Network Enhances Fear Extinction. Biol Psychiatry in press.

Stein, D. J., Ipser, J., McAnda, N. (2009). Pharmacotherapy of posttraumatic stress disorder: a review of meta-analyses and treatment guidelines. CNS Spectr 14, 25-31.

Stein, M. B., Ron Norton, G., Walker, J. R., Chartier, M. J., Graham, R. (2000). Do selective serotonin re-uptake inhibitors enhance the efficacy of very brief cognitive behavioral therapy for panic disorder? A pilot study. Psychiatry Res 94, 191-200.

Storch, E. A., Murphy, T. K., Goodman, W. K., Geffken, G. R., Lewin, A. B., Henin, A., Micco, J. A.,

Sprich, S., Wilhelm, S., Bengtson, M., Geller, D. A. (2010). A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry 68, 1073-1076.

Storch, E. A., Merlo, L. J., Bengtson, M., Murphy, T. K., Lewis, M. H., Yang, M. C., Jacob, M. L., Larson, M., Hirsh, A., Fernandez, M., Geffken, G. R., Goodman, W. K. (2007). D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol 22, 230-237.

Storsve, A. B., McNally, G. P., Richardson, R. (2010). US habituation, like CS extinction, produces a decrement in conditioned fear responding that is NMDA dependent and subject to renewal and reinstatement. Neurobiol Learn Mem 93, 463-471.

Striessnig, J., Pinggera, A., Kaur, G., Bock, G., Tuluc, P. (2014). L-type Ca channels in heart and brain. Wiley Interdiscip Rev Membr Transp Signal 3, 15-38.

Striessnig, J., Koschak, A., Sinnegger-Brauns, M. J., Hetzenauer, A., Nguyen, N. K., Busquet, P., Pelster, G., Singewald, N. (2006). Role of voltage-gated L-type Ca2+ channel isoforms for brain function. Biochem Soc Trans 34, 903-909.

Stutzmann, G. E., LeDoux, J. E. (1999). GABAergic antagonists block the inhibitory effects of serotonin in the lateral amygdala: a mechanism for modulation of sensory inputs related to fear conditioning. J Neurosci 19, RC8.

Sung, J. Y., Shin, S. W., Ahn, Y. S., Chung, K. C. (2001). Basic fibroblast growth factor-induced

activation of novel CREB kinase during the differentiation of immortalized hippocampal cells. Journal of Biological Chemistry 276, 13858-13866.

Suris, A., North, C., Adinoff, B., Powell, C. M., Greene, R. (2010). Effects of exogenous glucocorticoid on combat-related PTSD symptoms. Ann Clin Psychiatry 22, 274-279.

Suzuki, A., Josselyn, S. A., Frankland, P. W., Masushige, S., Silva, A. J., Kida, S. (2004). Memory

reconsolidation and extinction have distinct temporal and biochemical signatures. J Neurosci 24, 4787-4795.

Sweatt, J. D. (2009). Experience-dependent epigenetic modifications in the central nervous system. Biol Psychiatry 65, 191-197.

Sweeney, F. F., O'Leary, O. F., Cryan, J. F. (2013). GABAB receptor ligands do not modify conditioned fear responses in BALB/c mice. Behav Brain Res 256, 151-156.

Szapiro, G., Vianna, M. R., McGaugh, J. L., Medina, J. H., Izquierdo, I. (2003). The role of NMDA glutamate receptors, PKA, MAPK, and CAMKII in the hippocampus in extinction of conditioned fear. Hippocampus 13, 53-58.

Szczytkowski-Thomson, J. L., Lebonville, C. L., Lysle, D. T. (2013). Morphine prevents the development of stress-enhanced fear learning. Pharmacol Biochem Behav 103, 672-677.

Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., Rao, A. (2009). Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930-935.

Takeda, A., Tamano, H. (2014). Cognitive decline due to excess synaptic Zn(2+) signaling in the hippocampus. Front Aging Neurosci 6, 26.

Tang, Y. P., Shimizu, E., Dube, G. R., Rampon, C., Kerchner, G. A., Zhuo, M., Liu, G., Tsien, J. Z. (1999). Genetic enhancement of learning and memory in mice. Nature 401, 63-69.

Tart, C. D., Handelsman, P. R., Deboer, L. B., Rosenfield, D., Pollack, M. H., Hofmann, S. G., Powers, M. B., Otto, M. W., Smits, J. A. (2013). Augmentation of exposure therapy with post-session administration of D-cycloserine. J Psychiatr Res 47, 168-174.

Tasan, R. O., Bukovac, A., Peterschmitt, Y. N., Sartori, S. B., Landgraf, R., Singewald, N., Sperk, G.

(2011). Altered GABA transmission in a mouse model of increased trait anxiety. Neuroscience 183, 71-80.

Telch, M. J., Bruchey, A. K., Rosenfield, D., Cobb, A. R., Smits, J., Pahl, S., Gonzalez-Lima, F. (2014).

Effects of Post-Session Administration of Methylene Blue on Fear Extinction and Contextual Memory in Adults With Claustrophobia. Am J Psychiatry.

Terlau, H., Seifert, W. (1990). Fibroblast Growth Factor Enhances Long-term Potentiation in the Hippocampal Slice. Eur J Neurosci 2, 973-977.

Terzian, A. L., Drago, F., Wotjak, C. T., Micale, V. (2011). The Dopamine and Cannabinoid Interaction in the Modulation of Emotions and Cognition: Assessing the Role of Cannabinoid CB1 Receptor in Neurons Expressing Dopamine D1 Receptors. Front Behav Neurosci 5, 49.

Thompson, B. M., Baratta, M. V., Biedenkapp, J. C., Rudy, J. W., Watkins, L. R., Maier, S. F. (2010).

Activation of the infralimbic cortex in a fear context enhances extinction learning. Learn Mem 17, 591-599.

Tian, F., Marini, A. M., Lipsky, R. H. (2010). NMDA receptor activation induces differential epigenetic modification of Bdnf promoters in hippocampal neurons. Amino Acids 38, 1067-1074.

Tian, F., Hu, X. Z., Wu, X., Jiang, H., Pan, H., Marini, A. M., Lipsky, R. H. (2009). Dynamic chromatin remodeling events in hippocampal neurons are associated with NMDA receptor-mediated activation of Bdnf gene promoter 1. J Neurochem 109, 1375-1388.

Tomilenko, R. A., Dubrovina, N. I. (2007). Effects of activation and blockade of NMDA receptors on the extinction of a conditioned passive avoidance response in mice with different levels of anxiety. Neurosci Behav Physiol 37, 509-515.

Toth, I., Neumann, I. D., Slattery, D. A. (2012a). Central administration of oxytocin receptor ligands affects cued fear extinction in rats and mice in a timepoint-dependent manner. Psychopharmacology (Berl) 223, 149-158.

Toth, I., Dietz, M., Peterlik, D., Huber, S. E., Fendt, M., Neumann, I. D., Flor, P. J., Slattery, D. A.

(2012b). Pharmacological interference with metabotropic glutamate receptor subtype 7 but not subtype 5 differentially affects within- and between-session extinction of Pavlovian conditioned fear. Neuropharmacology 62, 1619-1626.

Tronson, N. C., Corcoran, K. A., Jovasevic, V., Radulovic, J. (2012). Fear conditioning and extinction: emotional states encoded by distinct signaling pathways. Trends Neurosci 35, 145-155.

Trouche, S., Sasaki, J. M., Tu, T., Reijmers, L. G. (2013). Fear extinction causes target-specific remodeling of perisomatic inhibitory synapses. Neuron 80, 1054-1065.

Trugman, J. M., James, C. L., Wooten, G. F. (1991). D1/D2 dopamine receptor stimulation by L-dopa. A [14C]-2-deoxyglucose autoradiographic study. Brain 114 ( Pt 3), 1429-1440.

Tsai, L. H., Graff, J. (2014). On the resilience of remote traumatic memories against exposure therapy-mediated attenuation. EMBO Rep.

Tsankova, N. M., Berton, O., Renthal, W., Kumar, A., Neve, R. L., Nestler, E. J. (2006). Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 9, 519-525.

Veinante, P., Freund-Mercier, M. J. (1997). Distribution of oxytocin- and vasopressin-binding sites in the rat extended amygdala: a histoautoradiographic study. J Comp Neurol 383, 305-325.

Verma, D., Tasan, R. O., Herzog, H., Sperk, G. (2012). NPY controls fear conditioning and fear

extinction by combined action on Y(1) and Y(2) receptors. Br J Pharmacol 166, 1461-1473.

Vervliet, B. (2008). Learning and memory in conditioned fear extinction: effects of D-cycloserine. Acta Psychol (Amst) 127, 601-613.

Vervliet, B., Baeyens, F., Van den Bergh, O., Hermans, D. (2013). Extinction, generalization, and return of fear: a critical review of renewal research in humans. Biol Psychol 92, 51-58.

Viviani, D., Charlet, A., van den Burg, E., Robinet, C., Hurni, N., Abatis, M., Magara, F., Stoop, R.

(2011). Oxytocin selectively gates fear responses through distinct outputs from the central amygdala. Science 333, 104-107.

Walker, D. L., Ressler, K. J., Lu, K. T., Davis, M. (2002). Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats. J Neurosci 22, 2343-2351.

Waltereit, R., Mannhardt, S., Nescholta, S., Maser-Gluth, C., Bartsch, D. (2008). Selective and

protracted effect of nifedipine on fear memory extinction correlates with induced stress response. Learn Mem 15, 348-356.

Wang, C. C., Lin, H. C., Chan, Y. H., Gean, P. W., Yang, Y. K., Chen, P. S. (2013). 5-HT1A-receptor

agonist modified amygdala activity and amygdala-associated social behavior in a valproate-induced rat autism model. Int J Neuropsychopharmacol 16, 2027-2039.

Weber, M., Hart, J., Richardson, R. (2007). Effects of D-cycloserine on extinction of learned fear to an olfactory cue. Neurobiol Learn Mem 87, 476-482.

Wei, W., Coelho, C. M., Li, X., Marek, R., Yan, S., Anderson, S., Meyers, D., Mukherjee, C., Sbardella, G., Castellano, S., Milite, C., Rotili, D., Mai, A., Cole, P. A., Sah, P., Kobor, M. S., Bredy, T. W.

(2012). p300/CBP-Associated Factor Selectively Regulates the Extinction of Conditioned Fear. J Neurosci 32, 11930-11941.

Weiner, D. M., Levey, A. I., Sunahara, R. K., Niznik, H. B., O'Dowd, B. F., Seeman, P., Brann, M. R.

(1991). D1 and D2 dopamine receptor mRNA in rat brain. Proc Natl Acad Sci U S A 88, 18591863.

Wellman, C. L., Izquierdo, A., Garrett, J. E., Martin, K. P., Carroll, J., Millstein, R., Lesch, K. P., Murphy, D. L., Holmes, A. (2007). Impaired stress-coping and fear extinction and abnormal corticolimbic morphology in serotonin transporter knock-out mice. J Neurosci 27, 684-691.

Werner-Seidler, A., Richardson, R. (2007). Effects of D-cycloserine on extinction: consequences of prior exposure to imipramine. Biol Psychiatry 62, 1195-1197.

Wessa, M., Flor, H. (2007). Failure of extinction of fear responses in posttraumatic stress disorder: evidence from second-order conditioning. Am J Psychiatry 164, 1684-1692.

Whittle, N., Singewald, N. (2014). HDAC inhibitors as cognitive enhancers in fear, anxiety and trauma therapy: where do we stand? Biochem Soc Trans 42, 569-581.

Whittle, N., Hauschild, M., Lubec, G., Holmes, A., Singewald, N. (2010). Rescue of impaired fear extinction and normalization of cortico-amygdala circuit dysfunction in a genetic mouse model by dietary zinc restriction. J Neurosci 30, 13586-13596.

Whittle, N., Schmuckermair, C., Gunduz Cinar, O., Hauschild, M., Ferraguti, F., Holmes, A., Singewald, N. (2013). Deep brain stimulation, histone deacetylase inhibitors and glutamatergic drugs rescue resistance to fear extinction in a genetic mouse model. Neuropharmacology 64, 414423.

Wilhelm, F. H., Roth, W. T. (1997). Acute and delayed effects of alprazolam on flight phobics during exposure. Behav Res Ther 35, 831-841.

Wilhelm, S., Buhlmann, U., Tolin, D. F., Meunier, S. A., Pearlson, G. D., Reese, H. E., Cannistraro, P., Jenike, M. A., Rauch, S. L. (2008). Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry 165, 335-341; quiz 409.

Willard, S. S., Koochekpour, S. (2013). Glutamate, glutamate receptors, and downstream signaling pathways. Int J Biol Sci 9, 948-959.

Windle, R. J., Shanks, N., Lightman, S. L., Ingram, C. D. (1997). Central oxytocin administration

reduces stress-induced corticosterone release and anxiety behavior in rats. Endocrinology 138, 2829-2834.

Wittchen, H. U., Jacobi, F., Rehm, J., Gustavsson, A., Svensson, M., Jonsson, B., Olesen, J., Allgulander, C., Alonso, J., Faravelli, C., Fratiglioni, L., Jennum, P., Lieb, R., Maercker, A., van Os, J., Preisig, M., Salvador-Carulla, L., Simon, R., Steinhausen, H. C. (2011). The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21, 655-679.

Woods, A. M., Bouton, M. E. (2006). D-cycloserine facilitates extinction but does not eliminate renewal of the conditioned emotional response. Behav Neurosci 120, 1159-1162.

Wrubel, K. M., Barrett, D., Shumake, J., Johnson, S. E., Gonzalez-Lima, F. (2007). Methylene blue

facilitates the extinction of fear in an animal model of susceptibility to learned helplessness. Neurobiol Learn Mem 87, 209-217.

Wu, D. (2005). Neuroprotection in experimental stroke with targeted neurotrophins. NeuroRx 2, 120128.

Xu, J., Zhu, Y., Contractor, A., Heinemann, S. F. (2009). mGluR5 has a critical role in inhibitory learning. J Neurosci 29, 3676-3684.

Xu, Y. L., Gall, C. M., Jackson, V. R., Civelli, O., Reinscheid, R. K. (2007). Distribution of neuropeptide S receptor mRNA and neurochemical characteristics of neuropeptide S-expressing neurons in the rat brain. J Comp Neurol 500, 84-102.

Yamada, D., Wada, K., Sekiguchi, M. (2011). Facilitating actions of an AMPA receptor potentiator upon extinction of contextually conditioned fear response in stressed mice. Neurosci Lett 488, 242-246.

Yamada, D., Zushida, K., Wada, K., Sekiguchi, M. (2009). Pharmacological discrimination of extinction and reconsolidation of contextual fear memory by a potentiator of AMPA receptors. Neuropsychopharmacology 34, 2574-2584.

Yamamoto, S., Morinobu, S., Fuchikami, M., Kurata, A., Kozuru, T., Yamawaki, S. (2008). Effects of single prolonged stress and D-cycloserine on contextual fear extinction and hippocampal NMDA receptor expression in a rat model of PTSD. Neuropsychopharmacology 33, 21082116.

Yang, C. H., Shi, H. S., Zhu, W. L., Wu, P., Sun, L. L., Si, J. J., Liu, M. M., Zhang, Y., Suo, L., Yang, J. L. (2012). Venlafaxine facilitates between-session extinction and prevents reinstatement of auditory-cue conditioned fear. Behav Brain Res 230, 268-273.

Yang, Y. L., Lu, K. T. (2005). Facilitation of conditioned fear extinction by d-cycloserine is mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase cascades and requires de novo protein synthesis in basolateral nucleus of amygdala. Neuroscience 134, 247-260.

Yang, Y. L., Chao, P. K., Lu, K. T. (2006). Systemic and intra-amygdala administration of glucocorticoid agonist and antagonist modulate extinction of conditioned fear. Neuropsychopharmacology 31, 912-924.

Yang, Y. L., Chao, P. K., Ro, L. S., Wo, Y. Y., Lu, K. T. (2007). Glutamate NMDA receptors within the

amygdala participate in the modulatory effect of glucocorticoids on extinction of conditioned fear in rats. Neuropsychopharmacology 32, 1042-1051.

Yao, Y. L., Yang, W. M., Seto, E. (2001). Regulation of transcription factor YY1 by acetylation and deacetylation. Mol Cell Biol 21, 5979-5991.

Yee, B. K., Hauser, J., Dolgov, V. V., Keist, R., Mohler, H., Rudolph, U., Feldon, J. (2004). GABA

receptors containing the alpha5 subunit mediate the trace effect in aversive and appetitive conditioning and extinction of conditioned fear. Eur J Neurosci 20, 1928-1936.

Yehuda, R., Bierer, L. M., Pratchett, L., Malowney, M. (2010). Glucocorticoid augmentation of prolonged exposure therapy: rationale and case report. Eur J Psychotraumatol 1.

Yen, Y. C., Mauch, C. P., Dahlhoff, M., Micale, V., Bunck, M., Sartori, S. B., Singewald, N., Landgraf, R., Wotjak, C. T. (2012). Increased levels of conditioned fear and avoidance behavior coincide with changes in phosphorylation of the protein kinase B (AKT) within the amygdala in a mouse model of extremes in trait anxiety. Neurobiol Learn Mem.

Yokoyama, M., Suzuki, E., Sato, T., Maruta, S., Watanabe, S., Miyaoka, H. (2005). Amygdalic levels of dopamine and serotonin rise upon exposure to conditioned fear stress without elevation of glutamate. Neurosci Lett 379, 37-41.

Yu, H., Wang, Y., Pattwell, S., Jing, D., Liu, T., Zhang, Y., Bath, K. G., Lee, F. S., Chen, Z. Y. (2009).

Variant BDNF Val66Met polymorphism affects extinction of conditioned aversive memory. J Neurosci 29, 4056-4064.

Zanoveli, J. M., Carvalho, M. C., Cunha, J. M., Brandao, M. L. (2009). Extracellular serotonin level in

the basolateral nucleus of the amygdala and dorsal periaqueductal gray under unconditioned and conditioned fear states: an in vivo microdialysis study. Brain Res 1294, 106-115.

Zelikowsky, M., Hast, T. A., Bennett, R. Z., Merjanian, M., Nocera, N. A., Ponnusamy, R., Fanselow, M. S. (2013). Cholinergic blockade frees fear extinction from its contextual dependency. Biol Psychiatry 73, 345-352.

Zhang, G., Asgeirsdottir, H. N., Cohen, S. J., Munchow, A. H., Barrera, M. P., Stackman, R. W., Jr.

(2013). Stimulation of serotonin 2A receptors facilitates consolidation and extinction of fear memory in C57BL/6J mice. Neuropharmacology 64, 403-413.

Zimmerman, J. M., Maren, S. (2010). NMDA receptor antagonism in the basolateral but not central

amygdala blocks the extinction of Pavlovian fear conditioning in rats. Eur J Neurosci 31, 16641670.

Zoicas, I., Slattery, D. A., Neumann, I. D. (2014). Brain Oxytocin in Social Fear Conditioning and its Extinction: Involvement of the Lateral Septum. Neuropsychopharmacology.

Zushida, K., Sakurai, M., Wada, K., Sekiguchi, M. (2007). Facilitation of extinction learning for

contextual fear memory by PEPA: a potentiator of AMPA receptors. J Neurosci 27, 158-166.

Figure legends

Figure 1. Different modes of fear alleviation and sites of possible pharmacological intervention. A, Fear alleviation is mediated via different mechanisms leading to acute or sustained fear relief. Sustained fear relief can be obtained either with exposures to the feared cues/situations or, in some instances, also without them. For a detailed description of the involved mechanisms, see (Riebe et al., 2012). Pharmacological interventions to boost fear relief can target different mechanisms at various levels. Examples are given with numbers 1-4, for detail see text. B, Fear conditioning represents a training phase in which a novel conditioned stimulus (CS) is paired with an unconditioned stimulus (US) (redline). Throughout fear training and testing, fear is measured as a conditioned response (y-axis), typically freezing, fear-potentiated startle, increased heart rate, and other quantifiable behavioural measures of fear. Following this training period, mice undergo a consolidation phase which transfers the labile newly formed fear memory into a stable long-term memory. Fear can be extinguished by repeated presentations of the CS (without the US; red line) resulting in fear extinction. Following the extinction training session, and akin to fear learning, consolidation processes are initiated to stabilize this labile fear extinction memory into a long-term memory. Poor extinction is evidenced by high fear responding (red bar), and successful extinction retrieval is shown by reduced fear (green) during a retrieval test. Extinguished fear can recover via three main mechanisms: spontaneous recovery (recovery of extinguished fear responses occurs with the passage of time in the absence of any further training.), fear renewal (when the conditioned CS is presented outside the extinction context, for example the conditioning or novel contexts), and fear reinstatement (when un-signalled presentations of the US are interposed between the completion of extinction training and a subsequent retention test). Drugs (green arrows) can be administered either immediately prior to (to induce extinction acquisition also called 'within-session extinction' and/or extinction consolidation) or immediately following (to rescue/boost extinction consolidation processes) the training session to modulate extinction mechanisms. A clinical aim of drug augmentation strategies is to promote good extinction retrieval and to protect against return-of-fear phenomena to provide good 'longterm extinction'. C, Fear memory can be reactivated (red bar) by presentation of the CS, which transfers the stabilized memory into a labile phase which requires reconsolidation (a process by which previously consolidated memories are stabilized after fear retrieval). The fear memory can then be tested during another retrieval test (red bar) to assess reconsolidation. Drugs (green arrow) can be administered either immediately prior to or after the retrieval session to modulate reconsolidation mechanisms. This effect can then be tested during subsequent retrieval tests. Evidence for successful interference with reconsolidation of the original fear memory is revealed in reduced freezing during the test session.

Figure 2 Anatomy of fear extinction and expression.

Fear extinction and expression rely on neuronal processing in an anatomical circuitry centering on the AMY, PFC, and HPC. Glutamatergic and GABAergic neurons, among others, are important components of connectivity and regulation of fear. The AMY is critically involved in the expression of aversive (fear) memories. While fear neurons in the BA send excitatory projections directly to the centromedial AMY (CeM) driving expression of fear (right panel), during extinction (left panel), the infralimbic cortex (IL) inhibits CeM output by driving inhibitory ITC neurons. IL inputs might also synapse directly on "extinction" neurons

within the BA. "Extinction" neurons can influence activity within the central AMY (CeA) through several routes, possibly by driving inhibitory ITC or CeL (off PKC+) neurons that limit CeM activity. There is also a BA-CeL pathway contributing to ultimate inhibition of the CeM. The hippocampus is involved in contextual aspects of extinction via its projections to both the IL and the BA, among other brain regions. Hence, inhibitory memories built following extinction are encoded by the AMY and the PFC and are modulated by the HPC. It is thought that extinction training and exposure therapy produce long- lasting changes in synaptic plasticity and interneuronal communication in this circuitry ultimately reducing fear responses via output stations including the CeM. For further details, the reader is refered to recent reviews of (Orsini & Maren, 2012; Duvarci & Pare, 2014).

Figure 3 Overview of pharmacological targets and signaling cascades proposed to be important in mediating synaptic plasticity underlying extinction.

The formation of extinction memories requires an intricate regulatory network of signal transduction and gene transcription and translation, leading to a complex pattern of intracellular changes and long-term structural changes. Various pre- and postsynaptic membrane receptors including ionotropic and metabotropic glutamate receptors, cannabinoid receptors, 5-HT, and dopamine receptors have been shown to be important targets. Main downstream mechanisms include calcium entry through NMDAR and VGCC in concert with AMPA receptors initiating synaptic plasticity via calcium-dependent protein kinases (e.g. PKA, PKC, PKM and CamKII, phosphatases (e.g. calcineurin) and activation of the ERK/MAPK pathway. Subsequent interaction with transcription factors, such as CREB and Zif268 within the nucleus results in a wide range of newly synthesized proteins, such as BDNF important for synaptic plasticity including LTP formation. BDNF activated TrkB receptors further regulate the ERK/MAPK pathway. Finally, epigenetic modifications are important in translating neurotransmitter/neuromodulator signaling activity generated at the synapse into activation/repression of the desired genomic response in the cell nucleus. As outlined in the text, boosting these synaptic plasticity mechanisms by pharmacological means may constitute the establishment of novel drug targets to promote fear extinction.

Figure 4 Overview of research on the role of the serotonergic system in extinction

Figure 5 Overview of research on the role of the dopaminergic system in extinction

Figure 6 Overview of research on the role of the glutamatergic system in extinction

Figure 7 Overview of research on the role of the GABAergic system in extinction

Figure 8 Overview of research on the role of the cannabinoid system in extinction

Figure 9. Schematic representation depicting the epigenetic regulation of fear extinction.

DNA methylation is associated with suppression of gene transcription. The precise molecular processes through which this occurs are complex. In brief, methylation of cytosines at CpG dinucleotides recruits methyl-DNA binding proteins, at specific sites in the genome. Proteins that bind to methylated DNA, including methyl CpG-binding protein 2 (MeCP2) and methyl CpG-binding domain protein 1 (MBD1), have both a methyl-DNA binding domain and a transcription-regulatory domain. The transcription-regulatory domain recruits adapter/scaffolding proteins, which in turn recruit HDACs, including HDAC2, to repress gene

transcription [reviewed in (Sweatt, 2009). Following extinction related neuronal activity a number of molecular mechanisms are invoked, ultimately leading to facilitated histone acetylation and subsequent enhancement of gene transcription. These mechanisms include enhancement of HAT activity, such as PCAF (see text) and a reduction in HDAC activity by mechanisms which include nitrosylation (NO) of HDACs, including HDAC2, which facilitates dissociation of HDAC from the chromatin. Moreover, enhanced histone acetylation may also be mediated by the conversion of DNA demethylation which is mediated by the Tet family of methylsytosine dioxygenases. Emerging pharmaceutical evidence is showing that HDAC inhibitors can facilitate gene transcription by enhancing histone acetylation in the promoter region of extinction-relevant genes (see text).

Figure 10 Strategy for translating research from humans to mice and back, focusing on human disorders of fear dysregulation. Rodent models of enhanced fear and impaired extinction (induced by genetic or environmental manipulations) closely resemble human symptomatology, particularly the fear dysregulation that occurs in PTSD, panic, and phobic disorders. Using these models increases the chances of identifying candidate genes for human anxiety disorders by reducing the problems of genetic heterogeneity and a variable environment. It is also important to study the involvement of these candidate genes in patients, as well as using unbiased genome-wide association studies and genome-wide epigenetic approaches to identify previously unknown genetic pathways contributing to risk in humans. Subsequently, elucidating the function of the identified gene and its epigenetic regulation using rodent models as well as the human population increases our knowledge of the neurobiology of fear disorders, which, at the same time, is necessary to improve the models. It is also necessary to use rodent models to test the ability to pharmacologically enhance extinction of fear and diminish fear expression prior to clinical test phases. Arrows demonstrate how the different levels of understanding, from genetics to epigenetics to neural circuits, can inform each other, as well as how they can be informed across species due to the high level of convergence of shared fear-related processing across mammals.

Box 1: Why pharmacological augmentation of extinction?

A limitation of extinction-based exposure therapy is that patients can often relapse with the passage of time, with changes in context (out of the therapy context), or under conditions of stress or other provocations, such as experiencing trauma reminders. In the parlance of learning theory, extinction memories are labile and fragile. A key goal for pharmacotherapy, therefore, is to identify compounds that overcome this fragility, by bolstering the formation, persistence and possibly context independence of extinction memories. One approach to achieving this goal is to use drugs as adjuncts to exposure therapy (cognitive enhancers) as a way to augment the extinction learning process. In this review, we discuss the various neurochemical and molecular signalling pathways that have been targeted to this end. On the one hand, there remain significant challenges to overcome, including the selective targeting of extinction-related processes without concurrent effects on original fear memories. On the other hand, there are clearly a plethora of potentially promising avenues to pursue, and we are optimistic that real advances can be made in treating trauma-related disorders.




Without exposure


With exposure

2 ^ Extinction

e.g. BZDs e.g. DCS, GCs e.g. ß-

O r^lsSl f

e.g. BDNF

Safety learning

Reconsolidation disruption


Drugs Drugs




Retrieval (Test)


O fear neuron # extinction neuron — Glutamatergic — GABAergic O fear neuron # extinction neuron — Glutamatergic — GABAergic

synaptic vesicle

AMPAR ¿'AR VfC 'H7, 0,

3 Nat PKMi^. Ca2+- cAMP ; CamKII*' I \

\\ /1 ♦ X — IP3

°r \\ /Rem2-CaM ^ DAG


fc. A* "

^ ' AMPAR . • eCB synthesis trafficking \ Ng+ / pKM{

I CamKII" | GC receptor X / Rem2—CaM


® / i src

------i \ \ /GDP

\ <© / Rho

jjjp RhoGAP -»

scsMItog MEK^ ¿..Calcine",m GTP


=rp ' R5K R0CK_


' >. • \

structural ~~* plasticity

actin polymerization

Ac .Ac Ac ,

.HAT. ¿,



e.g. BDNF


Important facts

SefCl • abnormal dendrite & spine morpholgy in BLA and IL pyramidal neurons; enhanced iheta wavi synchronisation between mPFC and LA

chronic Citalopram reduced GluNR28 in the BLA

5-HT1A receptors are concentrated in the CeA

Translational aspects

Beneficial efleets in combination with CBT

Escitalopram (healthy volunteers) Fluvoxamine Paroxetine Sertraline Fluoxetine

Systemic interventions



X SERT: acute fluoxetine [1] chronic Citalopram [2)

■ 5-HT2A: MDL 11.93914)


X SERT: chronic fluoxetine [1] + 5-HT1A. 8-OH-DPAT |5]

+ 5-HT2A TCB-2 (4)

psilocybin |7]

■ 5-HT2A/C: ketansenn [7|


J, SERT: chronic fluoxetine [1:9:11-12]

acute venlafaxine [13] + 5-HT1A: tandospirone {6] " S-HT3: granisetron_


1 SERT: subchronic (9d) citalopram [2] chronic fluoxetine [9-12:18]

acute venlafaxine [13] 5-HT3 overexpression [14] SERT knock-out [15] ■ 5-HT3: granisetron [8]

SERT [15-16] 5-HT3 [3] A SERT: chronic citalopram [2] ♦ 5-HT1A: 8-OH-DPAT [5]


X SERT: chronic fluoxetine [9-10:17]

chronic venlafaxine 113]_


A SERT: acute fluoxetine [1]


™ Antagonist ^ Agonist X block ^X^ knock-out




selective lesion of 5-HT AMY projections by 5,7-di-OH-tryptamine infusions [18]



[1] Lebron-Milad et at, 2014

[2] Burghardt et al. 2013

[3] Kondo et al. 2014

[4] Zhang etal, 2013

[5] Wang etal ,2013

[6] Saito etal, 2013

[7] Cattow etal. 2013

[8] Park & Wiliams, 2012

[9] Karpova et al , 2011

[10] Deschaux et al , 2011

[11] Camp etal., 2012

[12] Popova etal. 2014

[13] Yang et al, 2012

[14] Harrel & Alien 2003

[15] Welman et al. 2007

[16] Hartley etal, 2012

[17] Deschaux et al . 2013

[18] Izumi et al. 2012


5-HT 5-hydroxytryptamine (serotonin)

BA basal amygdala

BLA basolateral amygdala

CA1-3 cornu ammonis 1-3

CeA central amygdala

CeL centrolateral amygdala

CeM centromedial amygdala

DG dentate gyrus

HPC hippocampus

dlTC intercalated cells, dorsal

vfTC intercalated eels, ventral

LA lateral amygdala

mPFC medial prefrontal cortex

PV Parvalbumm


selective lesion of 5-HT mPFC projections by 5.7-di-OH-tryptamine infusions [18]



Systemic interventions

DA innervation ot BLA pyramidal and PV* interneurons). CeA and ICNs Extinction training enhances DA mPFC levels (microdialysis) High Dl-class receptor expression in ICN


D1-class receptors modulate LA oscillatory Inhibitory network activity DA receptors modulate NMDA currents, thus influence LTP formation


amphetamine [2| cocaine [2]

# D1-class SKF 3839312]

+ D2-class; quinpirote |5|

™ D2-class raclopride [4]

sulpiride [5] _haloperidol [6|





■ D2-dass sulpiride |9]



Translational aspects

# Ol-díis SKF38393 [5]



amphetamine |10] — 02-cteM sulpiride [4|

amphetamine (16) + D2-dass. quirptrolo [3;S|


™ Antagonist 4H A9°n'sl ^ inverse Agonist 01-class: D1/D5 receptor D2-class: D2/D3/D4 receptor


■ Dl-class: SCH2339C [11]




# D1-class: SKF38393 [12) — 01-class: SCH23390111-12|



' D1-class: SCH23390 [11] ■ D2-dass: raclophde [4] ' 04: L-741,741115]

DI-class: SKF33393 [12] Dl-class SCH23390 [12]


01-class: SCH23390 (l^j




HIPPOCAMPUS I* OKIass SKf38393112] |

El-Ghundi et al. 2001 BorowsKi & Kokkrnidis, 1998 Nader & LeDoux, 1999 Mueller el al. 2010 Dubtovina & Zmo/eva 2010 Holtzman-Assif el at, 2010 Haaker el al, 2013 Abraham at al.. 2012 Ponnusamy el al., 2005 [10] Carmackeial.,2010 [111 Hikirtd & Maroun, 2008 [121 Fiorenza et al, 2012

[13) Morrow el at., 1999

[14) Fernandez Espejo. 2003

[15) Pie liter & Fendt. 2006 [16¡ Muelle! el al. 2009]



BA basal amygdala

BLA basolateral amygdala

CA1-3 cornu ammonis 1-3

CeA central amygdala

CeL centiotateral amygdala

CeM centromedial amygdala

DA dopamine

DG dentate gyrus

ICN intercalated nuclei

dITC intercalated cells, dorsal

vlTC intercalated eels, ventral

LA lateral amygdala

LTP long term potentiation

NMDA N-mettiyl-d-aspartate

mPFC medial prefrontal cortex PV Paralbumin




(JAMPA: PEPA |i-2| фнмол DCS|i^-e]

cQt iriGUtS: CDPPB [71 + mGlofl' AUMMiiei



»»гргсиЛМЗ) R02S-SM1 [14-li|

ф mGluR? АМГЮв2 [34]

-»"PÖüRiliri тОЬЛ'ПвЗ»


PAWPA: PEPA[1] h MHDA DCS 11,21]

МКЧМ1 [9-12)3940] СРР1Ш11

35mauR5:CPCCOEIII4 ■noioRsiir;



» NM OA: CPP Hb) teaming



• mdoRi CPCCOEI |421

MTEP teaming [42| h AMND82 |Л|


— AMPA CNQX |6frM]

<0 NMDA: DCS [S1J reí», к NMDA ЛР-5 |5T]Iraming

4 mGluR/: AMN082165| 4 mGtuRS DCPG |65]

tft KIMDA 200: СЮ |63)



ДР-5147.43, 66-58:62

J negative alloslenc modulator

™ Antagonist + Agonist X knoc*-ogl


I ф AMPA PEPA ft Pi]


4 mCluR7:AMMQjZ|4j]

I.. 2006

|37] [36] |39]

[54] 155]

[61] [62] [63]

Yamaäa et al.. 2009 Zushida et al. 2007 Zushida et al. 2009 Silvestrietal., 2003 Lehneret al.,2010 Bai et ai, 2014 Gass & Olive. 2009 Whittle et а!.. 2013 Baker & Azorlosa. 1996 Lee st al.. 2006 Liuetal. 2009 Storvse et sl. .2010 Sotres-Bayonet al.. 2007 Dalton et al.. 2003 Dalton et al. 2012 Kim etai,, 2007 Xu et al.. 2009 Callaerts-Vegh et al Yarrada et al., 2011

waiKeret ai., 2002

Ledgerwood et al.. 2003, 2004. 2005 Pernes et al.. 2005 Yang & Lu. 2005

Woods & Bouton. 2006

werner-SeiaierS Richardson, 2007

Weber et al. 2007

Yang & Lu. 2007

Hemer et al., 2008

Yamamoto et ai„ 2008

Matsumoto et al 2003

Langton & Richardson, 200в, 2010

Bouton 2008

im et ai,,2009

Tothetat, 2012

Gupta ei al 2013

Matsuda et al.. 201.0

Fendl et al. 2008

Davis et al . 2013

Langten et al.. 2007

Chan & McNally, 2009

Santini et al.. 2001

Mao et al . 2013

Johnsen et al.. 2000

Tothetal . 2012

Burgos-Robles et al.. 2007

Morawska & Fendt. 2012

Florenza et al.. 2012

Laurent et al.. 2008

Laurent & Westbrook. 2008a

Sotres-Bayonet al.. 2009

BolkanS Lattal.2013

Renetal.. 2013

Gomes et al . 2010

Szapiro et al.. 2003

Cammarota et al.. 2005

Fans et ai.. m2

Linetal,, 2003

Zimmerman & Maren. 2010

Mao etat, 2006

Akiravetai. 2W9

Parsons et al.,2010

Lee & Kim. 1998

Ogdenet al., 2014

uao et al . 2009

Dow et ai„ 2013

Laurents Werstbrook,, 2008b

Gaddyn et ai 2008

Fontanez-Nuin etat. 2011

Fendt et ai . 2013

Sepulveda-Qrengo et al.. 2013


GabAa receptor

Systemic interventions

# extinction training

Important facts

The ailoslenc benzodiazepine binding sile s locate

" " ----- ling to the recepl

в CI-channel

ITC GABAergic neurons eontan айоЗЛй and 6 GABA.subunrts Knock-out o( the GA8A-synlhesuing enzymes GA06S or GA067


GA065 [2|


Ipbahn CRF* cells 127]

+ GABA. - BZD bindmg site: chkxdiazepo««Jo [4| [5-6.261

no effect on extinction consolidation/ retrieval

GAD $5121

alpha 1 in CRF • cefls ¡27/

♦ GABA. - BZD BuxJmg site: diazepam 18-9]

midazolam {5-6:10.26


consolidation/ retrieval

™ GABA* - GABA binding

extinction training + GABA.-GABA bmdmg

♦ extinction consolidation/ retrieval

HeMt et tri. 2012 Sangha et ai. 2009 Jacobson et el. 2006 Goldman. 1977 Hart et al. 2009 Hart et al. 2010 Harris & Westbrook. 1998 Pereira ел el. 1989 Bouton et al, 1990 Bustos et al. 2009 Heaney et al. 2012 Kim & Richerdson. 2007 Kim* Richardson. 2009 McGaugh et al 1990 Sweeney etat., 2013 Akuav et al. 2006 Laurent & Wostbrook. 2008 Laurent et al. 2008 Bertau & McGaugh, 2006 Sierra-Mercado et al 2011 Yee el al 2004 Corcoran et al. 2005 Laurent & Westbrook. 2009 Thompson et al 2010 FitzgerakJ et al. 2014 Hart et al. 2014 Gafford et al, 2012

basal amygdala basolateral amygdala benzodiazepine ammonis 1-3 daterai amygdala amygdala chloride dentate gyrus intercalated eels, dorsal intercalated eels, vt y amino butync acid glutamate decarboxylase


Figure 8

Important facts

Anandamide (AEA)

Systemic interventions


Cb1 lorebram or cortical GLU cells or D1-expressing neurons 11-6]

# CB1: AM2S1 [9]

■f CB1: high dose WIN55.212-2 |i


■ CB1: SR141716 [10;17]


'0085 T EXTINCTION TRAINING de-novo synthesis of eCB following neuronal activation (within minutes) + CB1: W1N55.212-2 [8]

eCB strongly involved in negative feedback control of the HPA axis

Extinction enhances endocannabirtoid (eCB) tissue levels in the BLA

Reduced eCB levels in PTSD patients

eCB regulate synaptic plasticity in BLA (LTDi)

BLA CCK* intemeurons express CB1


- Antagonist ^ ^^

* Agonist , enhanc8d

# inverse Agonist

' eCB level AM3506, AM404 [11-12:17]

+ CB1: WIN55.212-2 [8:11]


EXTINCTION TRAINING + CB1/2: cannabidlol [15] HU210 [18] " eCB level: AM404 [18] URB597 [18]

CB1: WINS5.212-2 [18]


+ CB1:

WIN55.212-2 [13]

+ CB1 WIN55.212-2 [8] — CB1: SR141716 [1:8:11]


• eCB level AM3506 [13] ♦ C81: WIN55.212-2 [13]


+ ' eCB lev«!: Am350 [12]


+ CB1: WIN55.212-2113] ♦ CB1/2: anandamide [14]



CB1 AM251 (14]


|1] Marsicano et al . 2002

[2| Cannich et al. 2004

[3] Kamprath et al. 2006

[4] Dubreucq et al. 2010

[5] Plendl & Wotjak 2010

[6] Terzian et al, 2010

[7] Niyuhire et al. 2007 18] Pamplona et al. 2006

[9] Reich et al, 2009

[10] Suzuki et al, 2004 ¡11) Pamplona et al, 2008

[12) Gunduz-Cinar et al. 2012

[13) Ganon-Elazar &Akirav2013

[14] de Oliviera AKrarez et al, 2008

[15] do Monte etat.. 2013 ¡16] de Bitencourt et al, 2008

[17] Chhatwal et al. 2005

[18] Lin et al, 2009

[19] Kuhnerl et al , 2013


BA basal amygdala

BLA basotateral amygdala

CA1-3 comu ammonis 1-3

CB cannabinoid

CCK cholecystokinin

CeA central amygdala

CeL contralateral amygdala

CeM centromedial amygdala

D1 dopamine receptor 1

DG dentate gyrus

eCB endogenous cannabinoid

GLU glutamate

HPA hypothalamus-pituitary-adrenal

ICN intercalated nuclei

dITC intercalated cells, dorsal

vITC intercalated eels, ventral

LA lateral amygdala

LTDi long term depression, inibitory

mPFC medial prefrontal cortex

PTSD post-traumatic stress disorder

PV Parvalbumin


+ CB1/2: cannabrfol [16) anandairude |16]


+ CR 1-2 Ccinnabidkl [16]

Transcriptional Repressor Complex


Successful fear extinction (high extinction-related neuronal activity)

t HAT activity, I HDAC activity

Facilitated Transcription

Tet I—"—*-. Me-^OH-Me © ©______

ffl \ \ —^ Transcriptional

Human Disorders of Fear Regulation Rodent Models of Fear Regulation

Fear Conditioning, Stress, ExtinptfSD, Panic L

Gene - Environment Interactions

Impairment in natural recovery

Exposure based psychotherapy

Genes which modulate fear extinction

Candidate Gene, GWAS, and Epigenetics

Genetic Strains & Mutant Behavior mode,s Lines with enhanced fear ^^ 0f impaired or impaired extinction extinction

Manipulate genes to understand mechanism: Knockout, knockin, siRNA, inducible viral approaches + drug targets

Epigenetic correlates to human fear disorders

Examine epigenetic pathways

DNA Methylation, Histone Modification Alter epigenetics pharmacologically and genetically

Neural Circuits governing fear extinction ^-^

Neurobiology of Extinction Circuits: Gene-circuit interactions; optogenetics; DREADDS identification of site-selective drug targets

Clinical Trials of Drugs/Methods to Enhance exposure-based psychotherapy

Enhancing extinction in genetic & behavioral mouse models of extinction deficits and enhanced fear